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Murine Zfp106 is an 1,888 amino acid protein with two N-terminal and two C-terminal zinc finger 
domains with a beta-propeller upstream of the C-terminal zinc fingers. The transcription of the 
protein was found to be controlled through two promoter regions, leading to two isoform families, 
P1 and P2 Zfp106. The splice variants from each promoter are thought to have distinct starting 
exons and n-terminal regions. However, the isoforms are not well studied. Since its identification, 
Zfp106 has been implicated in RNA metabolism, transcription control, immune response, and 
muscle and testis development. It has been found to be capable of binding C9ORF72 repeats as 
well as being associated with TDP43 and FUS. However, its function is unknown. 
The aim of this study is to understand the role of Zfp106 in vivo through the use and development 
of various mouse models targeting exons specific to either the P1 or P2 family of isoforms. To 
begin with, we studied the Zfp106LacZ mouse model whose homozygous mice showed severe 
muscle atrophy beginning at 4 weeks leading to a premature death by 16 weeks. Research has 
supported the theory that the muscle atrophy is due to a motor neuron dysfunction potentially 
stemming from perturbed mitochondrial and spliceosome function. We, along with other 
researchers, found that this mouse model is not a complete disruption of Zfp106 through qPCR 
and RNAseq. We then found that this mouse model is an effective depletion of Zfp106 exon 2 and 
3 which are exclusive to the P1 Zfp106 isoform family. Additionally, the Zfp106LacZ mouse model 
has an increased amount of the 1b exon associated with P2-Zfp106 in the skeletal muscle.  
Next, we established a CRISPR mouse line (ΔZfp106) targeting an exon common to the full-length 
splice variants of both the P1 and P2 family of isoforms, exon 5. This was in an attempt to dissect 
whether or not the muscle atrophy in the Zfp106LacZ mice was due to the interruption of exons 2 
and 3 or from the increase in the P2 Zfp106 isoforms. Motor neurons derived from homozygous 
ΔZfp106 mouse embryonic stem cells, were found to be susceptible to CPA-induced endoplasmic 
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reticulum stress and rotenone induced mitochondrial stress.  Interestingly, the in vivo penetration 
rate of the muscle atrophy phenotype of homozygous ΔZfp106 mice is 60% for male and 12.5% 
for female mice. This is in stark contrast to the 100% penetration rate of the Zfp106LacZ mice. The 
reason behind this is currently unclear but may be due to either the incomplete backcrossing of the 
mouse model, a difference in the splice variants affected by the Zfp106 targeting, or because the 
muscle atrophy in the Zfp106LacZ mouse model is caused in part by the increase in the expression 
the P2 Zfp106 family of isoforms. These two mouse models show that affecting the expression of 
the full-length isoforms of P1-Zfp106 can lead to muscle atrophy.  
In an attempt to see if the Zfp106LacZ muscle atrophy was due to a lack of Zfp106 in the skeletal 
muscle, spinal cord, or necessitated its depletion in both, we derived a mouse line from the 
Zfp106LacZ that conditionally depletes exon 3 which impairs the expression of full length P1 
Zfp106. This was used to target exon 3 removal to the skeletal muscle (Myf5), cholinergic neurons 
(ChAT), simultaneously (Myf5/ChAT), or a whole body depletion (Ella2). Surprisingly, the whole 
body depletion of Zfp106 exon 3 did not lead to muscle atrophy even though its removal leads to 
a frame shift and premature stop codon. The lack of a muscle atrophy phenotype may be because 
of the expression of a splice variant without exon 3, thereby rescuing the neuromuscular pathology. 
Lastly, to better understand the role of the P2 Zfp106 in vivo, we created a mouse line with a 
CRISPR mediated knockout of exon 1b (ΔP2). Exon 1b is the start exon of the P2 Zfp106 isoform 
family and the introduction of a destructive INDEL should independently affect the P2 isoform 
family. Interestingly, this mouse model showed no observed neuromuscular dysfunction or 
metabolic disorder, responding to a glucose bolus similarly with controls. The lack of a phenotype 
may be due to compensation by other Zfp106 isoforms or that the P2 isoform family is important 
in other biological roles. 
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Altogether, this study uses multiple mouse models to better understand the role of Zfp106 in vivo. 
We observed muscle atrophy when inhibiting the expression of exons associated with the P1 
Zfp106 family in both the Zfp106LacZ and ΔZfp106 mouse lines although they had different 
penetration rates in homozygous mice. In contrast, the exon 3 specific removal of Zfp106, which 
should affect the P1 Zfp106 family of isoforms did not show muscle atrophy. The ΔP2 mouse 
model perturbing the 1b isoform did not have a neuromuscular phenotype. Altogether, the 
interruption of murine Zfp106 isoforms that express exon 2 and exon 5 are integral to the function 
of Zfp106 in the neuromuscular system. Future work focusing on gaining a better understanding 
of the splice variants of Zfp106, as well as developing a reliable antibody towards Zfp106, will 










Our lab first took note of Zfp106 following an effort to find a yet-unidentified potential 
transcription factor that is important in the development of muscle or cardiac tissue. Through these 
queries, we searched for a protein fitting the following four categories: contains a Zinc Finger 
Motif, is expressed in cardiac tissue, is expressed in skeletal muscle, and was available in the 
Knockout Mouse Project (KOMP) mouse repository. The list of proteins following these criteria 
were then analyzed further using publicly available microarray data to determine if their expression 
correlated with the differentiation of myoblasts into myotubes4. One of the top results from this 
search led to Zfp106, and we began our work in studying the function of Zfp106 in order to 
understand its physiological role (Figure 1).  
 
  




Zfp106, the murine orthologue of human ZNF106, is mapped to the mouse chromosome 2 and has 
22 exons, 21 of which are coding5,6. The overall structure of the longest isoform of Zfp106 was 
described to be an 1,888 amino acid protein with four zinc finger domains, two N-terminal C2H2 
and two C-terminal CWCH25-7. Upstream of the C-terminal zinc finger domains, are seven WD40 
domains forming a beta-propeller (Figure 2)6. These functional groups indicate the potential role 
of Zfp106 in DNA binding as well as mediating protein-protein interactions6. 
Discovery of the son of insulin receptor mutant (SIRM) 
While characterizing an in vivo mouse model with the insulin receptor knocked out (IR-/-), 
researchers noticed an unknown band in the detergent extracts of the mouse liver that was tyrosine 
phosphorylated following IGF1 treatment8. Further investigation of this band, led to the discovery 
of Son of Insulin Receptor Mutant (SIRM), a protein largely expressed in insulin-responsive 
tissue9. In 3T3-L1 adipocyte-like cells, SIRM was implicated in the insulin receptor pathway 
capable of binding both Grb2 and Fyn Kinase through its SH3 binding domain. This interaction 
was dependent on insulin signaling with its activation leading to the dissociation of SIRM and 




Grb2 or Fyn Kinase. Additionally, SIRM was found to be phosphorylated by both Fyn Kinase and 
the insulin receptor kinase. 
SIRM was later found to have a high sequence identity with Zfp1065.  It was determined that SIRM 
was actually an incorrectly mapped and prematurely truncated variant of Zfp106 misidentified due 
to a frame shift in the original attempt at mapping of the protein’s N-terminus5. Correcting for this 
error, SIRM was confirmed to be an isoform of Zfp106: Sh3bp3 which initiates from the second 
promoter region (P2)6.  
Zfp106 Isoform Expression 
Zfp106 has two main families of isoforms whose expression is driven by two distinct promoter 
regions: Nuclear response factor 1 (Nrf-1) and Myogenin (MyoG) leading to the expression of the 
P1 and P2 isoform families respectively. Following the expression pattern of NRF-1, the P1 
isoforms are expressed ubiquitously6,10. The second promoter region contains 3 ebox and Mafbx 
motifs and is bound by MyoG. This binding initiates the transcription of the P2 isoform family, 
which has an increased expression in excitable tissue like cardiac and striated muscle6. Supporting 
this, the expression of exon 1b, which is specific to the P2 isoform family, increases in correlation 
with MyoG expression6.  
The resulting proteins from the two promoter-led isoforms have distinct N-terminal regions. The 
P1 controlled isoform has an additional N-terminal zinc finger and cytochrome-c binding domain, 
which implicates this isoform in the redox pathway5. The P2 controlled isoform lacks the first zinc 
finger while integrating an additional SH3 binding domain (Figure 3).  
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Besides the determination of the two major isoform families from the two promoter regions, the 
splice variants are not well studied outside of a single publication11. In this study, RT-PCR 
amplification using primer pairs aligned with exon 1F/6R and exon 1bF/6R of skeletal muscle 
cDNA to map the P1 and P2 isoform families respectively.  Here, each promoter family was 
identified to have a splice variant that skipped both exons 4 and 5 in addition to the full length 
isoform11. Of note, the researchers found that both the P1 and P2 full length isoforms are not stable 
when transiently transfected in Cos7, HeLa or HEK293 due to an unknown mechanism leading to 
their instability in cells, causing them to rely on a Tet-off recombinant adenovirus system to 
express the protein11. All of the isoforms overexpressed in cells ran slower on SDS-PAGE gels 
than expected considering their molecular weight and appeared as doublets in their western blot, 
Figure 3 Zfp106 P1 and P2 isoforms. 
A) Schematics depicting Zfp106 P1 and P2 promoter led isoform families and the resulting 
translated proteins. The green vertical line depicts exon 1 as a non-coding exon, the dashed 
horizontal line represents the inclusion of all of the intervening exons between the two labeled 
ones. 




both trends were not affected by phosphatase treatment11. Additionally, in this study, they 
developed a C-terminal antibody towards Zfp106. Using this to identify Zfp106 in the heart and 
testes showed a band running at 170kDa and 210 kDa respectively. 
Altogether, more work needs to be conducted to better understand the splice variants of Zfp106. 
The current knowledge is limited to focusing on the N-terminus of the protein and understanding 
the splice variant regulation of Zfp106 would be beneficial for designing in vivo models 
manipulating the gene as well as elucidating its function. 
Localization of Zfp106 
Zfp106 localization was found to be cell type dependent. Zfp106 is expressed in the nucleolus 
during proliferation as well as in nuclear speckles adjacent to the spliceosome machinery11,12. 
Zfp106 is thought to be targeted to the nucleus through a bipartite nuclear localization domain in 
exons 6 and 711,12. Zfp106 is sequestered in the nucleolus by a protein-protein interaction with 
lysine rich nucleolar protein (KNOP1 also known as TSG118) which binds the final 500 amino 
acids (containing the beta-propeller and C-terminal zinc fingers) in Zfp106’s C-terminal 
domain11,12. The dependence of the localization of Zfp106 on this protein-protein interaction meant 
that the down regulation of KNOP1 was found to release Zfp106 from the nucleolus into the 
cytoplasm when C2C12 cells are differentiated from myoblasts to myotubes, although this finding 
was not replicated by another study11,12. The localization of Zfp106 in Cos7 cells is dependent on 
RNA transcription when it is not co-expressed with TSG118. Without TSG118, GFP-Zfp106 was 
found to be expressed in a nuclear speckle pattern. This localization is dynamic and dependent on 
pre mRNA transcription. The use of 5,6-dichloro-1-β-Dribofuranosylbenzimidazole (DRB), which 
inhibits RNA polymerase II elongation, leads to the reversible translocation of Zfp106 to the 
nucleolus dependent on DRB.  
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The change in the localization of Zfp106 suggests that it may play different roles dependent on the 
presence or absence of binding proteins and the differentiation state of the cells. Together with the 
variable isoform expression, Zfp106’s role in human physiology may be dynamic and may respond 
to the demands and state of the cells expressing the protein. 
Zfp106 interactions and functions 
The role of Zfp106 has not yet been determined. However, it has been implicated in the insulin 
pathway and the RNA spliceosome. The change in the protein motifs, timing of expression, and 
type of tissue each isoform is expressed in points to the possibility that they may have variable 
roles depending on the type and state of the cell it is expressed in6. 
Protein-Protein interactions 
Through yeast two hybrid screening, the N-terminal 500 amino acids of Zfp106 was found to bind 
RBM39 while the C-terminal 500 amino acids binds TSG11811,12. The interaction between Zfp106 
and RBM39 was confirmed in Cos7 cells through the immunoprecipitation of the overexpressed 
epitope tagged Myc-N-terminal 500 amino acids of Zfp106 with HA-RBM39. TSG118 binding 
was supported in mammalian cells through the co-precipitation of Myc-TSG118 and XP-Zfp106 
in HeLa cells. Through affinity purification-mass spectrometry, 3xFLAG-2x-STREP-Zfp106 was 
found to interact with TDP-43, FUS, Nucleolin and NUP 107 in HEK293T cells. Anti-Flag-Zfp106 
immunoprecipitation confirmed its interaction with TDP-43 and FUS in Neuro2a cells.  
The SIRM (Sh3bp3) isoform of Zfp106 was found to interact with Grb2 and Fyn kinase in a 
differentiation and insulin dependent manner. When NIH3T3-L1 cells were differentiated into 
adipocyte-like cells SIRM was found to bind both proteins, an association which is disrupted in 
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response to insulin treatment9. Zfp106 was also found to be a potential target for phosphorylation 
for Fyn kinase and the insulin receptor tyrosine kinase9. 
IGF-1R/InsR pathway 
Zfp106, originally investigated under the name SIRM, was discovered due to its increased 
expression in the liver extracts of IR-/- mice8,9. From this study, it was determined that Zfp106 is 
modulated by insulin. Zfp106 was found to be expressed in insulin-responsive tissues like the heart 
and skeletal muscle, brain, kidney, and liver. Zfp106 expression decreased in SV40 transformed 
hepatocytes from WT and IR-/- mice in response to insulin9. Zfp106 was also found to bind to Grb2 
and Fyn kinase, proteins which have been found to be involved in the insulin signaling cascade13,14. 
Altogether, the preferential expression of Zfp106 in insulin sensitive tissues and its interaction 
with Grb2 and Fyn kinase supports its involvement in the insulin receptor pathway. Of note, the 
original mapping of SIRM was wrong and, correcting for this, was determined to be an P2-family 
Zfp106: Sh3bp35.  Despite the incorrect mapping of SIRM, it is believed that the original findings 
from this study holds true for a splice variant of Zfp1065,6.  
Reinforcing its potential role in metabolic health, recent genome wide association analysis of the 
Arab population supports the role of Zfp106 in metabolic variation15. In their study a single 
nucleotide polymorphism (SNP) W>R mutation in ZNF106, the human homologue of Zfp106, 
was identified as a risk variant associated with increased glycated hemoglobin (HbA1c) at a close 
to genome-wide statistical significance15. 
RNA spliceosome 
The localization of Zfp106 to the nucleolus together with the presence of zinc-finger motifs 
prompted the investigation of its ability to bind nucleic acids. Zfp106 was identified in a screen 
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for polyA mRNA-binding proteins16. To see if Zfp106 can directly bind RNA, an individual-
nucleotide resolution Cross-Linking and ImmunoPrecipitation (iCLIP) assay was performed using 
C- or N-terminally TY1 epitope tagged Zfp106 in Neuro2a cells12. This assay uses UV light to 
bind proteins with RNA17. From this a Zfp106-RNA band was detected supporting ability to bind 
RNA. Using end-targeting proteomics of isolated chromatin fragment (ePICh), ZNF106 (the 
human orthologue of Zfp106) was found to regulate ribosomal RNA transcription initiation by 
recruiting RNA polymerase I to the rRNA promoter region18. In Cos7 cells the localization of 
Zfp106 (without TSG118) fluctuates between a nuclear speckle pattern and the nucleolus 
dependent on RNA transcription12. 
Pathogenic GGGGCC repeats 
Zfp106 has been shown to bind, and is potentially sequestered by the multiple GGGGCC repeats 
of a pathogenic variant of C9ORF72 linked to familial ALS2,19. Pulling down biotinylated 
r(GGGGCC)8 RNA identified Zfp106. This was supported through the use of electrophoretic 
mobility shift assay (EMSA) showing Zfp106 can bind specifically to r(GGGGCC)8. This together 
with the data regarding Zfp106’s interaction with TDP-43 and FUS, implicating it in the 
spliceosome machinery, may mean that Zfp106 is sequestered by the pathogenic repeats which 
could impair its function2. Supporting its ability to bind GGGGCC repeats, the co-expression of 
Zfp106 rescued the pathology associated with the overexpression of (GGGGCC)30-GFP in 
drosophila. In this study, Gal4-UAS driven expression of (GGGGCC)30-GFP in the glutamatergic 
neurons in drosophila caused a 50% lethality due to a failure to eclose from the pupal phase and 
neurological issues in the surviving flies. In addition to this, the overexpression of (GGGGCC)30-
GFP leads to reduced neuromuscular junctions measured by anti-brunchpilot (Brp) 
immunofluorescence and quantification. Interestingly murine Zfp106 co-expression with the 
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pathogenic (GGGGCC)30-GFP in was found to fully suppress the lethality associated with 
(GGGGCC)30-GFP overexpression and partially rescued the locomotor and Brp effects2.   
Zfp106 and the Minor Histocompatibility complex 
The histocompatibility complex helps the body distinguish self from non-self. Major 
histocompatibility complex class I and class II proteins present peptides to the cell surface for 
identification by T-cells20. Minor histocompatibility antigens are peptides bound to the major 
histocompatibility complexes that act as alloantigens. The incompatibility of the minor 
histocompatibility of the donor and recipient can cause tissue rejection despite efforts to match the 
major histocompatibility21,22. Zfp106 is implicated in the minor histocompatibility complex as the 
H3a gene responsible for the immunodominant H2-Db-restricted complex of the mouse autosomal 
H3 complex5. This means, that polymorphisms of the Zfp106 gene between organ transplant 
donors and recipients can lead to graft rejection23.  Supporting its role as a minor histocompatibility 
antigen, Zfp106 single nucleotide polymorphisms in the gene has leading to donor-recipient 
incompatibility has been found to lead to corneal transplant rejection in both swine and mouse24,25. 
Zfp106LacZ KOMP KO mouse 
The knockout mouse project (KOMP) is a program conducted by the International Mouse 
Knockout Consortium with the goal of individually mutating and disrupting all protein-encoding 
genes in the mouse genome through gene trapping or gene targeting26. In a gene-trap, a flippable 
splice acceptor followed by a LacZ and neomycin resistance cassette and a polyA tail was inserted 
after exon 2 (Zfp106 coding exon 1)27-29. In addition to the gene-trap, exon 3 (Zfp106 coding exon 
2) is flanked by two LoxP sites. After the removal of the gene trap, cre recombination results in 
tissue specific depletion of exon 3 which leads to a frame shift and transcription of a premature 
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stop codon. One of the in vivo mouse models developed by KOMP was Zfp106lacZ (Figure 4). This 
was briefly described as a mouse model with muscular abnormalities30.  
The effect of the gene-trap was assessed in the Zfp106LacZ homozygous and heterozygous mice. 
As there is no reliable antibody towards murine Zfp106, the levels of Zfp106 in the mouse model 
was measured using RNA-seq, northern blot and quantitative RT-PCR (qPCR) techniques in both 
skeletal muscle and spinal cord. In the spinal cord, Zfp106LacZ homozygous mice showed ~20% 
expression via RNAseq and anywhere between 0.4% to 20% using qPCR2,7. The large difference 
in these levels may be due to the primers used to measure Zfp106 expression. However, only one 
publication explicitly disclosed that their qPCR primers align to exons 21-22 while the other does 
not, so this is difficult to tell22. In the skeletal muscle, the Zfp106LacZ mice have a 15-20% 
expression by qPCR as measured by amplifying Zfp106 exons 4-512. 
Zfp106LacZ characterization 
After the mouse model was developed, three publications exploring and characterizing this 
knockout mouse model were released. The researchers agree that the Zfp106LacZ homozygous mice 
demonstrate a progressive neuromuscular disease noticeable beginning at 4 weeks2,7,12. As the 
disease progresses, the mice show signs of kyphosis and tuck their limbs in when picked up by 




their tail2,7,12. The mice die prematurely due to an inability to thrive by week 15 at the earliest and 
6 months at the latest2,7,12. The discrepancy between the two endpoints is that the 15-week endpoint 
is thought to be the humane end point, set as the time in which the animal has lost 20% of its peak 
body weight or when they are unable to right themselves within 20 seconds after being placed on 
their side, while the 6-month end point may be the natural endpoint of the mice4,9. Importantly 
Zfp106LacZ heterozygous mice show no phenotype and there was no gender difference in both 
heterozygous and homozygous mice7.  
Body weight measurements vary. In one study, 3-week old female homozygous mice are 
significantly lighter than WT controls and this difference progressively widens until 15 weeks2,7. 
Another study did not find any difference at 4 months of age12. Importantly, heart weight was not 
significantly different in Zfp106 homozygous mice12.   
Characterizing the behavioral phenotypes of the mice, female Zfp106LacZ homozygous mice were 
found to have decreased grip strength and rotarod performance at 6- and 13-weeks. Using a 
SHIRPA screen, which is a phenotypic screen that focuses on analyzing neurological function in 
6-week female homozygous mice, ~66% show signs of mild to moderate tremors, >50%  have 
limb grasping defects and all the mice have severely impaired wire hanging abilities and are unable 
to maintain a grip when made to walk down a vertical wire7,31. Assessing the mice in an open field 
paradigm for 30 minutes, Zfp106LacZ homozygous mice showed a progressive decline in the 
amount of distance and time spent moving from 7- to 14-weeks7. Measuring the mice using a 
Locotronic system, homozygous mice show significantly more front and rear leg errors vs. WT 
controls, a trend which increases significantly by 14 weeks7. Overall, the homozygous mice show 
muscle weakness with neurological symptoms. 
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As the Zfp106LacZ homozygous mice have severe muscle atrophy, the neuromuscular system was 
characterized. The neuromuscular system involves the brain, motor neurons, sensory neurons and 
skeletal muscle fibers32. A dysfunction in one part of the system can deleteriously affect the other 
parts. Of note, as the brain of Zfp106LacZ homozygous mice were determined to be unaffected by 
the end point, the studies focus on the other parts of the system7,12.  
Skeletal Muscle  
The skeletal muscle of Zfp106LacZ homozygous mice have decreased function. At 15 weeks of age, 
the isometric force of fast-twitch muscles tibialis anterior (TA) and extensor digitorum longus 
(EDL) of the homozygous mice show a decrease in maximum force of 75% and 50% respectively7. 
The decrease in force is accompanied by a lessening of motor units noticeable by 7 weeks of age. 
Interestingly, the EDL muscle are progressively more fatigue resistant with 15 week old 
homozygous mice showing ~66.7% more fatigue resistance compared with controls7. TA, EDL, 
gastrocnemius and soleus muscles are lighter in homozygous mice compared with controls at 16 
weeks. Staining and imaging of skeletal muscle shows ~80% atrophy, increase in nuclearity and 
fibrosis by 14 weeks2,7. NADH-TR and ATPase staining shows an increase in type 1 fibers in the 
gastrocnemius and soleus. Soleus muscle have an increase in fiber size variation with fewer overall 
fiber number7. At 16 weeks, there are signs of myofiber atrophy with an 80% decrease in average 
cell surface area (CSA). Additionally, there was the presence of pseudohypertrophied and 
regenerating myofibers with centralized nuclei. Using transmission electron microscope showed a 




The sensory system of Zfp106LacZ homozygous mice was studied by histology focusing on the 
L4/L5 dorsal roots of 15-week old female mice. Compared with WT controls, there is a loss of 
large and small myelinated and unmyelinated sensory axons with no evidence of axonal 
regeneration or demyelination. L4 and L5 dorsal root ganglia (DRG) of homozygous mice were 
smaller compared with WT littermates7. 
Motor Neurons 
The motor neurons of Zfp106LacZ homozygous mice were studied. Toluidine blue staining of L4/L5 
ventral roots show a loss of fibers with no clear signs of regeneration and demyelination7. The 
number of motor neurons in the sciatic pool of the lumbar spinal cord (L3-L6) was reduced by 
35% and 50% in 7- and 15-week old mice respectively7. At 2-weeks of age, transverse sections of 
sciatic nerves showed a slight reduction in overall bundle diameter while myelination and motor 
nerve axon diameters are grossly normal7.  At 16-weeks, the axon diameters in the sciatic nerves 
are reduced. Choline acetyl transferase (ChAT) stains of showed a significant decrease in the 
number if ChAT+ cells with a concurrent increase in microglia and active astrocytes2,12.  
Neuromuscular Junction 
The neuromuscular junction was visualized through the use of α-bungarotoxin staining the motor 
end plate and α-syntaxin1 staining the presynaptic nerves and nerve terminals. One day after birth 
(P1) there was no change compared with controls. At 4 and 16 weeks there are signs of progressive 
denervation with end plates lacking nerve terminal juxtaposition. Additionally, the morphology of 





Transcriptional regulation changes in Zfp106LacZ mouse models 
Analysis of the pathways affected by in the Zfp106LacZ homozygous mice through RNA-seq, the 
spinal cord of 6-week Zfp106LacZ homozygous mice show changes in numerous pathways 
including inflammatory response, immune cell trafficking, and cell motility7.  Microarray data 
from hindlimb skeletal muscle showed an up-regulation of the alpha and embryonic isoforms of 
acetylcholine receptors (Chrna1 and Chrng) and aldehyde dehydrogenase 3 family member A1 
(Aldh3a1) which protects against oxidative stress. Assessing both skeletal muscle and spinal cord, 
there are several genes that are dysregulated in both systems that are also changed in mouse models 
of Amyotrophic Lateral Sclerosis (Lgals1, Lgals3, Gpnmb, and Hsb1) and Charcot-Marie-Tooth 
(Mpz, Pmp22, Hspb1, Prx)12. However, there were no pathological features that are usually 
associated with motor neuron disease like the mislocalization of TDP-43, FUS or increase protein 
ubiquitination and autophagy12. 
Disfunctions identified in the Zfp106LacZ mouse model 
Mitochondrial Dysfunction 
Zfp106LacZ homozygous mice were found to have a mitochondrial dysfunction in primary motor 
neurons isolated from Zfp106lacZ mice. Using a tetramethylrhodamine (TMRM) assay they 
observed that the mitochondrial membrane potential (Δψm) was hyperpolarized33. Dosing the 
primary cells with oligomycin, an F1Fo-ATP synthase inhibitor, led to a decrease in the Δψm 
evidencing the cells’ dependence on ATP to maintain the mitochondrial membrane potential. This 
deviates from the expected dependence on oxidative phosphorylation34. Then, targeting the redox 
state of NADH or FAD as a measure of respiratory chain activity and the rate of substrate supply, 
they determined the redox index, a ratio of the maximally oxidized (response to FCCP) and 
21 
 
maximally reduced (response to NaCN) signals. From this they found that the redox index of 
NADH was significantly increased in homozygous Zfp106LacZ homozygous motor neurons. 
Together, the accumulating substrate and increased redox index of the homozygous motor neurons 
suggested that Zfp106 deficiency leads to the inhibition of the NADH-dependent Complex I. 
Additionally, there was a decrease in FAD++ levels as the cells rely more heavily on Complex II. 
Altogether, these experiments support the notion that the Zfp106lacZ genetic modification leads to 
an inhibition of mitochondrial Complex I and a hyperpolarization of the Δψm leading to an increase 
in reactive oxygen species and neuronal death7,35.  
Splicing changes 
In neuro2a cells, Zfp106 was found to be able to bind RNA through a UV-crosslinking assay 
iClip36. The C-terminal 500 amino acid regions of Zfp106 were found to bind RBM39 (a protein 
associated with alternative splicing)12,37,38. From this, the authors hypothesized that the lack of 
Zfp106 in vivo leads to muscle atrophy due to a dysfunctional RNA spliceosome. Zfp106’s role in 
the RNA spliceosome machinery is further supported by its ability to bind RNA as well as recruit 
RNA polymerase I to the RNA12,18. Supporting this, the missing protein causes a shift in the 
isoforms of NOGO that are expressed, resulting in the  overexpression of NOGO-A, a neurite 
outgrowth inhibitor in skeletal muscle that can lead to myofiber denervation39,40. This increase in 
NOGO-A may be one of the factors contributing to the dysfunctional NMJ and muscle atrophy 
observed in the Zfp106LacZ mice. 
Zfp106LacZ rescue 
A transgenic mouse line aimed at rescuing the muscle atrophy phenotype of Zfp106LacZ by 
overexpressing Zfp106 specific to the motor neuron was developed (MNX-1 driven expression of 
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3xFLAG2xSTREP N-terminally tagged full length Zfp106)41-43. When crossed with the 
homozygous Zfp106LacZ/LacZ mice, the resulting progeny were reported to have a less severe muscle 
wasting phenotype and a stronger grip strength2. Of note, this rescue was not a complete rescue 
even though the transgenic mouse line led to the overexpression Zfp106 to 1.5-2.0 times higher 
than the amount of Zfp106 in the spinal cord of wild type mice2. This partial rescue supports the 
hypothesis that Zfp106 plays an important role in the health of the motor neurons but may also 
point to Zfp106 having an important in another tissue. 
Other Zfp106 Mouse Models 
A clustered regularly interspaced short palindromic repeats (CRISPR) based mouse model by 
targeting exon 2 of Zfp106 causing an INDEL that led to a premature stop codon through non-
homologous end joining (NHEJ)44-48. It is reported that this model recapitulates the muscle atrophy 
phenotype observed with Zfp106LacZ mice2. 
Objective of this work 
This study focuses on Zfp106 and aims to better understand its function and role in vivo through 
the analysis of its two main promoter-led isoform families P1 and P2. The first part of this project 
focuses on the in vivo effect of the depletion of Zfp106 through the Zfp106lacZ mouse model 
developed by the knockout mouse project (KOMP). However, this model is not a true knockout, 
as the gene trap placement does not interrupt the P2 isoform initiated from a secondary promoter. 
In fact, the gene-trap was found to increase the expression of the P2-specific start exon, exon 1b, 
in skeletal muscle. To assess whether the muscle atrophy phenotype of the Zfp106LacZ model needs 
both the disruption of P1-Zfp106 family isoforms and an increase of P2-Zfp106 isoforms, we 
developed ΔZfp106. ΔZfp106 is a mouse model carrying an INDEL in exon 5 which should 
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prevent the translation of both the P1 and P2 full length isoforms. Therefore, the P2 full length 
isoform cannot become overexpressed in contrast to what is observed with the Zfp106LacZ mouse 
model.  
A subsequent attempt to understand whether the atrophy observed in the Zfp106LacZ mouse model 
is due to a disruption of the P1 isoform in cholinergic neurons, muscle or both. This was tried 
through the tissue specific deletion of exon 3, unique to the P1 isoform, that leads to a frame shift 
and premature stop codon to see if this would recapitulate the muscle atrophy seen.  
Lastly, we studied the effect of the in vivo deletion of the P2 isoform family of Zfp106 by using 
CRISPR Cas9 to cause a non-homologous end joining (NHEJ) event into exon 1b, the start exon 
specific to the P2 isoforms. The NHEJ event led to an INDEL that causes a premature stop codon 
in mouse embryonic stem cells (mESC). These altered mESCs were then used to establish a P2 
deletion mouse model (ΔP2).  
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Chapter 1.3.1: Characterization of the KOMP Zfp106LacZ mice 
Introduction 
Homozygous Zfp106LacZ mice develop severe non-developmental muscle atrophy noticeable by 
4-weeks of age leading to a premature death due to an inability to thrive by approximately 16 
weeks2,7,12. These mice have a dysfunctional neuromuscular system with abnormalities with the 
sensory and motor neurons, the neuromuscular junction, and muscle2,7,12. The cause of the muscle 
atrophy is thought to be stemming from motor neuron loss although the depletion of the protein 
may be contributing to a myopathy as well7,12. The following study examines the effect of the 
Zfp106LacZ gene-trap in vivo with a focus on skeletal muscle. This focus was done as the expression 
of Zfp106 is high in this tissue and we originally hypothesized that its depletion would lead to a 
disruption here primarily6,9. Much of this work characterizing the mouse model was conducted 
before the publication of the other analyzing the effect of Zfp106 depletion on motor neuron health.  
Skeletal muscle homeostasis is established through a balance between protein synthesis and 
degradation49. Hypertrophy results when there is a higher rate of anabolism as compared to 
catabolism. Conversely, when the rate of protein degradation is higher, the muscle atrophies50. 
This equilibrium can be disrupted by various factors including a change originating from the 
muscle itself (myopathy), an alteration in the neurons innervating the muscle (neuropathy), as well 
as a disturbance in the NMJ (myasthenia)51. 
Unhealthy and dying motor neurons have been shown to lead to muscle atrophy through 
denervation. The specific classification of the disease is dependent on the population of the neurons 
affected52. Amyotrophic lateral sclerosis involves the degeneration of both the upper and lower 
motor neuron53. Primary lateral sclerosis is a disorder concentrated on the upper motor neuron 
while progressive muscular atrophy involves the lower motor neurons54,55. The loss of innervating 
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motor neurons leads to the denervation of skeletal muscles abolishing the signaling needed to 
maintain muscle activity and health leading to muscle wasting52. Previous studies have shown a 
significant loss of motor neurons in the Zfp106LacZ mouse model and is thought to be the primary 
pathology leading to muscle atrophy in the homozygous mice2,7,12. 
The interaction between the nervous system and the skeletal muscle occurs in the synapse forming 
the neuromuscular junction (NMJ). NMJ are specialized synapses form between the innervating 
motor neuron and the innervated muscle fibers56. Here, acetylcholine released by innervating 
neurons binds and activates the acetylcholine receptors in the muscle leading to the depolarization 
of the muscle fiber triggering the contraction of the muscle. Diseases primarily affecting the 
neuromuscular junction are classified as myasthenia.  However, because the NMJ serves as a link 
between the innervating neuron and the skeletal muscle, the health of the NMJ can be affected by 
both tissues56. In humans, myasthenia gravis is the loss of control of muscle function due to the 
patient’s immune system attacking their own acetylcholine receptors, compromising the NMJ57. 
This disruption of signaling can lead to the loss of the feedback loop between motor neuron and 
muscle compromising the health of both tissues ending in neuronal fiber contraction and muscle 
atrophy58.  
Myopathies leading to muscle weakness can be caused by a loss of muscle fiber or a channelopathy 
that alters function without fiber death59. Focusing on the muscle fibers, fiber size and health is 
governed by the balance between anabolism and catabolism. This is in large part maintained by 
the IGF/insulin pathway, patently by the IGF/Insulin-PI3K-Akt Signaling cascade60. The 
activation of Akt resulting from IGF/insulin receptor (IGF-R/Ins-R) ligand binding leads to the 
activation of mammalian Target of Rapamycin (mTOR) which increases protein synthesis61. At 
the same time, in the cytoplasm of the skeletal muscle, Akt phosphorylates and sequesters FoxO 
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thereby inhibiting its function and reducing the rate of protein degradation62. The FoxO family 
stimulates the expression of atrogenes involved in the ubiquitin-proteasome complex and the 
autophagy-lysosome pathway which increases the rate of protein degradation63.  Altogether, the 
IGF-1R/insulin pathway has been heavily implicated in muscle homeostasis, growth, and atrophy. 
This is exemplified by a recent study using skeletal muscle specific IGF-1R/Insulin-R KO mice 







Analyzing ZNF106 (the human orthologue of Zfp106) expression in human tissues and cells, we 
found that it is present in excitable and insulin-sensitive tissues like the heart and skeletal muscle 
(Figure 5A), confirming previous findings6,9,12. Non-excitable tissue like the lung, liver and spleen 
did not have any detectable amounts of Zfp106 although previous studies point to its expression 
in the murine liver9. To profile Zfp106 expression in further detail and confirm previous studies 
linking Zfp106 upregulation to the terminal differentiation of myoblasts into myotubes, we 
examined the effect of differentiation on its transcription. As originally observed, Zfp106 
expression increases with the differentiation of myoblasts to myotubes (Figures 1 and 5B)6,12. 
Zfp106 expression was also found to increase in human induced pluripotent stem cells and 
differentiated cardiomyocytes, confirming the conservation of the trend of increased Zfp106 






Figure 5 ZNF106/Zfp106 expression.  
A) Tissue specific ZNF106 expression in various human tissues.  
B) Zfp106 expression in myoblasts and myotubes (** p<0.01, mouse primary myoblast, n=9 and 
differentiated myotube at day 7, n=9, ** p<0.01 using unpaired Student’s t-test mean ± S.D.).  
C) ZNF106 expression in induced pluripotent stem cells (iPSC) and myocytes (* p<0.05, human 
iPSC lines, n=7 and differentiated myocytes at day 19, n=7, mean ± S.D.).  
Acknowledgement: Dr. Masayuki Yazawa for the RT-PCR ZNF106 tissue expression experiment. 
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Zfp106LacZ mice display severe muscle atrophy 
The KOMP knockout mouse project employed the gene-trap technique to disrupt the expression 
of Zfp106 (Figure 4)26-29. Zfp106LacZ/+ heterozygous mice have no muscle atrophy and live until 2 
years without any neuromuscular pathologies (Data not shown)7. Homozygous Zfp106LacZ/LacZ 
mice are born in normal mendelian ratios.  The mice display initial signs of muscle weakness by 
week 4, leading to early mortality by week 16 due to an inability to thrive. At 8 weeks old, the 
mice have severe skeletal muscle atrophy and can no longer extend their hind limbs when 
suspended by their tail (Figures 6A and 6B). Both male and female mice were found to have an 
overall decreased body weight at 8 weeks compared to controls, a trend which grew more severe 
by the 16-week time point (Figures 6C and 6D). As a measure of the muscle strength of the 
homozygous Zfp106LacZ/LacZ mice, they were subjected to an inverted screen test. Here the mice 
are induced to hang upside down on an inverted cage wire-rack. They are then scored based on the 
amount of time they are able to hang on with a maximum allotted time of 1 minute. While most 
mice are able to complete this task successfully at 8 weeks, the homozygous mice are unable to 
carry their body weight. All of the homozygous mice lose their grip and fall when the wire rack is 
rotated past 90° while control mice were able hold on until the termination of the test at 1 minute 





Figure 6 Characterization of Zfp106LacZ mice. 
A) Photograph of control (Ctrl) and homozygous (Hom) mice showing hind limb atrophy. 
B) Photograph of control (heterozygous, Het) and Hom mice. 
C) Body weight of male and female mice at 8 week old (**P<0.01 using unpaired two-tailed 
student’s t-test, male Ctrl n=10; Hom n=7; female Ctrl n=13; Hom n=7, mean ± s.e.m.). 
D) Body weight of control and mutant mice at 4, 8 and 16 weeks of age (***P<0.005 using 
unpaired two-tailed student’s t-test, n=11, 35, and 9 for Ctrl and n=7, 26 and 9 for Hom, 
respectively, mean ± s.e.m.). 
E) Inverted screen test score at 8 weeks old (Ctrl n=5; Hom n=3). 
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To determine if the difference in the body weight of the Zfp106LacZ/LacZ mice was mirrored in their 
skeletal muscles, three hindlimb muscles (gastrocnemius, extensor digitorum longus (EDL), and 
soleus) were harvested and weighed. Qualitatively, the homozygous mouse muscles were 
noticeably smaller than the WT and Heterozygous counterparts (Figure 7A). This is recapitulated 
in the weights of all three muscle types in both male and female mice at 8 weeks as compared with 
controls (Figures 7B and 7C).  To assess how the muscle mass changes over time, Zfp106LacZ/LacZ 
homozygous hind-limb muscle weights were compared at three time points: 4 weeks, 8 weeks, and 
16 weeks of age and compared with controls. These ages were chosen because 4 weeks is the onset 
of the muscle weakness, 8 weeks is the time point of significant muscle atrophy, and 16 weeks the 
terminal time point for this mouse model. At week 4, there is no significant discrepancy in muscle 
mass (measured by gastrocnemius muscle weight). By week 8, the homozygous mouse muscles 
are significantly lighter an effect amplified by week 16 (Figure 7D). Supporting the previous 
observations of the Zfp106LacZ mouse model, the body and muscle weight characterizations 
demonstrate that Zfp106 deficiency leads to severe muscle atrophy with no obvious consequence 
in either the prenatal or early postnatal development of the skeletal muscle7. Given the timing of 
the muscle atrophy, Zfp106 may be important in the maintenance of the muscle homeostasis 
system. Beginning at week three, the skeletal muscles switch to a hypertrophy-dependent stage 
rather than growing from myonuclear accretion. This switch to reliance on hypertrophy may 
highlight the potential role of Zfp106, as it is at this point that the initial signs of skeletal muscle 




Examination of Skeletal Muscle Fibers 
Muscle fibers, categorized by the myosin heavy chain isoforms (MyHC) they express, respond to 
various stresses differently. Broadly, type I slow twitch muscle fibers are more sensitive to 
denervation while type II fast twitch muscle fibers are more vulnerable to diabetes and aging66,67. 
Of note, fast twitch muscle fibers degenerate first in models of ALS, showing a fast to slow fiber 
type switch in SOD1 mice68,69 Therefore, the Zfp106LacZ/LacZ homozygous mouse hindlimb muscle 
fiber types, compositions, and sizes were measured to better understand the nature of the muscle 
atrophy present in the Zfp106LacZ mouse model. The experimental goal of which was to determine 
whether the muscle atrophy was fiber-type specific or if it affected both the fast and slow twitch 
fibers to the same extent. Skeletal muscle histology using ATPase staining was conducted to 
identify fast- and slow-twitch muscle fibers in the EDL and soleus of control and Zfp106LacZ/LacZ 
homozygous mice (Figure 8A). Quantification of the fiber composition showed no significant 
Figure 7 Skeletal muscle measurements of Zfp106LacZ mice.  
(A) Comparison of muscle sizes of Gastrocnemius, EDL and soleus muscles of 8 week mice.  
(B) Muscle weight of gastrocnemius muscle of male and female mice at 8 week old (** p<0.01, 
Ctrl vs KO, mean ± s.e.m.). 
(C) Muscle weight of soleus and EDL muscles at 8 week old (* p<0.05, Ctrl vs KO, mean ± s.e.m. 
using unpaired Student’s t-test, Ctrl vs. KO mice). 
(D) Gastrocnemius muscle weight of control and KO mice at 4, 8 and 16 weeks of age (n=11, 35 
and 4 for Ctrl and n=7, 26 and 5 for KO, respectively. *** p<0.0001 by two-way ANOVA, Ctrl 
vs. KO, mean ± s.e.m.). 
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change between control littermates and Zfp106LacZ mice in the muscle composition of either fiber 
types in both the soleus and EDL muscles (Figure 8B). On the other hand, the cell surface area 
(CSA) of the muscle fibers are significantly decreased in the Zfp106LacZ/LacZ homozygous mice for 
both fiber types in the soleus and EDL muscles (Figure 8C).  
To further characterize the muscle effect of the Zfp106LacZ model on skeletal muscle fibers, the 
population distribution of the CSA of either fiber types was examined. This more granular 
Figure 8 Skeletal Muscle Histology of Zfp106LacZ.  
A) Representative images of ATPase stain of the soleus and EDL muscles of control (Ctrl) and 
KO mice. Scale bar, 100µm. 
B) Quantification of fast- and slow-twitch fiber type in soleus and EDL muscles of Ctrl and KO 
mice. Sample numbers for each are shown on the bar graphs (n.s. not significant using unpaired 
Student’s t-test mean ± s.e.m.). 
C) Cell Surface Area (CSA) of fast- and slow-twitch fiber types in soleus and EDL muscle of Ctrl 
and KO mice. (Ctrl Soleus Fast, n=198 fibers; Hom Soleus Fast, n=248 fibers; Ctrl Soleus Slow, 
n=314 fibers; Hom Soleus Slow, n=279 fibers; Ctrl EDL Fast, n=185 fibers; Hom EDL Fast, n=199 
fibers; Ctrl EDL Slow, n=215 fibers; Hom EDL Slow, n=170 fibers;  *** p<0.001 using unpaired 
Student’s t-test, Ctrl vs. KO mice. n.s. not significant, mean ± S.D.). 




dissection may evidence changes in the skew or modal distribution of the fibers which can help 
describe what underlies the decrease in the average CSA70. It may be that the smaller average CSA, 
as compared with controls, is due to an appearance of a smaller subpopulation with or without an 
alteration of the larger fiber types which therefore appears as a bimodal distribution. Otherwise, 
the decrease in CSA may be due to an overall shift in the muscle fiber sizes with the distribution 
of the muscle fiber sizes shifting to the smaller end due to the lack of Zfp106. The population 
distribution of the Zfp106LacZ/LacZ homozygous mouse muscle fibers shows a unimodal distribution 
for both homozygous and control mice (Figure 9A). There is a decrease in the median and mean 
of the homozygous mice compared with controls. (Figure 9B). This is coupled with an increase in 
the range of the homozygous mice, for all except the slow twitch EDL fibers in the homozygous 
mice, where there was a decrease in the interquartile range (IQR). This means that there is an 
increase in the overall spread of the population of the muscle fiber sizes and a decrease in the 
distribution of the middle 50% of the population. The skewness of the populations shows an 
increase in the proportion of smaller fibers in both fiber types of the soleus muscle and the slow 
twitch fiber of the EDL in the homozygous Zfp106LacZ/LacZ mice. Interestingly, the fast twitch EDL 
muscle fibers have a normal skew, meaning that the data do not lean heavily toward smaller or 
larger fiber sizes. Overall, the decrease in fiber size is due to an overall shift towards smaller 




Figure 9 Skeletal muscle fiber size distribution. 
A) 8-week old mouse soleus or EDL muscle fiber distribution. 
B) Table of the descriptive statistics of the 8-week muscle fibers. ***P≤0.01 using the F-test to 




Ultrastructure of Zfp106LacZ skeletal muscle 
Examining the ultrastructure of the affected skeletal muscle is useful in informing the potential 
causes of muscle atrophy. Abnormalities including vacuoles, myofibillar disorganization and 
inclusion bodies can result from dysfunctions in the lysosome, myosin chain expression, and the 
presence of nemaline myopathy respectively71,72.  Using electron microscopy analysis, we 
observed no difference in the ultrastructure of the 16-week old skeletal muscles as compared with 
control littermates (Figure 10). The data shows a non-fiber specific muscle atrophy that does not 
disrupt the sarcomeric and mitochondrial organization of the skeletal muscle. 
Neuromuscular Junction of Zfp106LacZ mice 
Figure 10 Representative electron microscope images of gastrocnemius muscle of 16 
week old WT and Homozygous mice. 
Acknowledgement: Dr. Masayuki Yazawa and Yoko Yabe for muscle harvest. Dr. Shinji 
Komazaki for the electron microscope imaging. 
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The neuromuscular junction (NMJ) of the Zfp106LacZ mouse model was studied next. The NMJ 
acts as the communication hub between the innervating motor neurons and the innervated muscle 
fibers. As such, a dysfunction in the NMJ can lead to muscle atrophy or neuronal death56. To study 
the NMJ, the gastrocnemius muscle was harvested from both control and homozygous mice at 6, 
8, and 16 weeks. These times were chosen to assess the progression of muscle atrophy from near-
onset to near-end point. By 6 weeks, the mice show signs of muscle atrophy and it would be of 
interest to examine if the NMJ health is already compromised by this age.   
The acetylcholine receptors (AChR) were imaged using bungarotoxin while the innervating 
neurons were imaged by through a neurofilament stain (Figure 11A). At 6 weeks the 
Zfp106LacZ/LacZ homozygous mice have a significantly higher proportion of non-innervated and 
collapsed post synapses (Figures 11B and 11C). This phenotype gets progressively worse and the 
muscle atrophy increases in severity as the mice age until the terminal time point of 16 weeks 
(Figures 11 A-G). Importantly, previous studies found that at 4 weeks of age, the NMJ displays 
end plates lacking nerve terminal juxtaposition in the Zfp106LacZ homozygous mice12. This 
suggests a disrupted neuromuscular junction is apparent before the onset of muscle atrophy which 
prevents the proper communication between the innervating motor neurons and the skeletal 
muscle. Although the NMJ and the skeletal muscle show evidence of degradation, it is still difficult 
to identify the key tissue affected by Zfp106 depletion given how each component of the 
neuromuscular system may affect the signaling needed to maintain the structure of the NMJ and 
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Changes in protein expression and activation involved in muscle homeostasis 
Muscle atrophy is due to an imbalance in protein homeostasis; an increase in catabolism without 
a compensatory increase in anabolism leads to muscle loss74. The markers for both cellular 
functions were measured using quantitative RT-PCR (qPCR). For this study, we focused on the 
change in traditional anabolic pathway markers, myogenin and myostatin, as well as ribosome 
biogenesis markers: RPS6kb1 and RN45S60,75-78.  We also investigated the ubiquitin-proteasome 
pathway through E3 ubiquitin ligase Muscle RING finger 1 (MuRF) and the proteosomal proteins, 
proteasome subunit alpha (psmA) and 26S proteasome non-ATPase regulatory subunit 11 
(PSMD11)79,80.  The homozygous Zfp106LacZ/LacZ mice showed an upregulation of factors involved 
in both protein synthesis and degradation. There was an 59x increase in the transcription of the 
anabolic pathway myogenesis marker myogenin (MyoG) in the homozygous Zfp106LacZ/LacZ mice 
as compared to controls (Figure 12A). In addition to this increase, and consistent with what has 
been observed in rat models of denervation and human neuromuscular diseases, the homozygous 
Zfp106LacZ/LacZ mice have a significantly decreased level of myostatin, an inhibitor of protein 
synthesis (Figure 12A)81,82.  Ribosome biogenesis was also increased in the Zfp106LacZ/LacZ mice 
as measured by Rn45s expression while Rps6kb1 had no significant change (Figure 12B). In 
parallel, there were significant increases in the transcription of molecules that contribute to 
catabolism. The transcript levels of psmA, MuRF and PSMD11 are significantly increased by 
195%, 368%, and 233% respectively (Figure 12C). These catabolic factors may outpace the 
increased rate of protein synthesis, resulting in the muscle atrophy that was observed in the 
Zfp106LacZ/LacZ mice similar to what was reported in denervated skeletal muscle83. Looking at the 
IGF pathway, there were no changes at the transcript level of either IGF1 or Irs1 in the homozygous 
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At 8 weeks of age, the Zfp106LacZ homozygous mice display severe muscle atrophy. Therefore, it 
is difficult to determine if (or how much of) the changes in the gene expression associated with 
muscle homeostasis are due to the muscle atrophy rather than a loss of Zfp106. To assess this, we 
compared the gene expression of mice at 4 and 8 weeks of age normalized to controls. The 4 week 
timepoint was chosen as the homozygous mice have been reported to have gait abnormalities with 
no difference in gastrocnemius weights between control and homozygous mice, showing a muscle 
dysfunction without an overt atrophy phenotype (Figure 7D; data not shown)7. At 4 weeks, the 
signaling pathways should be less affected by the molecular mechanisms associated with severe 
muscle atrophy making it a good timepoint to compare how these pathways change as the atrophy 
progresses. Of note, none of the molecular markers studied are significantly different compared 
with controls at 4 weeks of age (data not shown). However, when compared with the 8-week old 
mice, the expression of anabolic markers MyoG, RPS6kb1, and RN45s is enhanced in the 8-week 
old homozygous mice as compared with the 4 week old mice (Figures 13A and 13B). In contrast, 
the expression of myostatin shows no difference between the two ages (Figure 13A). This may be 
because at 4 weeks of age, the mice may already be beginning to adjust its protein expression 
profile to prevent muscle atrophy and is already suppressing myostatin even though this is not-
significant from the data. Catabolic markers like MuRF and PSMDII are also significantly 
increased in the 8-week old mice showing an increase in the activity of the proteasome degradation 
pathway (Figure 13C). In the IGF pathway, Akt2 levels are significantly increased by 8 weeks 
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The IGF-1R/insulin pathway is involved in the regulation of muscle homeostasis This pathway 
can control hypertrophy through mTOR and atrophy through the suppression of FoxO49. Previous 
studies examining SIRM (Zfp106 isoform Sh3bp3) implicated it in the IGF/insulin pathway9. We 
then examined the proteins involved in the IGF1R/InsR signaling cascade. Phosphorylated 
IGF1R/InsR and non-phosphorylated InsR levels proteins were decreased in homozygous 
Zfp106LacZ/LacZ mice as compared with controls. The amount of phosphorylated Irs1 detected was 
decreased in homozygous Zfp106LacZ/LacZ mice as compared to control littermates. Non-
phosphorylated IGF1R and Irs1 protein levels did not change significantly consistent with the 
qPCR results (Figures 12D and 14B). There was also a marked increase in Akt expression while 
there was no increase in its activation at S473. This result is supported by the increased mRNA 
level of Akt2 observed in the Zfp106LacZ mice (Figure 12D). This means that the level of Akt is 
heightened but the protein is not being activated, potentially due to the inactivity of the 
IGF1R/InsR pathway. There is also an increase in the inhibition of the FoxO family as seen through 
the phosphorylation of FoxO1 at T24 and FoxO3 at T31. However, there is a concurrent overall 
increase in non-phosphorylated FoxO1 (Figures 14A-C). This imbalance evidenced by an 
increased amount of uninhibited FoxO may explain the upregulation of the proteasome MuRF, 
PSMA and PSMD11, resulting in increased catabolism and muscle atrophy. The increase in Akt2 
may be compensatory in response to the increase in FoxO, as Akt2 is a known regulatory molecule 





Figure 14 InsR/IGF1R pathway.  
A) Western blot of proteins insulin/IGF-1R-PI3K-Akt pathway that influence muscle homeostasis. 
Control are WT and Heterozygous mice while KO are the Global Zfp106LacZ mice. 
B) Quantification of the Western Blot bands normalized to beta-tubulin then vs. controls. (*p<0.05, 
**P<0.01 using unpaired Student’s t-test with Welch’s correction if necessary. Ctrl, n=3; Hom, 
n=3, mean ± S.D.). 
C) Simplified cartoon summarizing the findings from the Western blot assay of homozygous 






This chapter describes our study of the KOMP Zfp106LacZ mice. Homozygous mice have severe 
muscle atrophy and prematurely die by 16-weeks. We began our work focusing on studying the 
mouse skeletal muscle as it is here that Zfp106 is highly expressed and we originally assumed that 
the Zfp106LacZ model to be a true knockout. This means we believed that the gene-trap should lead 
to a severe shortfall in the expression of the protein affecting the muscle the most. Together with 
other studies published since we began our experiments using this mouse model determined that 
the skeletal muscle, neuromuscular junction, and motor neurons are disrupted2,7,12. Presently, the 
general consensus is that the muscle atrophy is largely due to a neuronal dysfunction, as supported 
by the MNX-1 Zfp106 overexpression rescue of the Zfp106LacZ mouse2. This does not mean that 
it is wholly a neurological issue and there may be some myopathic ramifications of the Zfp106 
gene-trap contributing to the severity of the phenotype. Studies focusing on isolating the gene-trap 
to the muscle or neuron need to be conducted to better explore this topic. Of note, the interpretation 
that the Zfp106LacZ muscle atrophy originated from a neurological dysfunction was determined 
after the majority of our work characterizing the effect of the Zfp106LacZ depletion on skeletal 
muscle was accomplished and although probably not the primary cause of the muscle atrophy, I 
thought it important to report our data exploring the effect of the gene-trap on the skeletal muscle 
in depth. 
Zfp106LacZ characterization  
We determined that Zfp106 has decreased body weight, hind-limb muscle, and grip strength at our 
8- and 16-week time points. This concurs with general consensus of the published characterization 
of the mouse2,7,12. Of note, our study supports a significant decrease in body weight by 16-weeks, 




may be due to a variation in the feed, housing or in-bred strain which are not detailed in the outlying 
study. 
Studying the fiber type distribution in the soleus or EDL hindlimb muscles of the Zfp106LacZ 
homozygous mice shows an overall decrease in CSA without a preferential decrease in fast or slow 
twitch muscle fibers. Previous studies showed a decreased fiber number and increased slow twitch 
muscle fibers in the gastrocnemius and soleus muscles7. This difference may be technical (staining 
or counting), or due to a difference is sampling age (14-week vs. 16-week). Consistent with their 
study however, we noted a larger distribution of fiber types as well as an observed increase in large 
fast-twitch muscle fibers in the soleus muscle (Figure 9)7.  
Another distinct difference between our study and those previously reported is the ultrastructure 
of the gastrocnemius muscle at 16-weeks of age of the homozygous mice12. Our data suggests that 
the gene-trap has no effect on the ultrastructure of the gastrocnemius muscle while another lab 
reported a significant disruption of the sarcomere. Both studies were conducted at the same time 
point and hind limb muscle and the stark difference in results is difficult to reconcile.  
Looking at the NMJ, our data is similar with the published experiment showing progressively 
increased denervation of the NMJ as the mice age. However, our study is limited as we did not use 
a presynaptic marker like SV2 or synaptophysin. Future work should include these markers to 





Signaling pathways influencing muscle homeostasis 
In this study, we determined that there is an increase in the transcription of factors associated with 
the anabolic as well as the catabolic pathways. We believe that the rate of catabolism outpaces 
anabolism thereby leading to muscle atrophy. Looking at the expression of these factors at 4 weeks 
of age, before the onset of muscle atrophy, shows that most of these factors are not different from 
controls. This means that the imbalance is not evident at this time making it unlikely that it is a 
change here that is the precipitating event to muscle atrophy. Of note, the 4 week old Zfp106LacZ 
homozygous mice have a non-significantly decreased expression of myostatin, which may support 
the muscle already adjusting its expression profile to combat muscle atrophy. This study is limited 
by the fact that it only measures these factors at a transcript level. More work should be conducted 
at the protein level looking at the activation as well as expression of the anabolic and catabolic 
protein markers at 4 and 8 weeks of age. 
Examining the IGF-1R/InsR pathway shows a change in the expression of several of the proteins 
and their phosphorylation compared with controls. Phosphorylation of IGF-1R/InsR and Irs1 was 
decreased meaning that the signaling cascade is less active. This may explain why even though 
there is a marked increase in Akt, there is no increase in its activation through phosphorylation at 
S473. Phosphorylated and non-phosphorylated FoxO levels are increased in the homozygous mice 
which may explain the upregulation of the proteasome MuRF, PSMA and PSMD11, resulting in 
increased catabolism and muscle atrophy. This study is done at 8 weeks, a single time point when 
the muscle atrophy already severe. Therefore, it is difficult to dissect whether the protein 
expression and activation levels are due to the gene-trap interrupting Zfp106 expression or because 
of the muscle atrophy. Further studies should be conducted at 4 weeks to see if there is a 




homozygous mice respond to insulin at 4 weeks of age to see if the IGF-1R/Insulin pathway is 






Homozygous mice derived from the KOMP Zfp106LacZ mouse model display muscle weakness by 
4 weeks of age leading to a premature death by 16 weeks in both male and female mice due to the 
inability to thrive. As the pathology progresses, the homozygous Zfp106LacZ mice lose weight, 
which is reflected by a significant loss of hind limb muscle mass. Further inspection of the skeletal 
muscle identified a non-fiber specific muscle atrophy with an overall decrease in muscle fiber cell 
surface area. This decrease affected the muscle fibers non-discriminately and caused a shift in the 
mean and median of the skeletal muscle fiber size. The neuromuscular junction of the homozygous 
mice was compromised with a progressively increasing amounts of denervated and collapsed post-
synapse as the disease progresses from 6 to 16 weeks of age.  
Looking more closely at the signaling pathways involved in muscle homeostasis shows a 
significant change in the anabolic and catabolic proteins at 8 weeks. There is a notable increase in 
FoxO expression and activity which may explain the increase in the proteasomal proteins.  
The characterization of a dysfunctional skeletal muscle coupled with the death of the motor neuron 
pool identified previously, suggests that the muscle atrophy is not confined to one part of the 
neuromuscular system. Due to the interconnectedness of the system, it is difficult to determine 
exactly which systems are the cause of the muscle atrophy and which ones are changing in response 
although the current consensus is that the gene-trap leads to a neuropathy. Additionally, because 
of the dual promoter structure of Zfp106, the gene-trap technique may not have been sufficient to 
produce a true knockout of Zfp106. Previous investigations have noted that the mouse model has 
an approximate 20% transcript of Zfp106 left2,7,12. The incomplete removal of Zfp106 may have 




Chapter 1.3.2: Zfp106 expression in Zfp106LacZ mice 
Introduction 
The KOMP project follows the complete mapping of the mouse genome with the overarching goal 
to knockout every gene of the mouse genome. One of the methods used in this effort is the gene 
trap technique26. A gene trap interrupts the transcription of a target gene by inserting a splice 
acceptor followed by a LacZ and neomycin resistance cassette and a polyA tail after the exon 2. 
This construct is flanked by two FRT sites allowing it to be removed through flippase 
recombination. In addition to the gene trap, there is a loxP site flanking exon 3 (Figure 4)27-29. This 
strategy is useful in interrupting gene isoforms initiated from their first coding exon. However, 
this does not take into account genes that have multiple isoforms following different promoter 
regions not affected by the gene trap. In fact, the insertion of a gene-trap upstream of a second 
promoter region was used to create an isoform specific deletion of deleted in liver cancer 1 (dlc1) 
mice85.  
Zfp106 was previously mapped to have two promoter regions controlling the transcription of two 
major isoform families of the gene6. The first isoform family following promoter region 1, hereby 
designated the P1 isoform family, is ubiquitously expressed at low levels. The transcription of 
these isoforms initiates at exon 2 leading to a full-length transcript of the gene and is thought to be 
controlled by nuclear respiratory factor 1 (NRF1). The second major isoform family, called the P2 
isoform family, is controlled by a downstream promoter region located in the intronic region 
between exons 3 and 4, which was found to be driven by MyoG. These splice variants are highly 
expressed in excitable tissues including the heart and skeletal muscle (Figure 5A)6,9,12. 
Additionally, the expression of the P2 isoform family increases with the terminal differentiation 




expression of a unique exon, exon 1b. The full-length splice variant of the P2 isoform family starts 
at exon 1b followed by the transcription of exon 4 then leading to the complete transcription of the 
rest of the gene. Aside from the difference in tissue expression of both isoforms, the transcript 
variation between the two major isoforms leads to a loss of the first N-terminal zinc finger in the 
P2 isoforms, which includes a binding motif for cytochrome c. However, in place of the zinc finger 
motif, the integration of coding exon 1b leads to the expression of an SH3 binding motif (Figure 
15)6.  
 
Due to the presence of two known promoter regions in Zfp106, it is important to investigate 
whether the KOMP KO mouse model Zfp106LacZ was indeed a true knockout of the gene or 
Figure 15 Dual promoter regions of murine Zfp106.  
A) Map of tm1a KOMP gene trap with the placement of the P1 and P2 promoter 
regions of Zfp106.  
B) Schematic of each major isoform family expressed and whether they are affected 




whether it was simply a P1 specific knockout. Compensating for the lack of a reliable antibody 
towards murine Zfp106, the levels of Zfp106 was measured in the Zfp106LacZ mice using RNA-
seq, northern blot, and qPCR in both skeletal muscle and spinal cord. In the spinal cord, Zfp106LacZ 
homozygous mice showed ~20% expression via RNAseq and 0.4%-20% using qPCR2,7. 






Antibody detection of Zfp106 in the Zfp106LacZ model 
The antibodies allowing for the endogenous detection of the murine orthologue of Zfp106 are not 
reliable as observed by us and other researchers7. The antibodies, developed by commercial 
providers Abcam and Bethyl Laboratories as well as our lab, were raised using a human ZNF106 
peptide sequence that is highly conserved with the murine orthologue Zfp106 (Figure 16A). 
Originally, we attempted to detect Zfp106 expression through a western blot assay and observed 
bands at ~200kDa and ~100kDa present in both male and female control and Zfp106LacZ 
homozygous mice (Figure 16B). The identity of these bands was unknown but hypothesized to 
potentially be the P2 Zfp106 isoform due to the assumed P1 Zfp106 knock out of the Zfp106LacZ 
homozygous mice. Therefore, we sought to identify these bands. To do this, we used a bottom-up 
proteomic approach86. For this experiment, gastrocnemius muscle from Zfp106LacZ homozygous 
mice were harvested and the muscle lysate was enriched by immunoprecipitation using antibodies 
targeting the C-terminus of Zfp10687. The immunoprecipitated protein was then run on an SDS-
PAGE gel and the bands were analyzed separately for the control and Zfp106LacZ homozygous 
mice. This proteomic analysis begins with the enzymatic digestion of the proteins followed by 
liquid chromatography and tandem mass spectral analysis (LC/MS/MS). From this assay, Zfp106 
was not detected in the ~200 kDa band of both the WT and homozygous mice showing that this 
band, as analyzed, does not contain Zfp106 (Figure 16B, green box). Expanding the analysis to 
the 50kDa to 190kDa region of the gel, Zfp106 was detected in the WT mice as the 134th out of 
135 proteins in order of abundance (Figure 16B, blue). Interestingly, doing the same analysis of 
the bands in homozygous mice led to the detection of Zfp106 once with an abundance of 492nd out 




abundance of protein was detected and therefore deemed unreliable. From this, we concluded that 
the Zfp106 C-terminal antibody is not reliably detecting the murine orthologue of Zfp106 and the 





Figure 16 Antibody detection of Zfp106. 
A) Peptide sequence alignment used to inoculate and create antibodies against Zfp106 by Abcam 
(ab84674), Bethyl (A301-527A), and in house. Amino acids correspond to hZNF106 1833-1883 
and mZfp106 1838-1888. Red box delineates mismatch, blue box highlights a mismatch to an 
amino acid with similar properties. 
B) Representative α-Zfp106 Western blot image of skeletal muscle lysate of control and 
Zfp106LacZ homozygous mice at 8 weeks of age. Estimated Zfp106 MW: P1-Zfp106 208kDa, P2-
Zfp106 206kDa. 
C) Experimental flow of the LC/MS/MS study aimed at determining if Zfp106 is present in the 
enriched Zfp106 fraction of the murine skeletal muscle. Enrichment is accomplished through the 
immunoprecipitation using Zfp106 antibody. The green and blue boxes delineate the sections of 





Transcription of Zfp106 in the Zfp106LacZ model 
Given that the antibodies available to detect Zfp106 are unreliable, we used quantitative RT-PCR 
(qPCR) to determine whether or not Zfp106 was still expressed in the Zfp106LacZ mouse model. 
We assessed the expression of Zfp106 in the spinal cord and skeletal muscle to measure the impact 
of the gene-trap on both tissues. The exons targeted to measure Zfp106 transcription represent the 
exons exclusive to the P1 isoforms, exons 2 and 3 and those that are thought to be common to both 
the P1 and P2 isoforms of Zfp106. The qPCR results investigating the presence of Zfp106 in the 
Zfp106LacZ model showed that the gene trap technique leads to a significant reduction of exons 2-
3, 3-4, and 21-22 in the skeletal muscle (Figure 17A). Interestingly, there is a non-significant 
decrease of exon 4-5. In the spinal cord, the transcribed amounts of exons 2-3, 3-4, 4-5, and 21-22 
are significantly less (Figure 17B). This means that the gene trap effectively reduced the P1 
isoform in both the skeletal muscle and spinal cord as represented by the significant depletion in 
exons 2 and 3. This led to a decrease in exons 21 and 22 supporting the overall decrease in the 




   
Figure 17 Zfp106 expression in the Zfp106LacZ model.  
A) Zfp106 expression in skeletal muscle. (* p<0.05, ** p<0.01, *** p<0.001 
using one-way ANOVA with Dunnett’s multiple comparisons test vs. WT, 
Ctrl, n=5; Het, n=5; Hom=9, mean ± S.D.). 
B) Zfp106 expression in Spinal Cord. (* p<0.05, ** p<0.01, using one-way 
ANOVA with Dunnett’s multiple comparisons test vs. WT, Ctrl, n=7; Het, 




Expression of the P2 isoform in skeletal muscle of the Zfp106LacZ model 
RNA seq was conducted to explore whether exon 1b, the first exon exclusive to the P2 isoform 
family, was expressed in the skeletal muscle of the homozygous mice. Consistent with what was 
observed previously, it was found that, although reduced, Zfp106 is still expressed in these 
mice2,7,12. Qualitatively, the proportion of reads associated with exon 1b seems to be increased 
(Figures 18A and 18B). However, these RNAseq tracks are not quantitative as the reads are not 
normalized to any housekeeping genes. Therefore, the expression of exon 1b was measured 
through qPCR and was in fact found to be 10X higher than that of controls (Figure 18C). This may 
be explained by the fact that the P2 isoform expression is controlled by MyoG, which was found 
to be increased in the skeletal muscle of the homozygous mice as compared with controls (Figure 
12A). Interestingly, the increase in P2 isoform in the skeletal muscle may be leading to the non-
significant decrease in the mRNA containing exons 4-5 in skeletal muscle (Figure 17A). However, 
taking into account that exons 21-22 are significantly decreased, the splice variant that is 








Figure 18 P2 isoforms expression in Zfp106LacZ skeletal muscle. 
A) RNA seq tracks of Zfp106 WT and Homozygous mice showing the reads associated with 
Zfp106. 
B) Zoom-in of exon 1b of WT and Homozygous mice. 
C) qPCR of Zfp106 Exon 1b (*p<0.05 using an unpaired student’s two-tailed t-test with Welch’s 
correction, Ctrl, n=7; Hom, n=6, mean ± S.D.).  




Expression of the P2 isoform in spinal cord tissue of the Zfp106LacZ model 
The Zfp106LacZ mouse model is a global interruption of the gene. Previous experiments have found 
that the Zfp106LacZ model may develop muscle atrophy due to the protein’s deficiency in the motor 
neuron. This is supported by the damage and death of this tissue2,7,12. Therefore we used RNAseq 
to assess whether exon 1b was also increased in this tissue due to the protein depletion. Here it 
was found that similar to the skeletal muscle RNA, the RNA extracted from the spinal cord is 
depleted but not gone (Figure 19A). Interestingly, in contrast to the findings from the skeletal 
muscle RNA exon 1b does not increase in reads (Figures 18B, 19B, and 19C). This difference may 
be because of the increase in myogenin expression in the skeletal muscle leading to the increase 








Figure 19 P2 isoforms expression in Zfp106LacZ spinal cord. 
A) RNA seq tracks of Zfp106 WT and Homozygous mice showing the reads associated with 
Zfp106. 
B) Zoom-in of exon 1b of WT and Homozygous mice. 
C) qPCR of Zfp106 Exon 1b (n.s. is non-significant using an unpaired student’s two-tailed t-test 
with Welch’s correction, Ctrl, n=15; Hom, n=7, mean ± S.D.).  





Following the observations of other researches using the Zfp106LacZ mouse model, we studied the 
effect of the gene-trap on Zfp106 expression2,7,12.  In this study, we confirmed that, at the transcript 
level, the Zfp106LacZ mouse model is hypomorphic and is not a complete knockout of the Zfp106 
protein. It is however, an efficient interruption of the expression of exons 2 and 3 that are exclusive 
to the P1 Zfp106 isoform. As such, it is a useful tool in analyzing the in vivo effect of the depletion 
of these exons. Through qPCR and RNAseq experiments, we determined that the P2 isoform 
family, through the measurement of the expression of Zfp106 exon 1b, is heightened in skeletal 
muscle. Therefore, it is difficult to determine if the muscle atrophy observed is due to Zfp106 
depletion or the increase in one or several P2 isoforms of the protein. 
Limitations of the study 
This study relies on the measurement of mRNA as an estimation of the expression of Zfp106. 
However, a change in transcription of a gene does not necessarily mean that there is an effect on 
the translation and function of the protein. Therefore, a limitation of this study is the omission of 
proteomic work due to a lack of a reliable murine antibody. As an added complexity, the splice 
variants of Zfp106 have not been completely elucidated although there has been some theoretical 
speculation on what they may be11. This means that it is difficult to predict which isoforms of 
Zfp106 are being affected by the gene-trap and, therefore, which specific isoforms are missing and 
thereby leading to the neuromuscular defect in the mice. Our research has focused on the levels of 
Zfp106 as measured by the initial coding exons associated with either the P1 or P2 promoter driven 
isoforms (exon 2 and exon 1b) and cannot account specifically for any other previously 
unidentified promoter regions and splice isoforms. This means that the conclusion that can be 




overall amounts of Zfp106 with an increase of exon 1b in skeletal muscle. Additional work would 
need to be conducted to better understand the murine and human isoforms of Zfp106 and the 
affected isoforms in the Zfp106LacZ mouse model in order to identify the specific splice isoforms 
affected by the gene-trap and better gauge Zfp106’s role in neuromuscular health.   
Moving forward 
Identification of the Zfp106 splice variants 
The mRNA from Zfp106LacZ WT and homozygous mice from skeletal muscle and spinal cord can 
be further analyzed to better understand the isoforms of Zfp106 and how the gene-trap affects their 
transcription. To do this, northern blot experiments can be conducted by creating probes against 
exon 2 and exon 1b and using these probes separately on mRNA isolated from the WT and 
homozygous mouse muscle and spinal cord. The change in banding pattern when comparing the 
homozygous mice to the WT mice can uncover splice isoforms that are affected by the gene-trap. 
These samples can then be further interrogated using 5’RACE techniques that amplify the cDNA 
of Zpf106 allowing for the isolation sequencing of the various splice isoforms88,89. Overall, this 
experiment should allow us to identify the splice variants affected by the gene-trap that may be 
important in neuromuscular health.  
Development of a new antibody 
The lack of proteomic work to identify the expression of mZfp106 makes it difficult to understand 
the true impact of the gene-trap on Zfp106. This is because the depletion of exons 2 and 3, the 
upregulation of exon 1b is limited to the transcriptional level and cannot be extended to whether 
or not this has any effect on the translation of the protein and its function. To address this, a reliable 




creating a peptide directly for mZfp106, not the human orthologue. These antibodies can be raised 
against P1 and P2 isoform family specific exons 2 and 1b respectively as well as a common exon 
to both isoform families like exon 6, if acceptable peptide sequences are available90. Once the 
reliable antibodies are established, the expression of Zfp106 in these mice as well in other model 
systems can be validated. Of note, these antibodies are limited to the currently identified P1 and 
P2 Zfp106 family of isoforms. This approach cannot definitively account for newly identified 
promoter-driven isoform families. 
P1 and P2 isoform Tagging 
If isoform specific and a pan Zfp106 antibody cannot be raised, another approach to better 
understanding the splice variants of Zfp106 would be to use CRISPR/Cas9 to introduce reliable 
isoform specific epitope tags to either of the isoform family specific exons, exon 2 or 1b (Figure 
20)91. This direct genetic manipulation approach of Zfp106 is preferable to the over expression of 
the protein for two reasons, the size of Zfp106 and the unknown splice variations of the protein. 
The 5.6 kb size of Zfp106 leads to a decrease in lentiviral titer and cannot be delivered through an 
adeno associated virus thus making this approach untenable92. Additionally, the Zfp106 splice 
variants are unknown and the selection of the isoform to be expressed may be integral to inferring 
its function. Tagging the gene directly allows for the expression of the alternative splice variants. 
To tag Zfp106, guide RNA and donor DNA containing a flag tag and myc tag for the exon 2 and 




allowing for their detection. A limitation of this approach, however, is that the N-terminal tags 
may interfere with the function of the protein.  
  
Figure 20 Flag- and Myc- tagged Zfp106 isoforms.  
Schematic outlining the proposed used of CRISPR/Cas9 to insert a Flag tag and Myc tag to the P1 






The Zfp106LacZ mouse model successfully interrupts the expression of Zfp106 from exon 2 to 3. 
However, the model is hypomorphic with residual gene expression in both the skeletal muscle and 
spinal cord, corroborating what was observed in previous studies. Interestingly, in the skeletal 
muscle, the gene-trap does not significantly decrease the expression of Zfp106 exon 4-5 while 
these exons are significantly less than controls in the spinal cord. In skeletal muscle the expression 
of exon 1b is significantly increased compared with controls. This increase is not seen in the spinal 
cord of the homozygous mice. The increase in the skeletal muscle may be due to the significant 
increase of MyoG in this tissue, which has been shown to drive the expression of the P2 isoform 
family in the skeletal muscle (Figure 12A)6. Together, this may mean that this incomplete 
disruption of Zfp106, as well as the non-significant reduction of Zfp106 exon 4-5, may be due to 
the compensation of a splice variant of P2-Zfp106. Currently, the role of the P2 Zfp106 family of 
isoforms is unknown and the increase in P2 Zfp106 expression could be leading to the muscle 










The Zfp106LacZ mouse model inserted the gene-trap motif upstream of the second promoter region. 
This model does not represent a complete knockout of Zfp106 as determined by us and other 
investigating labs (Figure 17)2,7,12. In addition, we found that there is a significantly higher 
expression of Zfp106 exon 1b, the first exon of the P2 isoform family, in the skeletal muscle of 
the Zfp106LacZ mice (Figure 18). Therefore, it is difficult to determine if the muscle atrophy 
observed in the Zfp106LacZ mice is due to the depletion of splice variants belonging to P1-Zfp106 
or the overexpression of those included in P2-Zfp106.  
To address this, we developed a CRISPR mediated knockout of Zfp106 targeting exon 5, which is 
common to several of the identified murine isoforms initiated from either the P1 or P2 promoter 
regions (Figure 21A). Of note, this CRISPR deletion cannot be assumed to affect all of the isoforms 
of Zfp106 and is not expected to deplete Zfp106 isoforms skipping exon 5. More work identifying 
the splice isoforms of Zfp106 needs to be conducted in order to make a complete knockout. Exon 
5 was chosen as a viable target as it affects the full variants of both the P1 and P2 isoform families 
as well as Sh3bp3, the isoforms of Zfp106 most studied2,6,9,11,12.  In order to do this, we developed 
a guide RNA sequence targeting the 5’ region of Exon 5 (Figure 21B). This was then introduced 
together with Cas9 into mESCs from which we got both homozygous and heterozygous INDELs 
of the target region (Figure 21C; data not shown). We then chose one heterozygous mESC clone 
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Similarly, to the Zfp106LacZ mice, heterozygous ΔZfp106 mice show no muscle atrophy phenotype 
as compared with wild type controls while some ΔZfp106 homozygous mice show severe muscle 
atrophy (Figure 22A). The body weight of the male ΔZfp106 mice are significantly lighter than 
the control mice while the female homozygous mice do not weigh significantly less (Figures 22B 
and 22C). The mice were born at close to mendelian ratios and the earliest onset of noticeable 
muscle weakness in homozygous mice was 4 weeks, leading to a premature death by at most 20 
weeks in both males and females due to the inability to thrive (Figure 22D). In contrast with 
Zfp106LacZ homozygous mice, the penetration of the muscle atrophy phenotype is not 100%. Three 
out of five males and one out of eight female homozygous mice showed severe muscle atrophy 
(Figure 22E). The lower rate at which female muscle atrophy develops explains why homozygous 
ΔZfp106 female mice are not significantly lighter than controls. When presenting with muscle 
atrophy, the mice are unable to carry their own body weight in an inverted screen test by 8 weeks 
(Figures 22E-G). Altogether, the interruption of Zfp106 exon 5 leads to an in vivo model displaying 







Figure 22 Characterization of ΔZfp106.  
A) Representative images of control and homozygous mice.  
B,C) Weight over time of male and female mice respectively (n≥3 * p<0.05, ***p<0.001 using 
unpaired Student’s t-test, Ctrl vs. KO mice, Ctrl, n≥9; Hom, mean ± S.D.). 
D)  % homozygous mice that developed muscle atrophy (Total male, n=5; total female, n=8). Insets 
are the individual counts. 
E) % born of each genotype of male and female mice (Total male, n=24; total female, n=23). Insets 
are the individual counts. 
F,G) Inverted screen score of male and female mice at 8 and 16 weeks. Symptomatic female died 
at week 10. (8 weeks: Ctrl Male, n=9; Hom Male, n=3; Ctrl Female, n=4; Hom Female, n=7. 16 





The Zfp106LacZ mouse model had a profound and severe effect on the NMJ of the homozygous 
Zfp106LacZ mice.  We analyzed whether this phenotype is similar in the ΔZfp106 mice presenting 
with muscle atrophy. To do this, we excised the gastrocnemius muscle from homozygous ΔZfp106 
mice and the innervating motor neuron was stained with anti-neurofilament while the endplate was 
visualized using bungarotoxin, which targets the acetyl choline receptors. 
The NMJ of the ΔZfp106 homozygous mice are compromised similarly to the homozygous 
Zfp106LacZ/LacZ mice. The homozygous NMJ has multiple collapsed and denervated motor 
endplates, as well as collapsed and innervated motor endplates, while the cohort and aged matched 
WT control showed a normal innervated and formed NMJ (Figure 23A and 23B). Quantifying the 
NMJ images, it is evident that there are less innervated and more collapsed endplate structures in 
the homozygous mice. The significance of this difference could not be quantified as there is an 
insufficient number of samples (n=2) for the homozygous mice (Figures 23C and 23D). This shows 
that the NMJ of the ΔZfp106 mice are similarly compromised and is affected by the non-isoform 
specific depletion of the gene. Of note, a large number of the control mice NMJs are not innervated 
(Figure 23C). This may be due to the lack of a nerve terminal stain like SV-2 or synaptophysin 




   
Figure 23 ΔZfp106 NMJ immunocytochemistry stain. 
A) 20x representative fluorescent images of the NMJ stained for neurofilament and acetylcholine 
receptors (scale bar is 50µm).  
B) 80x representative fluorescent images of the NMJ stained for neurofilament and acetylcholine 
receptors of WT and Homozygous mice showing innervated formed, denervated collapsed and 
innervated collapsed NMJ (scale bar is 50µm). 
C) Quantification of the innervation of the post-synapses. (Ctrl, n=4; Hom, n=2). 




As the CRISPR mediated interruption of Zfp106 in the ΔZfp106 mice is global, we were not able 
to determine whether the muscle atrophy is deleterious to motor neuron survivability in isolation. 
Previous studies have found that the motor neuron (MN) is compromised in the Zfp106LacZ 
homozygous mice2,7,12. In order to assess the effect of the CRISPR mediated depletion of Zfp106 
exon 5 on the health of the motor neurons we took advantage of the fact that during the generation 
of CRISPR modified mESCs we developed a clone containing a homozygous deletion (Figure 
24A). This clone, and a WT control, were differentiated into motor neurons through directed 
differentiation of mESCs94. The differentiated motor neurons were then plated in a 96-well plate 
format. To assess if there is a variability in the differentiation rate of the cell lines, the cells were 
stained with DAPI, neurofilament, and HB9 (a motor neuron marker). The number of double 
positive, DAPI and HB9, cells were counted. From this it was found that there was no statistical 
difference between the two lines (Figure 24B and 24C). Of note, the differentiation efficiency of 
the mESC to motor neurons is surprisingly high as the average efficiency achieved is 40-60%. 
This overcount maybe due to poor quality or off target HB9 staining. As an alternative, a separate 







Figure 24 Motor neuron differentiation from mESC. 
A) Sequence alignment of the CRISPR INDEL in the homozygous mESC line. Red boxes highlight 
the stop codon generated from the frameshift.  
B) Representative fluorescence images of cells differentiated from mESC at 40x. Cells stained for 
Dapi, HB9, and neurofilament.  
C) Proportion of HB9+ cells imaged. (n.s. is non-significant, using student’s t-test, Ctrl, n=258 
cells; Hom, n=150 cells, mean ± S.D.). 
Acknowledgment: Dr. Hynek Wichterle, Dr. Emily Lowry, Dr. Tulsi Patel and Jonathon Costa for 






Motor neurons derived from mESCs are immature and considered to be representative of 
embryonic or early post-natal motor neurons96-98. This makes it difficult to use these cells as a 
model to understand the potential underlying cause of the muscle atrophy in ΔZfp106 mice when 
the physiological onset of atrophy is at earliest 4 weeks. To address this, we used a previously 
developed motor neuron survival screening assay to stress the differentiated motor neurons in order 
to enhance and accelerate the pathological cellular functions caused by the CRISPR mediated 
depletion of Zfp106 exon 5 in the ΔZfp106 mice98,99. 
The differentiated WT and homozygous ΔZfp106 motor neurons were exposed to mitochondrial 
(0.03 µM Rotenone), ER (10 µM Cyclopiazonic acid), and proteasomal (0.5 µM MG132) stressors 
through chemical intervention. This follows the findings that Zfp106 depletion in the Zfp106LacZ 
mouse model led to a compromise of the mitochondria in the motor neurons, an increase in the 
proteasomal markers, and the finding that motor neurons with an ALS-causing human superoxide 
dismutase 1 (hSOD1)G93A were susceptible to ER stress (Figure 12C)7,98. In addition, the response 
of the motor neurons to (0.5 µM) PHB1288, a neuroprotective agent that is thought to ameliorate 
ER stress by inhibiting MAP4K was measured (Figure 25A)99.  After treatment with either vehicle 
controls (DMSO) or the aforementioned chemicals, the health of the motor neurons was measured 
by assessing the average cell count, mean outgrowth (total projection length), mean branches, 
mean processes (# of processes/cell), significant growth (# of cells with a cumulative outgrowth 
length of greater than 33 µm), and mean cell body area (Figures 25B-G)98,99.  
Overall, the survival screen showed small but statistically significant decreases in the mean cell 
body area of the ΔZfp106 motor neurons when compared with controls in response to Rotenone 
and PHB1288 (Figures 25G). Additionally, the homozygous motor neurons showed a significant 




decrease in the mean outgrowth per cell (Figures 25C and 25E). This indicates that the 
homozygous deletion of Zfp106 leads to an increase in the susceptibility of the motor neurons to 
mitochondrial and ER stress. When ER stress is induced, ΔZfp106 motor neurons have shorter 
length but an increased number of outgrowths. This coupled with the decreased response to PHB, 
in the mean cell body area quantification, indicates that the Zfp106 deletion makes motor neurons 
more susceptible to ER stress that is not rescued through MAP4K inhibition. These preliminary 
results are interesting in establishing the potential cause of the atrophy observed in the ΔZfp106 






Figure 25 Motor neuron survivability assay.  
A) 96-well plate map for the survivability assay.  
B-G) Cell assay metrics measured. Ctrl vs. Hom CRISPR deletion cells. (** p<0.01, *** p<0.001, 
n.s. is non-significant using the student t-test, Ctrl, n≥7 wells; Hom, n≥7, mean± S.D.). 
Acknowledgment: Dr. Hynek Wichterle, Dr. Emily Lowry and Jonathon Costa for the design, 





In this study, we developed a CRISPR mediated disruption of exon 5 as a common exon that is 
predicted to inhibit the expression of the full length P1 and P2 Zfp106 isoforms. This mouse model 
is called ΔZfp106. Similarly, with the Zfp106LacZ homozygous mice, ΔZfp106 homozygous mice 
displayed muscle atrophy and had a disrupted NMJ. However, not all of the ΔZfp106 homozygous 
mice have muscle atrophy symptoms. The underlying cause of the difference in penetrance is not 
known. The inconsistent appearance of this phenotype may be due to the fact that the mice tested 
are second generation mice and the muscle atrophy phenotype may be made more robust with the 
additional generations of back crossing with C57Bl6 mice100. Alternatively, the difference in the 
penetration rate of the muscle atrophy may be due to the nature of the interruption of the gene in 
the ΔZfp106 model. The CRISPR mediated disruption of Zfp106 expression, compared to a gene-
trap, may allow for the expression of other Zfp106 isoforms that skip exon 5, decreasing the 
severity of the pathology following the genetic disruption. Additionally, the 100% penetration rate 
of the Zfp106LacZ mouse muscle atrophy may be influenced by the increase in a 1b exon containing 
Zfp106 isoform in skeletal muscle in addition to a decrease in a P1 Zfp106 splice variant, 
something which is prevented in the ΔZfp106 model.  
The in vitro analysis of the survivability of motor neurons derived from mESC showed that in 
response to ER stress, the ΔZfp106 motor neurons have shorter length but an increased number of 
neuronal processes as compared with controls. This is not rescued by PHB1288, the MAP4K 
inhibitor meaning that it may be due to a perturbation of a pathway outside of the MAP4K 
signaling cascade. Mitochondrial perturbation using rotenone led to a decrease in the mean cell 
body area of the differentiated motor neurons. To follow up on this experiment and to better 




ER stress susceptibilities of the differentiated motor neurons to see if this is dose dependent. This 
will allow us to confirm that the effect on soma size and neuronal process number and length is 
due to the chemical stresses. Additionally, this phenotype should be interrogated using other 
mitochondrial and ER stressors. Lastly, if the phenotypic change is indeed dose dependent, it 
would be interesting to attempt to rescue these changes using a chemical library98. 
Study Limitations/Ambiguity 
Experimental considerations 
Throughout this study, there are some experimental results that may be due to technical errors and 
should be interpreted with these caveats in mind. First is the neuromuscular junction stain. The 
lack of a pre-synaptic marker like SV2 or synaptophysin means that there may be an overcount of 
the number of denervated motor end plates, as reflected in the increased number of such in the 
control mice (Figure 23C). Future experiments should be redone and reassessed using a pre-
synaptic marker. Another is the high differentiation efficiency of the motor neurons from the 
directed differentiation (Figure 24C). This result may be due to background staining of the HB9 
marker which can be addressed by using a different motor neuron stain like Islet 1 to confirm the 





In Vivo Motor neuron counts  
The analysis of this mouse model is missing the staining and count of how the exon 5 interruption 
affects the motor neuron in vivo. Examining the effect of the depletion on the motor neuron can 
support the hypothesis that Zfp106 depletion is important in maintaining motor neuron health. The 
motor neuron can be stained by sectioning the ventral horn of symptomatic ΔZfp106 homozygous 
mice and staining for choline acetyl transferase (ChAT)2,7. The number of motor neurons can then 
be counted to see if it is diminished as compared with control mice. 
Lack of orthogonal validation 
Due to the lack of available Zfp106 antibodies, there was no proteomics work done in this study. 
This means that the CRISPR mediated depletion cannot be confirmed at a protein level. Therefore, 
this model cannot claim a complete Zfp106 disruption affecting protein expression. What we can 
say is that the exon 5 interruption was confirmed at a genetic level and that the CRISPR/Cas9 
introduced an INDEL, frameshift and a premature stop codon.  
Follow up studies  
Muscle atrophy penetrance 
One of the remaining questions from this study is why there is a difference in the penetration rate 
of the muscle atrophy phenotype between Zfp106LacZ and ΔZfp106 mouse models with the former 
mouse model have a 100% penetrance and the latter having a 60% penetrance in male and a 12.5% 
penetrance in female mice. This difference may be due to several factors including an incomplete 
backcross, as the mice are of the F2 generation. This can be mitigated by crossing the heterozygous 
Zfp106LacZ and ΔZfp106 mice together. This should theoretically mix their strains with each pup 




further crossed and the rate of muscle atrophy penetrance can be assessed. If the percentage of 
homozygous ΔZfp106 mice that have muscle atrophy go to 100% or the number of Zfp106LacZ 
mice drop below 100%, then it may be due to the genetic background of the mice. Another 
explanation is that the exon 5 depletion does not affect all of the Zfp106 isoforms that the 
Zfp106LacZ model does. This can be addressed by studying and comparing the mRNA splice 
variants expressed in the ΔZfp106 mice showing muscle atrophy symptoms, ΔZfp106 mice not 
showing muscle atrophy symptoms, the Zfp106LacZ homozygous mice and controls through 
northern blot. The splice variants can then be identified through 5’ RACE experiments any 
difference in the samples will serve as a candidate list for Zfp106 isoform splice variants that are 
integral to neuromuscular health. Lastly, the difference in the penetration rate of the two mouse 
models might be the P2 Zfp106 overexpression. First, the expression of exon 1b needs to be 
examined in skeletal muscle and spinal cord in the ΔZfp106 symptomatic and non-symptomatic 
mice. Then, P2 Zfp106 overexpression can be induced through breeding with a P2 Zfp106 
overexpression mouse model (Figure 37). If all of the double positive (P2 overexpression and 
ΔZfp106 homozygous) have muscle atrophy than the neuromuscular atrophy phenotype 






LoxP recombination of Exon 5 and 6 
The ΔZfp106 depletion model aimed to interrupt both the full-length P1 and P2 isoforms of murine 
Zfp106. As such, this model can minimize complications that can arise due to the unaffected full-
length P2 isoform in the Zfp106LacZ model. Additionally, the ΔZfp106 model led to an 
approximation of the muscle atrophy phenotype apparent in the Zfp106LacZ mice showing that exon 
5 depletion can lead to neuromuscular dysfunction. However, the ΔZfp106 model is global and 
cannot be restricted and studied in a tissue and temporally controlled manner. It would be useful 
generate a ΔZfp106 conditional knockout model using CRISPR. This can be accomplished through 
a two-step electroporation with gRNA constructs targeting the introns upstream of exon 5 and 
downstream of exon 6. Cre recombination will lead to a frame shift and introduction of a premature 
stop codon interrupting both the P1 and P2 isoforms of Zfp106 (Figure 26)101. This would allow 
researchers to have a Zfp106 mouse model affecting splice variants belonging to both isoform 
families whose tissue specific depletion can be controlled, enabling them to dissect the roles of 
Zfp106 in specifically in the motor neuron or skeletal muscle. Of note, floxing exons 5 and 6 could 





Figure 26 Development of a conditional Zfp106KO.  
WT Zfp106 exons 5 and 6 will be flanked with LoxP sites which will allow for 





Zfp106 exon 5 was identified as a common exon that affects the full-length P1 and P2 isoform 
family splice variants. As such, this was targeted for a CRISPR mediated INDEL in mESCs to 
disrupt the translation of Zfp106 past the exon. A heterozygous mESC colony carrying the ‘gag’ 
deletion was used to create the ΔZfp106 mouse line. Some homozygous ΔZfp106 mice displayed 
the severe muscle atrophy phenotype similar to the homozygous Zfp106LacZ/LacZ mice while others 
did not.  The imperfect penetration rate of the phenotype may be due to an insufficient 
backcrossing of the line as the mice studied were of the F2 generation. Other explanations for this 
difference are a discrepancy of the Zfp106 isoforms interrupted by either mouse model or the need 
for P2 overexpression in the skeletal muscle. Each possibility of which should be explored further.  
Assessing the potential cause of this muscle atrophy in vitro, motor neurons derived from the 
directed differentiation of WT or ΔZfp106 mESC lines carrying a homozygous INDEL disrupting 
Zfp106 exon 5 were tested in a survivability assay. Here it was found that there was a significant 
decrease in the cell body area of the ΔZfp106 MN line compared with control in response to the 
mitochondrial stressor rotenone. Additionally, CPA induced ER stress decreased the length of the 
neuronal processes while increasing their number. Understanding these heightened vulnerabilities 
of the ΔZfp106 motor neuron sets the path for potential avenues of research into what the exon 5 
interruption of Zfp106 does to motor neuron behavior. Subsequent studies should focus on 
conducting a dose response curve for each stressor which could then be followed up by a chemical 
screen to ameliorate the effects of the stress. The identity of the chemicals that protect the motor 
neurons can point to cellular pathways that may be integral to the pathology associated with 










Muscle homeostasis can be altered through changes in the signaling and health of the muscle, 
neurons, or in the neuromuscular junction52. The Zfp106LacZ mouse model was found to be an 
effective depletion of Zfp106 exons 2 and 3. The ΔZfp106 mouse model targeting a common exon, 
exon 5 led to the development of severe muscle atrophy similar to Zfp106LacZ mice albeit at a 
different penetration level. This means that the P2 overexpression is not necessary for the 
development of muscle atrophy, although it might be important in the penetration rate of the 
phenotype. These two models led us to believe that the skeletal muscle atrophy displayed by the 
Zfp106LacZ mice may be due, at least in part, to the disruption of a P1 Zfp106 isoform. Therefore, 
we sought to induce P1 Zfp106 depletion in either the skeletal muscle or choline acetyl transferase 
positive cells to understand whether the muscle atrophy in the mice is myopathic or neuropathic. 
To do this, we took advantage of the KOMP KO mouse gene trap design that allows for a tissue 
specific deletion of exon 3 (Figure 4). Because exon 3 is upstream of the transcription start site of 
the P2 isoform of Zfp106, the cre-mediated removal of this exon leads to a frame shift and 
premature stop codon which should disrupt isoforms from the first promoter region while leaving 
the P2 isoforms unadulterated (Figure 27). Therefore, this model should be able to recapitulate the 
gene trap P1 knockout in the Zfp106LacZ mice. The mice carrying the floxed exon 3 gene will be 
called Zfp106Flox moving forward.   
The first step in generating the Zfp106Flox mice was to remove the gene trap in the Zfp106LacZ 
mouse model leading to the derivation of Zfp106fl (tm1c)29. To do this, heterozygous Zfp106LacZ/+ 
were crossed with FLPeR, a mouse line that expresses FLPe under the control of the universally 
expressed Gt(ROSA)26Sor promoter and causes a whole body FLP recombination102. Zfp106fl 




that allow for the tissue specific expression of cre recombinase103,104. Of note, although largely 
expressed in the skeletal muscle, Myf5 has been found to be expressed in the neural tube, which 
develops into the spinal cord and brain105.  Zfp106fl/fl mice were also bred with the combination of 
the motor neuron and muscle specific cre driver lines, Myf5Cre and ChATCre simultaneously 
(Figure 27). Lastly, as a control, the Zfp106fl/fl mice were crossed with a ubiquitous cre line 
utilizing the adenovirus Ella promoter that leads to a germline cre recombination and deletion of 
exon 3106.   
 
  





Removal of the Gene-trap and the Establishment of Zfp106fl/fl mice 
Crossing ZfpLacz/+ with Rosa26 Flpe mice led to a germ line removal of gene-trap splice acceptor 
lacZ/neomycin cassette that prevented the expression of P1 Zfp106 past exon 2. Heterozygous and 
homozygous Zfp106fl mice do not have an observed neuromuscular phenotype (Figure 28A). At 8 
weeks both the whole body and skeletal muscle weights were not different between control and 
homozygous Zfp106fl/fl mice (Figures 28B and 28C). The mRNA levels of Zfp106 in either the 
homozygous or heterozygous mice are not different when compared with WT controls. This 
demonstrates that the removal of the gene-trap did not affect the transcription of Zfp106 (Figure 
28D). As the gene-trap removal did not lead to a neuromuscular defect, the homozygous Zfp106fl/fl 
mice were then available for further mouse generation. The Zfp106fl/fl were used to generate mice 
with either muscle (Myf5) or cholinergic neuron (ChAT) specific removal of Zfp106 exon 3. 
Additionally, moving forward Zfp106fl/fl mice are used as controls to assess the phenotypic effect 






Figure 28 Characterization of Zfp106fl/fl mice.  
A) Representative photographs of Control and Zfp106fl/fl mice at 8 weeks not 
evidencing muscle atrophy. 
B) Body weight of male 8 week old mice (Ctrl, n=4; Hom, n=7 n.s. is non-
significant, unpaired two-tailed t-test, mean ± S.D.). 
C) Average (left and right) gastrocnemius muscle weight of male 16 week old 
mice. (n.s. is non-significant, unpaired two-tailed t-test, Ctrl, n=4; Hom, n=7, 
mean ± S.D.). 
D) Expression of Zfp106 in skeletal muscle (n.s. is non-significant, using one-
way ANOVA with Dunnett’s multiple comparisons test vs.  WT. WT, n=4; 





Tissue specific removal of Exon 3 
Myf5 and ChAT promoter driven expression of cre is expected to lead to the expression of cre 
recombinase in skeletal muscle and cholinergic neurons (including motor neurons), respectively. 
As such, crossing mice carrying these cre drivers should lead to the disruption of P1 Zfp106 in 
either the cholinergic neurons ChATCre:: Zfp106fl/fl or skeletal muscle Myf5Cre:: Zfp106fl/fl 
through the tissue specific depletion of exon 3. Additionally, employing both cre drivers in tandem 
Myf5Cre::ChATCre::Zfp106fl/fl would be expected to drive the depletion of P1 Zfp106 in both 
tissues simultaneously. This would allow us to dissect whether the muscle atrophy in the globally 
depleted Zfp106LacZ mouse model is caused by the disruption of P1 Zfp106 in the skeletal muscle, 
cholinergic neurons or if the phenotype necessitates the removal of P1 Zfp106 in both.  
Interestingly, the deletion of Zfp106 exon 3 in all three scenarios (skeletal muscle, cholinergic 
neurons, and both simultaneously) did not lead to a recapitulation of the Zfp106LacZ phenotype 
(Figure 29). By 8 weeks of age, the mice did not show any signs of muscle atrophy or weakness 
displayed by the gene-trap Zfp106LacZ mouse model. In contrast to the Zfp106LacZ/LacZ homozygous 
mice with muscle atrophy, when suspended by their tail, the hindlimbs of any of the Cre::Zfp106fl/fl 
mice extend similar to controls at 8 weeks instead of tucking-in (Figures 6A and 29A). Waiting 
until 16 weeks, the terminal timepoint for Zfp106LacZ mice, the cre mice do not recapitulate the 
Zfp106LacZ phenotype. By 16 weeks, there is a slight decrease in body weight of the 
Myf5Cre::ChatCre::Zfp106fl/fl mice, but this decrease is not comparable to the decrease in body 
weight observed in the Zfp106LacZ mice (Figure 6C, 6D, and 29B). The decrease in body weight 
of the double cre driver mice is not reflected in the average gastrocnemius weight, as this model’s 
average muscle weight is non-significantly different from control mice. ChATCre::Zfp106fl/fl mice 




however, this difference is slight and may be due to sampling variability (Figure 29C). Both of the 
control and cre driven mice examined at 16 weeks reached the 1-minute time point during the 






Figure 29 Characterization of tissue specific Zfp106 exon 3 depletion. 
A) Representative photographs of Control (Zfp106fl/fl) and the various mice at 8 weeks not 
evidencing muscle atrophy. 
B) Body weight of male 16 week old mice (Ctrl, n=7; Myf5Cre, n=7; ChATCre, n= 7; Myf5 
ChATCre, n=3 * p<0.05, using one-way ANOVA with Dunnett’s multiple comparisons test vs. 
the control column, mean ± S.D.). 
C) Average (left and right) gastrocnemius muscle weight of male 16 week old mice. (* p<0.05, 
using one-way ANOVA with Dunnett’s multiple comparisons test vs. the control column, Ctrl, 
n=7; Myf5Cre, n=7; ChATCre, n= 7; Myf5 ChATCre, n=3, mean ± S.D.). 
D) Inverted screen score of both male and female mice at 16 weeks of age (Ctrl, n=6; Myf5Cre, 





The expression of Zfp106 in each mouse model was measured to ensure that the exon 3 of Zfp106 
was successfully removed using cre recombination in the targeted tissue. As expected, skeletal 
muscle samples from Myf5Cre and Myf5Cre/ChAT cre mice led to the significant depletion of 
exon 3 while no transcript depletion was observed with the ChAT Cre driver expression (Figure 
30A). Surprisingly, examining the spinal cord of expression of Zfp106, there is no measured 
depletion of Zfp106 exon 3 using any of the cre drivers (Figure 30B). This may be due to the low 
number of cholinergic neurons in the spinal cord even in the motor neuron rich regions107,108. This 
means that it is difficult to confirm if the ChAT driven cre-recombination of P1 Zfp106 occurred 
at the RNA level. As such, this study can simply conclude that Myf5Cre driven removal of Zfp106 





Figure 30 Zfp106 expression in cre driver Zfp106fl/fl mice.  
A) Expression of Zfp106 in skeletal muscle (* p<0.05, using one-way ANOVA with Dunnett’s 
multiple comparisons test vs. the control column, (Ctrl, n=14; Myf5Cre, n=3; ChATCre, n= 4; 
Myf5/ChATCre, n≥3, mean ± S.D.). y-axis is in log10 scale. 
B) Expression of Zfp106 in spinal cord (* p<0.05, n.s. is non-significant, using one-way 
ANOVA with Dunnett’s multiple comparisons test vs. the control column, Ctrl, n=12; Myf5Cre, 





Whole body cre recombination Ella2Cre::Zfp106fl/fl 
As the tissue specific exon 3 depletion did not recapitulate the Zfp106LacZ phenotype, and the 
success of the cre driver utilization in cholinergic neurons could not be confirmed, we sought to 
understand whether the whole-body exon 3 depletion recapitulates the muscle atrophy phenotype. 
This will allow us to understand whether we are targeting the removal of an exon whose depletion 
will lead to muscle atrophy similar to Zfp106LacZ which itself is a global Zfp106 gene-trap model. 
To do this, Zfp106fl/fl mice were crossed with Ella2Cre mice which uses the adenoviral associated 
Ella promoter to cause germ line cre recombination and the subsequent transmission of the cre 
recombined gene106. This leads to the development of heterozygous exon 3 floxed mice Zfp106flox/+ 
that are bred together to generate homozygous Zfp106flox/flox mice carrying the whole-body 
deletion of Zfp106 exon 3 (Figure 31). This mouse model will allow us to understand if exon 3 is 
integral to muscle homeostasis, irrespective of the tissue it is removed from. However, this model 
does not address the possibility that the muscle atrophy of these mice is due to the increased P2 
Zfp106 expression as this is non-significantly affected in the spinal cord and skeletal muscle of 












Similarly, to the mouse models with a tissue specific cre removal of exon 3, whole-body exon 3 
depletion (Zfp106flox/flox) mice did not show any muscle atrophy as compared with control mice 
(Figure 32A). The body weight and average gastrocnemius muscle weight are non-significant 
decreased in homozygous mice by 16 weeks (Figures 32B and 32C). Homozygous mice had 
indistinguishable muscle strength from controls, as assessed by the inverted screen test, being able 
to carry their body weight in the inverted screen test for the maximum allotted time of one minute 
(Figure 32D).     
Interrogating the RNA expression of Zfp106 in the whole-body exon 3 depleted mice confirmed 
the cre mediated removal of exon 3 in both the skeletal muscle and spinal cord. In fact, in the 
Figure 32 Zfp106flox/flox Characterization. 
A) Representative photographs of Control  and Zfp106flox/flox homozygous mice. 
B) Body weight of male 16 week old mice (n.s. is non-significant, using an unpaired student’s 
two-tailed t-test, Ctrl, n=8; Hom, n=3, mean ± S.D.). 
C) Average (left and right) gastrocnemius muscle weight of male 16 week old mice. (n.s. is non-
significant, using an unpaired student’s two-tailed t-test, Ctrl, n=4; Hom, n=3, mean ± S.D.). 
D) Inverted screen score of both male and female mice at 16 weeks of age (n.s. is non-significant, 




skeletal muscle of the homozygous mice the amount of exon 3 was below the limit of detection 
(Figures 33A and 33B). Interestingly, the heterozygous Zfp106flox mice shows a higher than 
expected decrease in exons 4-5, 21-22, and 1b in skeletal muscle. The exact mechanism behind 




Figure 33 Zfp106 expression in E2aCre::Zfp106flox mice. 
A) Expression of Zfp106 in skeletal muscle (n.s. is non-significant, using one-way ANOVA 
with Dunnett’s multiple comparisons test vs. the control column, Ctrl, n=3; Het, n=3; Hom, n=3, 
mean ± S.D.). y-axis is in log10 scale. 
B) Expression of Zfp106 in spinal cord (**P<0.01, n.s. is non-significant using  one-way 
ANOVA with Dunnett’s multiple comparisons test vs. the control column, Ctrl, n=5; Het n=6, 





The cre-mediated removal of exon 3 did not lead to muscle atrophy in any of the mouse models. 
This result is surprising as up to this point, it seemed that the P1 Zfp106 depletion was what was 
leading to the muscle atrophy phenotype. The non-development of muscle atrophy may be because 
of several factors including that exon 3 does not need to be included in the Zfp106 splice variant 
that is integral to neuromuscular health or that the premature stop codon caused by the frameshift 
does not lead to a nonsense mediated decay and the stop codon is read through by the translational 
machinery. 
To address the change in splice isoforms of the mouse model, the mRNA can be visualized using 
a northern blot with a probe against Zfp106 exon 2 comparing the Ella2 cre WT, Het, and Hom 
mice. If there is any shift in the splice variants present in the mRNA of each mouse, these isoforms 
can be the prime candidate for further investigation. 5’RACE can then be performed on the CDNA 
of each mouse model and the splice variants identified and subsequently quantified using 
quantitative RT-PCR. Any change in the splice variants or their amounts might give us a clue to a 
potential compensation occurring after the removal of exon 3. Of note, following the sequence of 
each of the Zfp106 exons, there are several potential splice variants beginning at exon 2 leading to 
the complete transcription of Zfp106. The longest splice variant (with the least number of exons 
skipped) that leads to an in-frame mRNA is from exon 2 directly to exon 7. This is interesting, as 
this would mean that this isoform does not contain exon 5 which we previously disrupted to lead 
to muscle atrophy. That being said, there is currently not enough known regarding the splice 





The issue with the translation machinery read through could be assessed through the addition of 
an epitope tag to the n-terminus of Zfp106 exon 2 in this mouse model. If the epitope tag is 
expressed and can be detected than it means that the mRNA originating from this exon are being 
translated into proteins. Alternatively, an antibody against the peptides encoded by exon 2 can be 
used to see if the protein is still expressed. 
Experimental Limitations 
Cre drivers 
The use of cre drivers to control LoxP recombination in a tissue specific manner can be affected 
by the promoter driving its expression. Myf5 Cre in particular is known to be expressed in the 
neural tube, which develops into the spinal cord and brain105. This means that the cre 
recombination could have occurred in these off-target tissues leading to Zfp106 recombination in 
these cells during development. If the mice developed muscle atrophy, it could have been due to 
these off-target effects.  
Lack of proteomic work 
Similar to the use of the other mouse models, the effect of exon 3 on Zfp106 expression cannot be 
analyzed at a proteomic level. This lack leads to many open questions including the potential factor 
of the preservation of the frame shifted mRNA leading to the expression of a protein that could 





Tissue specific rescue 
The cre-lox recombination of exon 3 could not recapitulate the muscle atrophy phenotype 
associated with the original Zfp106LacZ mouse model (Figures 6 and 31). Therefore, the question 
regarding which tissue has the primary dysfunction that is causing the muscle atrophy could not 
be answered though that experiment. Another way to address if the muscle atrophy is due to a 
dysfunction in the motor neuron or muscle is to remove the gene-trap in select tissues. This method 
should faithfully reproduce the disruption of Zfp106 in the Zfp106LacZ model. This can be done 
through the use of adeno associated viruses (AAV) that lead to the expression of FLP recombinase 
specific to either the peripheral nervous system or skeletal muscle. To target the skeletal muscle, 
Zfp106LacZ mice can be infected with rAAVrh.10 intraperitonially109. To remove the gene-trap in 
the peripheral nervous system AAV-PHP.S can be administered intravenously110. Both 
interventions should be administered at P7 before the onset of muscle dysfunction (Figure 34).  
These rescue experiments are aimed at preventing the muscle atrophy phenotype. For example, if 
the AAVs successfully cause the removal of the gene-trap in the skeletal muscle and the muscle 
atrophy does not develop then the phenotype can be thought to stem from a dysfunction in the 
skeletal muscle. If it does not, then the dysfunction observed in the skeletal muscle may be 
secondary to the interruption of Zfp106 expression in another tissue like the peripheral nervous 
system.  
The results of these experiments are important to determine where the lack of P1 Zfp106 is causing 
the most distress and can guide future research into better understanding its function once the tissue 
is known. If neither individual rescue is effective, the co-infection of AAV expressing FLP 




prevent muscle atrophy. Interestingly, if the AAV driven expression is successful in both the 
peripheral nervous system and skeletal muscle yet this does not lead to a full rescue, it shows that 
the lack of P1 Zfp106 in either tissue is not what is leading to the muscle atrophy and that it may 






Figure 34 AAV-mediated tissue specific Flp Rescue. 
A) FLP recombination schematic of the removal of the gene-hijacking motif. 





The full body Cre mediated removal of Zfp106 exon 3 does not recapitulate the muscle atrophy 
phenotype of Zfp106LacZ or ΔZfp106. Confirming the removal of exon 3 at the mRNA level, this 
result is surprising as the removal of this exon leads to a stop codon and a truncation of the isoforms 
beginning at exon 2 and splicing into any alternative exons 4 through 6. This means that any 
isoforms that are generated through a skip of exon 3, should not include exon 5 whose interruption 
was shown to lead to muscle atrophy. This means that, the whole-body deletion of Zfp106 exon 3, 
was expected to lead to muscle atrophy, at least in some mice. The lack of muscle atrophy of this 
mouse model is difficult to explain especially considering the lack of a method to validate the 
removal of Zfp106 at a protein level and the little that is known regarding Zfp106 splice variants. 
It is possible that the removal of exon 3 led to mRNA that did not undergo nonsense mediated 
decay and was translated into protein. Alternatively, a splice variant expressed in due to the 
removal of exon 3, and not the interruption of exon 5, is compensating for the loss of the isoform 
containing exon 3. Despite this, from this study we can conclude that the removal of exon 3 Zfp106 
in mice does not lead to muscle atrophy. However, more needs to be known about Zfp106 in order 















The Zfp106LacZ mice serve as a useful mouse model to understand the effect of the global removal 
of P1 Zfp106. However, given the many distinct differences between the P1 and P2 isoform 
families of Zfp106, a P2 specific depletion mouse model (ΔP2) would be valuable in order to better 
understand its role in vivo. Structurally, the P1 and P2 isoforms have different N-terminal motifs. 
The zinc finger in the P1 isoform was identified as a potential cytochrome-c binding domain and 
is substituted for an the SH3 binding domain in the P2 isoforms. Aside from the functional group 
difference, P1 Zfp106 is expressed ubiquitously and P2 Zfp106 is predominantly expressed in 
excitable tissue like the heart and skeletal muscle 6,9,12.  
We used CRISPR-Cas9 to generate an isoform family specific disruption of the P2 Zfp106 by 
introducing a double stranded break in the P2 isoform’s alternative first coding exon, exon 1b 
(Figure 35A)6. As such, a disruption of this exon is not expected to affect the expression of P1 
Zfp106 but it should abolish the expression of P2 Zfp106 isoforms. In order to do this, a guide 
RNA against the exon 1b was developed and electroporated into mESCs with Cas9 (Figure 
35B)111. This led to several colonies of mESCs expressing either a homozygous or heterozygous 
INDEL in exon 1b confirmed through sequencing. The heterozygous INDEL of Zfp106 exon 1b 
removing ‘tgggg’ was selected to be used to generate the in vivo mouse model ΔP2 as this leads to 







Figure 35 ΔP2 CRISPR targeting. 
A) Schematic of Zfp106 highlighting Exon1b and the sequence targeted for a CRISPR mediated 
double stranded break.  
B) Diagram of predicted location of Cas9 binding and the CRISPR double stranded break.  
C) Heterozygous INDEL in mESC clones used to generate a new mouse line. Green box 






The in vivo model of the P2 isoform family (ΔP2) depletion shows no muscle atrophy in both male 
and female heterozygous or homozygous mice. At 16 weeks, when suspended from their tail, the 
hindlimbs spread similarly with control mice (Figure 36A). Out of 49 mice total, approximately 
half were heterozygous while a third were homozygous and the remainder were wild type (Figure 
36B). Assessing the body weight of the P2 isoform depletion model shows no significant 
difference up to the measured 32 weeks (Figures 36C and 36D). The lack of a neuromuscular 
phenotype of the P2 isoform depletion may signal that P2-Zfp106 is not necessary for growth or 
normal physiological maintenance of the neuromuscular system. 
As Zfp106 was previously implicated in the IGF-R/InsR pathway, it was of interest to do an initial 
screen to see if the ΔP2 mice show a metabolic phenotype that can be revealed by their handling 
of glucose. To assess this, the mice were tested using a glucose tolerance test (GTT) by starving 
overnight (~16 hours) followed by a glucose bolus of 1g/kg.  The glucose levels of the mice are 
then monitored to assess if they spike and recover in response to glucose similarly with controls. 
An abnormal GTT would support either an issue with the release of insulin in response to glucose 
or a pathology of the response of skeletal muscle and other peripheral tissues to insulin112. The 






Figure 36 ΔP2 in vivo model characterization.  
A) 16-week old control and homozygous mice showing no noticeable atrophy. 
B) % born of each genotype of male and female mice (Total male, n=31; total female, n=18). 
Insets are the individual counts. 
C) The bodyweight of male mice vs. controls over time. (Ctrl, n≥5; Hom, n≥4). 
D) The bodyweight of female mice vs. controls over time (Ctrl, n≥3; Hom, n≥3). 





In this study, we developed and conducted the initial characterization of a CRISPR mouse model 
introducing an INDEL into exon 1b leading to a frameshift and premature stop codon in order to 
see if the depletion of P2-Zfp106 negatively impacted neuromuscular health. Before generating 
homozygous mice, we hypothesized that the removal of P2 Zfp106 isoform family could have a 
neuromuscular effect as it is the dominant form of Zfp106 in the skeletal muscle6,9. Additionally, 
we thought that there might be a metabolic phenotype as sh3bp3 was implicated in the 
insulin/IGF1R pathway6,9.  
Homozygous ΔP2 mice had no observable muscle atrophy and responded to a glucose bolus after 
overnight starvation similarly with controls. The homozygous mice were indistinguishable from 
controls in terms of weight for both male and female mice. These results may mean that the P2 
Zfp106 isoform family initiated through exon 1b is not necessary for the maintenance of 
neuromuscular health and glucose metabolism.  Of note, because the effect of this CRISPR 
deletion on P2 Zfp106 could not be confirmed at the protein level due to a lack of an antibody. 
Further studies should be conducted confirming the proteomic depletion of the P2 Zfp106 isoform 
family once a reliable antibody becomes available.  
The depletion of P2 Zfp106 may not necessarily mean that the isoform family does not have any 
role in the maintenance of neuromuscular health. It may be that P1 Zfp106 or another protein is 
compensating for the loss of P2 Zfp106. To confirm whether or not P2 Zfp106 has a role in skeletal 
muscle development, I propose taking a step back and attempting to see if this protein is involved 
in any major pathways associated with muscle maintenance like the IGF1/InsR pathway. This can 
be done in vitro and in vivo using the genetically tagged mouse models proposed in Figure 20 




mice derived from this experiment can be studied to better understand the role of P2 Zfp106 
isoforms and see if it associates with any pathway’s integral to neuromuscular health through the 
use of the integrated myc tag. If it is involved, P2 Zfp106 can then be interrupted again and we 
can observe if the Flag-tagged P1 Zfp106 isoforms compensate for its removal by investigating if 
there is any change in its expression or localization in response. 
Further experiments 
P2 Overexpression 
The CRISPR mediated deletion of P2 Zfp106 targeting exon 1b did not lead to a noticeable 
neuromuscular phenotype (Figures 35 and 36). This may be due to compensation by P1 Zfp106 or 
another protein masking its potential role in the neuromuscular system. In the Zfp106LacZ mouse 
model, homozygous mice showed an increase in exon 1b associated with the P2 Zfp106 isoform 
family by RNAseq and qPCR in the skeletal muscle. The effect of this increase may be worth 
investigating as this may have contributed to the muscle atrophy in the gene-trapped Zfp106LacZ 
model (Figure 18). Additionally, P2 Zfp106 transcripts have been found to increase in the 
differentiation of myoblasts to myotubes6. 
In an attempt to study the effect of the overexpression of the full length P2 Zfp106 isoform on 
skeletal muscle health, we developed a lentivirus carrying full length N-terminally flag tagged P2-
Zfp106. This virus was injected into the hindlimb of WT mice to assess if this overexpression 
would lead to muscle atrophy. However, this trial was unsuccessful as we could not measure any 
Zfp106 expression in the hindlimb (data not shown). We believe this may be due to the large size 
of Zfp106 deleteriously affecting the viral titer. Therefore, to investigate the potential role of P2 




Zfp106 motif to the Rosa26 locus can be created (Figure 37A)113. This will allow for the tissue 
and temporally specific overexpression of the P2 Zfp106 isoform in skeletal muscle in order to 
better understand its role in vivo (Figure 37B). As an example, P2 Zfp106 expression can be 
induced in vivo in skeletal muscle and the mouse muscle strength, the NMJ structure, and motor 













etailed targeting vector used to generate the targeted genetic insertion of the P2Zfp106 into the R
osa26 locus using the A
i38 
targeting vector. The construct w
ill be inserted in the intron 1 betw





ing the insertion of P2Zfp106 into the R
osa26 locus and the effect of crossing w
ith a m
uscle specific cre 
(M
yf5 C
re) expression line and the m
easurem







The interruption of exon 1b in the ΔP2 mice did not lead to a noticeable neuromuscular or 
metabolic phenotype. This may be because this isoform does not play a role in these systems or 
that there is a redundant protein that compensates for its loss. These results were surprising given 
the high expression of P2 Zfp106 in excitable tissue making it seem that this isoform has a role in 
skeletal muscle. However, the P2 isoform depletion may be useful in the future in order to assess 
other biological pathways.  
Future work should focus on understanding the role of P2 Zfp106. This will greatly be facilitated 
if and when a reliable antibody is developed for P2 Zfp106 or an epitope tagged version of the 
protein can be expressed. Once the potential pathways that P2 Zfp106 functions in is identified, 
we can than assess its role and better understand why its CRISPR mediated depletion did not lead 
to muscle atrophy. A P2 Zfp106 overexpression model would be interesting to study as it may 
negatively affect neuromuscular health. This is because, the expression of exon 1b is heightened 
in mouse skeletal muscle of homozygous Zfp106LacZ mice and the ΔZfp106 model, which prevents 
the expression of the full-length splice variants of P1 and P2 Zfp106, led to a muscle atrophy model 










This study focused on the genetic manipulation of Zfp106 to inhibit various isoforms of the protein 
and study whether or not their depletion leads to muscle atrophy (Figure 38). Homozygous mice 
from the first mouse model we studied, Zfp106LacZ, developed severe muscle atrophy beginning at 
4 weeks leading to death by 16 weeks. However, we, and others, found that the mouse model did 
not completely abolish Zfp106 expression in these mice. Although the gene-trap effectively 
targeted exons 2 and 3 which are associated with the P1 Zfp106 isoform family, exon 1b transcripts 
were increased significantly in the homozygous mice. This left us with a question of whether or 
not the muscle atrophy is due to the interruption of the transcription past exon 2 or because of the 
increase in P2 Zfp106 expression. In order to answer this, we developed a CRISPR mediated 
interruption of exon 5 (ΔZfp106) which is common to both promoter isoform families and affects 
the full-length isoforms of each. Homozygous ΔZfp106 mice developed severe muscle atrophy 
similarly with the Zfp106LacZ mice. However, in contrast to the Zfp106LacZ model the penetration 
rate of the phenotype is less than 100% with 60% and 12.5% of homozygous males and females 
developing atrophy respectively. This difference may be caused by various factors including the 
need for further backcrossing and the different effects of each model on the splice variants of 
Zfp106. As both the Zfp106LacZ and ΔZfp106 mouse models were effective interruptions of exons 
included in the P1 Zfp106 isoform family, these studies show that this isoform family may be 
important in neuromuscular health. Further work should be conducted in order to understand why 
there is a difference in the penetration rate of the phenotype, including the potential deleterious 
effect of an increase in the expression of a P2 Zfp106 isoform. 
In vitro motor neurons differentiated from homozygous ΔZfp106 mESC reacted differently to ER 
and mitochondrial stressors CPA and Rotenone respectively. Treatment of the motor neurons by 




led to smaller cell body area. These susceptibilities may be pointing out disrupted pathways in the 
motor neurons that would be worth pursuing in the future.  
As the Zfp106LacZ and ΔZfp106 mouse models point to the importance of a P1 Zfp106 isoform in 
neuromuscular health, we then tried to assess whether the muscle atrophy seen is due to P1 Zfp106 
depletion in the skeletal muscle, cholinergic neurons, or both. We did this by deriving an exon 3 
from the Zfp106LacZ mouse, which is a conditional knockout model that can be controlled by tissue 
specific cre drivers. We found that none of these mice were developing muscle atrophy so we used 
a whole body cre driver to see if the depletion was necessary in another tissue. Surprisingly, the 
whole-body exon 3 depletion mice did not develop muscle atrophy. These results may mean that 
exon 3 is not integral to the isoform that is needed to maintain neuromuscular health in mice in 
vivo. However, it is noteworthy that the closest exon that exon 2 can splice to that does not lead to 
a frameshift and premature stop codon is exon 7, skipping exon 5. This is contrary to the ΔZfp106 
results as the exon 5 interruption leads to a muscle atrophy phenotype. These results are difficult 
to reconcile and further work is needed to better understand the murine splice variants of Zfp106.  
Lastly, we developed a P2 Zfp106 specific knockout mouse model (ΔP2) by interrupting the 
expression of exon 1b using CRISPR. We did this expecting that it would cause neuromuscular 
dysfunction as the P2 Zfp106 isoforms are dominant in the skeletal muscle. We were also 
wondering if the P2 Zfp106 depletion would cause a metabolic phenotype as Sh3bp3, a P2 Zfp106 
isoform, was implicated in the IGF-1R/InsR pathway. The homozygous mice from this mouse 
model did not show a metabolic, phenotype as tested through a glucose tolerance test, or develop 
muscle atrophy. This may either be because P2 Zfp106 is not important in these systems or due to 




Altogether, in this study we determined that a gene-trap directly down stream of exon 2 
(Zfp106LacZ) and the CRISPR mediated interruption of Zfp106 exon 5 (ΔZfp106) leads to the 
development of muscle atrophy in vivo with difference penetrance rates. This supports the notion 
that an isoform in the P1 Zfp106 family is important in neuromuscular health although the 
difference in the penetration rate of both mouse models is currently unexplained. Contrary to this 
finding though, the whole-body removal of exon 3 (which should affect the full-length P1 Zfp106 
isoform) did not lead to muscle atrophy, supporting the notion that this exon might not be included, 
or at least can be excluded, in the P1 Zfp106 isoforms needed to maintain neuromuscular health in 
vivo. Lastly, we found that the depletion of the P2 Zfp106 isoform family does not have a 
deleterious effect on murine metabolism or skeletal muscle health. Of note, these studies relied on 
a transcription level measurement of Zfp106 expression to analyze each mouse model, due to a 
lack of a reliable antibody. This means that none of the mouse models could be confirmed to be a 








atic of the in vivo m
odels of Z
fp106. 
The five in vivo m
odels m
anipulating Zfp106, the expected Zfp106 gene products expressed, and the presence or absence of m
uscle 
atrophy. D
ashed red lines delineate a predicted splice variant that does not lead to a fram
e shift and prem
ature stop codon. M
odel 4: 
Zfp106


















Zfp106LacZ mice were purchased through the knockout mouse project (KOMP, Project ID 
#CSD26348, Knockout First). Mice were sacrificed at either 4, 6, 8 or 16 weeks after birth. The 
mouse colony was multi-housed fed ad-libitum with normal chow diet and kept following 
guidelines issued by Columbia University’s Institutional Animal Care and Use Committee 
(IACUC, Approved Protocol # AC-AAAJ5500). 
Mouse skeletal muscle tissue Sampling 
At the designated time point (4, 8, 6, or 16 weeks) mice were sacrificed by CO2 asphyxiation and 
cervical dislocation, following Columbia University IACUC guidelines. The gastrocnemius, 
soleus and EDL muscles were harvested and weighed. Half of each muscle was apportioned for 
use with assays (qRT-PCR and Western blot). RNA extraction, the tissues were homogenized and 
lysed in RLT buffer with beta-mercaptoethanol (Qiagen, Cat#: 79216). If the tissues were 
preserved for future protein work, the samples were flash frozen in liquid nitrogen, homogenized, 
and lysed in the lysis buffer (Abcam, Cat#: ab152163) supplemented with protease inhibitor 
complex (Sigma-Aldrich, Cat#: P8340) together with phosphatase inhibitor complex 2 (Sigma-
Aldrich, Cat#: P5726) and phosphatase inhibitor complex 3 (Sigma-Aldrich, Cat#: P0044).   If the 
tissue was to be sectioned or used in scanning electron microscope experiments, the tissue was 
initially frozen down in chilled isopentane (Sigma-Aldrich, 2-Methylbutane, M32631) and then 
placed in liquid nitrogen.  




Mice greater than 3 weeks old were subjected to an inverted screen test to measure their muscle 
strength. The inverted screen test conducted is a variation of the traditional inverted screen 
test114,115. The mice were placed on top of the mouse cage, instead of a screen, which was then 
inverted 180 degrees over 2 seconds. The mice were kept suspended until a maximum of 1 minute 
is reach. If the mouse in unable to achieve this, the mouse is inverted three times and the maximum 
time achieved is recorded. The Inverted screen test is scored as follows: 
Time (s) Score 












Glucose tolerance test 
The GTT was conducted as described previously112. In brief, the mice were starved overnight (~16 
hours). The day of the experiment, a baseline glucose measurement was taken from each mouse. 
The mice were then injected with a glucose bolus of 1g/kg and the glucose in mg/dL was measured 
at 15-minute intervals up to 1.5 hours.  
ATPase staining and quantification 
Mice sacrificed as mentioned above. Barbital substitute protocol was used for skeletal muscle 
ATPase staining. In brief, muscle samples were immediately frozen in isopentane. Cross sections 




temperature in 200mM sodium acetate solution adjusted to pH 4.60 with acetic acid. This was then 
rinsed in Milli-Q water and incubated for 30 mins at 37°C in 3mM ATP, 30mM CaCl2 and 55mM 
NaCl in 50mM glycine NaOH buffer adjusted to pH 9.4 with HCl. This was rinsed twice in Milli-
Q water and then immersed for 3 minutes in 1% CaCl2 and then for 3 minutes in 2% cobalt 
chloride.  The samples were submerged in 1% Ammoniumsulfate for 1 minute in the chemical 
hood. This was rinsed three times in Milli-Q water, dehydrated in ethanol, cleared in xylene and 
then mounted in permount (Fisher Scientific). 
RNA extraction/cDNA synthesis and qPCR 
qRT-PCR samples were prepared using the RNeasy RNA extraction kit. In brief, the RNA samples 
were purified then converted to cDNA using Superscript III RT enzyme. The qPCR is conducted 
using SYBR green master mix (TaKaRa/CloneTech) in a 96 well format. The plate is loaded on a 
StepOnePlusTM Real-Time PCR system (Life Technologies).  TaKaRa human tissue RNA samples 
were used for cDNA synthesis and conventional RT-PCR for Zfp106 gene expression profiling. 
Western Blot 
To perform Western blotting, in a cold room, these samples were first centrifuged for 5 minutes at 
12,000rpm. The supernatant was collected and prepared for loading onto an SDS-PAGE gel. The 
membranes were stained using the antibodies (see supplementary table 2). The signals were then 
visualized by incubation with horseradish peroxidase-conjugated secondary anti-mouse or anti-
rabbit antibodies. Pierce ECL Western Blotting Substrate was used as a chemical luminescent 
substrate to detect HRP. The contrast of the western blot exposures were heightened equally for 
both the control and KO bands for the IGF1R-β, InsR-β, IRS1 and p-IRS1S307 blots. 




Sample bands were quantified using the densitometry measurement tool. A single ROI was created 
to measure the signal and background bands for either the control or homozygous samples for each 
target protein. The background measurements was then subtracted from the signal. This was then 
normalized to the house keeping protein β-III tubulin. The normalized results of the homozygous 
mice were compared with controls by setting the average control value to 100% and normalizing 
the homozygous data. 
Neuromuscular junction (NMJ) immunohistochemical staining 
Neuromuscular junction staining was carried out similarly to previous established protocols116. To 
accomplish the staining, gastrocnemius muscle was harvested and weight followed by fixation in 
cold (-20°C) methanol for 5 minutes. The muscle is then rinsed in 1xPBS and the fascia is removed 
and the muscle tweezed into smaller pieces under a microscope. The muscles are then blocked for 
24 hours at 4°C in blocking buffer (3% BSA, 5% horse serum, 1% Triton X-100 in PBS). After 
blocking, the muscles are incubated in primary antibody for 48 hours at 4°C (1/800 Rabbit anti 
neurofilament, Sigma-Aldrich Cat#: AB1989; 1/800 tetramethylrhodamine α-Bungarotoxin, 
Invitrogen Cat#: T1175). Secondary antibody incubation was then conducted for 24 hours at 4°C 
(1/800 Donkey anti-rabbit Alexa 488, Invitrogen A-21206). The samples were tweezed further 
mounted using VECTASHIELD antifade mounting medium (Vector laboratories, H-1000) and 
imaged using a Nikon inverted microscope (Eclipse Ti) using GFP for TxRED filters.  
Zfp106 enrichment for the LC/MS/MS experiment 
Gastrocnemius muscle was harvested from both control and homozygous Zfp106LacZ mice. The 
muscle was then homogenized and lysed in the lysis buffer (Abcam, Cat#: ab152163) 




incubated with Zfp106 primary antibody (Abcam, Cat#: ab84674) for 1 hour at 4°C while 
inverting. The lysate was then added to a 2mg/mL protein G sepharose bead slurry (GE Healthcare, 
Cat#: GE17-0618-01) resuspended in lysis buffer and allowed to incubate together overnight at 
4°C while inverting. The sample was then run on an SDS-PAGE gel and visualized with EZ blue 
Coomassie stain (Sigma-Aldrich, Cat#: G1041). The gel was then processed through trypsin 
digestion and analyzed using an orbitrap Q Exactive HF.  
Neuromuscular junction quantification 
Neuromuscular junctions were quantified for two aspects: innervation and post-synapse formation. 
Full innervation was counted as an overlap of the neurofilament stain with the bungarotoxin stain. 
Partial innervation was when the neurofilament reached but did not overlap with the post-synaptic 
stain. No innervation was determined when the post-synapse was not connected to any 
neurofilaments. Formed post-synapses were categorized if a clear defined structure was apparent 
while collapsed post-synapses are when there is no discernable structure. All samples were 
quantified by a researcher blinded to the genotype of the animal. 
Motor neuron culture 
mESC were differentiated into motor neurons following a protocol established previously94. 
Briefly, mESC were initially cultured at 5x105-7.5x105 cells in ADFNK medium in 10cm Nunc 
Delta dishes (Thermo Fisher, Cat#: 150318). Motor neurons were then differentiated from mESC 
through the use of ADFNK supplemented with 1µM retinoic acid (Sigma-Aldrich, Cat#: R2625) 
and 0.5µM Smoothened agonist SAG (Sigma-Aldrich, Cat#: 566660) in suspension for 48 hours. 
The suspension media was changed to ADFNK medium supplemented with 10ng/mL GDNF 




Forskolin (Sigma-Aldrich, Cat#: F6886) for 24 hours. The embryoid bodies were subsequently 
dissociated using 0.05% Trypsin EDTA and plated at 2000 cells/well on a 96-well plate (Cellstar, 
Cat#: 655090) coated with 10mg/mL polyornithine (Sigma-Aldrich, Cat#: P4957), 1mg/mL 
laminin (Sigma-Aldrich, Cat#: L2020), and 4µg/mL fibronectin (Gibco, Cat#: PHE0023). During 
plating, the cells were treated with uridine/fluorodeoxyuridine (UFDU) to inhibit cellular 
proliferation.  
Motor neuron survival test 
Motor neuron survival tests were conducted in collaboration with the Wichterle lab and was 
conducted as previously reported98,117,118. Plated cells in the 96 well plate format were treated with 
either 0.5µM DMSO (24hrs and 48 hours), 0.5µM PHB1288 (48hrs), 10µM CPA (48hrs), 0.05µM 
MG132 (24hrs), or 0.03µM Rotenone (24hrs). After the specified treatment time, the cells were 
stained with 2µM Calcein at 5-7 minutes at 37°C which was quenched with 0.025% Brilliant black 
solution and imaged using the plate runner HD (Trophos) and analyzed using metamorph.  
Motor Neuron Immunocytochemistry 
Cells in a 96-well format were fixed using 4% PFA at RT for 15 minutes. The cells were blocked 
with blocking buffer (3% BSA, 0.1% Triton X-100) for 1 hour at room temperature. After this, the 
cells were stained with primary antibody (1/1000 Rabbit anti neurofilament, Sigma-Aldrich Cat#: 
AB1989; 1/200 mouse anti HB9, Santa Cruz Biotechnologies Cat#: sc-515769) overnight at 4°C. 
The cells were then stained with secondary antibody (1/1000 Donkey anti rabbit, Abcam Cat#: 
ab150076; 1/1000 Goat anti mouse, Abcam Cat#: ab150113) for 1 hour at room temperature. 




Scientific Cat#: 62249). The cells were then imaged using an inverted fluorescent microscope 
using the Dapi, Cy3, and FITC.  
Myoblast isolation and myotube differentiation 
We isolated mouse primary myoblasts using standard protocol using 0.2% trypsin and plated the 
cells onto collagen I-coated dishes (BD Falcon BioCoat Collagen I). For myoblast isolation and 
culture, we used Ham’s F-10 (Life Technologies, #11550-043) containing 20% fetal bovine serum 
(Gibco) and 2.5 ng/ml basic FGF (R&D Systems 233-FB-25 or PeproTech #100-18C). For 
differentiation into myotubes, we used DMEM (Life Technologies #10313-039, high glucose) 
containing 1% GlutaMax I, 2% Horse serum (Life Technologies, heat-inactivated). Myotubes were 
harvested at day 7 after differentiation for RNA preparation and cDNA synthesis. 
CRISPR mESC and F1 generation mouse genotyping 
mESC clones and F1 generation mouse lines were genotyped using a subcloning method using a 
Zero Blunt TOPO PCR cloning kit (Invitrogen Cat#: 450245). Mouse genomic DNA was 
amplified using the primers described below and ligated into the Blunt TOPO vector. One Shot 
TOP10 chemically competent E. coli cells were transformed by heat-shock and incubated at 37°C 
on kanamycin resistant Luria Broth (LB) agar (Invitrogen Cat#: C404010). Individual colonies 
were cultured in LB broth at 37°C and the DNA was purified using QIAprep spin miniprep kit and 
sequenced using SP6 sequencing primers (Qiagen Cat#: 27104) and aligned with the expected WT 
sequence using Serial Cloner ver. 2.6).  
CRISPR mouse genotyping 
Subsequent mouse generations were genotyped by amplifying and sequencing the genomic DNA 




Cat#: F-531 L). The resulting peak ab1 files were deconvoluted using ICE analysis 
(www.ice.synthego.com) which identified the proportion and characterization of INDELS. 
INDELS identified to be present in 50% of the population were determined to be heterozygous, if 






Culture of the patient and isogenic iPS cell lines 
Human iPSCs were cultured using a standard feeder-free protocol with Essential 8 medium and 
Geltrex (Thermo-Fisher/Gibco #A1517001) following the manufacturer’s instructions. Human 
isogenic control and patient iPSC lines were differentiated into cardiomyocytes using the 
monolayer-based in vitro differentiation protocol119. 
Statistical Analysis 
Graphpad prism software was used to conduct the statistical analysis for each experiment when 
necessary. The statistical tests used for each figure are described in their corresponding legends. 
Two-tailed students T-test was used when comparing two separate groups of observations. 
Welch’s correction was used when the variance between the two groups was statistically different. 
One-way ANOVA with Dunnet’s correction was used for multiple comparisons against a specified 
data set. All error bars represented standard deviation unless otherwise indicated. P values <0.05 






Traditional Genotyping protocols 
Target 
Genotype 






















62°C 1min 30 300bp 
R:CCCCACAACGGGT
TCTTCTGTTAGTCCC 











































Myf5Cre WT F: 
CGAGACGCCTGAAG
AAGGTCAACCA 















































































N/A N/A N/A 
 
mZfp106 specific qPCR primer sequences 
Protein mRNA Primer Sequence 
Exon 2-3 F: GAGTGCTTCAGATCTGGTCACT 
R: GCCCTTGAGGTTCTCAAGTTCCCTGTGATGCA 
Exon 3-4 F: ACTTGAGAACCTGAAGGGCAG 
R: CCTCTTCCTCTTCCTTTCCAT 
Exon 4-5 F: ACATTTCTGGCCAGTTGCAC 
R: TGTTACTGGGAGGTTCATCTTGT 
Exon 21-22 F: GGCGTTGTGGATCACTTGAAACAACAC 
R: CATGAATCTATTTTGCTGTCATCTTCAGCGTG 
Exon 1b F: CCAGTGGGGAGCATTGAATG 
R: CCTCTTCCTCTTCCTTTCCAT 
 
Protein specific qPCR primer sequences 
Protein mRNA Primer Sequence 
Akt2 F: GCATCCACTCTTCCCTCTCA 
R: CCAACACCTTTGTCATACGC 
Glut1 F: GCAGTTCGGCTATAACACTGG 
R: GAGACCAAAGCGTGGTGAGT 
Glut4 F: CAGCGCCTGAGTCTTTTCTT 
R: CAGTGTTCCAGTCACTCGCT 
Igf1 F: TTCAGTTCGTGTGTGGACCGAG 
R: TCCACAATGCCTGTCTGAGGTG 
Irs1 F: GGATTTGCTGAGGTCATTTAGG 
R: TATGCCAGCATCAGCTTCCA 
Mstn F: GATGACAGCAGTGATGGCTCTTTG 
R: CCACAGTTGGGCTTTTACTACTTTG 
MuRF F: GCAATATGGATTATAAATCTAGCCTGATTC 
R: GCGGTTGGTCCAGTAGGG 
MyoD F: ACGCACACTTCTCTACTGCG 
R: CTGCAGACCTTCGATGTAGC 
MyoG F: CGCCATCCAGTACATTGAGC 
R: TTCTGGACATCAGGACAGCC 





Psmd11 F: GAGCGGTAAGATGGCGGC 
R: CTTGTCCAGTCTTCGCCAGG 
Rn45s F: CTGACACGCTGTCCTTTCCCTATTAAC  
R: GCAAGCCCGGGAAAGCAGGAAG 
Rps6kb1 F: CAGCCAGAAGATGCAGGCTCTG 
R: CCGAAGTAGCTCAAAACATTCTGGTC 
 
Western Blot antibodies 
Antibody Concentration Source Manufacturer 
IGF1R-β 1:1,000 Rabbit Cell Signaling 
p-IGF1RβY1135/1136  
p-InsRβY1150/1151  
1:200 Rabbit Cell Signaling 
InsR-β 1:500 Rabbit Cell Signaling 
IRS1 1:1,000 Rabbit Cell Signaling 
p-IRS1S307 1:1,000 Rabbit Cell Signaling 
p-AktS473 1:2,000 Rabbit  Cell Signaling 
Akt (pan) 1:1,000 Rabbit Cell Signaling 
FoxO1 1:1,000 Rabbit Cell Signaling 
p-FoxO1T24 p-FoxO3aT32 1:1,000 Rabbit Cell Signaling 
βIII-tubulin 1:8,000 Mouse R&D systems 
 
Immunocytochemistry Antibodies 
Antibody Concentration Source Manufacturer 
Neurofilament 1:1,000 Rabbit Cell Signaling 
HB9  1:200 Rabbit Cell Signaling 
Tetramethylrhodamine  
α-Bungarotoxin  





Chapter 2: Development of an improved light-inducible transcription tool 































Chapter 2.1 Introduction to the FKF1/GI Project 
Introduction 
Optogenetic tools aim to control the signaling cascades and molecular interactions that influence 
cellular activity through light120. The initial landmark use of an optogenetic tool was in the field 
of neuroscience wherein channelrhodopsin-2 was stimulated with light to allow for a millisecond-
timescale control of neuronal spiking121. From here, the field of optogenetics expanded to enable 
the manipulation of proteins by inducing or inhibiting protein-protein associations, changing 
protein conformation, and altering gene expression122. Through the use of these tools, specific 
aspects of a signaling cascades can be turned on or off with fine spatiotemporal control using 
light120,123. As the field progresses, optogenetics may facilitate more complex scientific 
applications like cell patterning, allowing researchers to make mature tissues and organs in the lab, 
a process which requires the precise spatiotemporal control the can be achieved by using 
light120,124. In comparison, more traditional tools used to manipulate protein activity like 
overexpression systems or knockout models and chemical stimulation do not necessarily have the 
same control120.  Of note optogenetic tools, although increasingly useful, are limited in certain 
respects. As an example, tools that use blue light are difficult to activate in vivo as the light only 
penetrates the body at approximately 1mm depth125. To increase penetration depth, tools using 
infrared or far red light are being developed, meanwhile invasive surgeries like window 
craniotomies are needed to embed light probes into the model organism’s body to affect the 
tools120,126.    
Organisms, like plants, have developed to utilize light to affect molecular signaling pathways in 
response to their environment127,128. As such, a plant model organism Arabidopsis Thaliana has 




cryptochromes, and Light-oxygen-voltage (LOV) proteins 129-131. Flavin-binding, kelch repeat, F-
Box (FKF1), a member of the LOV family, was found to dimerize with Gigantea (GI) in response 
to blue-light stimulation to control circadian rhythm of Arabidopsis Thaliana132-134.  FKF1 and GI 
were used together to create an optogenetic tool base on light-activated dimerization by Dr. 
Yazawa131. This was used to induce protein-protein interaction as well as induce transcription, the 
latter of which was accomplished by fusing FKF1 to the transactivation domain VP16 and GI to 
the DNA binding domain135. In this initial publication, N-LOV G128D (a truncated mutant variant 
of FKF1) and GI coupling led to an increase in transcription of the target gene by 4.8x131. 
Project Aims/Why the project matters 
The aim of this project was to improve upon the previously developed optogenetic tool FKF1/GI 
G128D created by Dr. Yazawa to increase its utility and potential application131. To do this we 
focused on creating a tool with a low dark leak, meaning that the tool does not spontaneously 
dimerize and induce transcription. Once this was accomplished, we aimed on improving the 
induction of the tool so that the levels of transcription that follow light activation of the tool are 
significantly higher. The improvement of the tool was conducted through random mutagenesis and 
screening as well as the development of the proper arrangement of the bait and prey halves of the 
tool. Once completed, the application of the tool was tested in vitro and in vivo to better understand 
and characterize the new technology. 
This project is important as optogenetics gives researchers a viable method to spatially and 
temporally control gene expression using relatively innocuous stimuli such as blue light. As 
optogenetic tools continually improve, I believe that the precise control of target gene expression 
can be used to aid better manipulating genes like master transcription regulators that can enhance 




This project significantly improved the performance of FKF1/GI blue light dependent transcription 
regulation and may further aid in its adoption as a viable tool in our research arsenal.  
Project impact/follow-up 
Creation of an in vivo model 
The use of optogenetic tools allows for precise spatiotemporal control of gene expression, protein-
protein interactions and protein localization allowing researchers to manipulate cellular 
behavior122. Here we developed a new variant of FKF1/GI: NLOV(H105L)/GI that has a very low 
background leak and responds to blue light stimulation leading a 292x induction of luciferase. 
However, our tool is dependent on the Gal4UAS system which is not present in mammalian 
cells136. This limits its utility to control the expression of genes as the targeting system as well as 
the optogenetic tool needs to be introduced into the target animal. To address this, I would like to 
adapt the all-in-one NLOV(H105L)/GI tool by replacing the Gal4UAS binding domain with a zinc 
finger protein as completed previously with the LITEZ system (Figure 39)137. This will allow for 
the optogenetic manipulation of target genes138,139. Once the in vitro function of the tool is 
confirmed, it can then be introduced into the Rosa26 locus of a mouse and be used to affect the 





The initial development of the FKF1/GI optogenetic tool was developed by Dr. Yazawa131. The 
mutations and the arrangement of bait and prey of the FKF1/GI and Cry2/CIB1 tools were 
conducted by Daniel Awari and Seon-Hye E. Park. I took over the project completing the in-depth 
characterization of the FKF1/GI and CRY2/CIB1-based systems. To do this, I began by testing the 
optimal ratio of the optogenetic tools finding a 1:1 and 5:1 ratio works best for NLOV:GI and 
CRY2:CIB1 respectively. Once established, I studied the effect of variable illumination protocols 
on the performance of the tool, testing the reversibility of both systems and finding that, similarly 
with previous studies, the FKF1/GI dimerization is not reversible while the CRY2/CIB1 is. Further 
comparison was done outside of the luciferase assay using destabilized GFP (dsGFP) through 
western blot measurements and GFP expression through FACS sorting. I then went on to apply 
the improved FKF1/GI system by using master transcription regulators like Sox9 showing that the 
expression of downstream factors can be induced. I also showed the spatial control of the tool by 
Figure 39 Development of an optogenetic tool targeting endogenous sequences. 
A) Schematic of the development of an improved LITEZ system utilizing the ZFP-
NLOV(H105L)-IRES-GI-VP16 to optogenetically control target gene expression using blue light. 
B) Simplified diagram showing the insertion of ZFP-NLOV(H105L)-IRES-GI-VP16 optogenetic 






expressing mKate2. Lastly, as the optimal ratio of the FKF1/GI construct was 1:1, I developed an 
all-in-one expression plasmid with the IRES or 2A sequences included. Here, I found that the 
FKF1/GI construct expressed with GI-VP-16-IRES-Gal4DBD-NLOV(H105L) transfected into 
Hek293T cells increases the induction of the tool to 292x, three times that of the plasmids 
transfected individually and 60x the performance of the tool that was originally developed by Dr. 
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Chapter 2.2 Abstract 
Light-inducible systems allow spatiotemporal control of a variety of biological activities.  Here we 
report newly optimized optogenetic tools to induce transcription with light in mammalian cells, 
using the Arabidopsis photoreceptor Flavin Kelch-repeat F-box 1 (FKF1) and its binding partner 
GIGANTEA (GI) as well as CRY2/CIB1.  By combining the mutagenesis of FKF1 with the 
optimization of a split FKF1/GI dimerized Gal4-VP16 transcriptional system, we identified 
constructs enabling significantly improved light-triggered transcriptional induction.  In addition, 
we have improved the CRY2/CIB1-based light-inducible transcription with split construct 
optimization. The improvements regarding the FKF1/GI- and CRY2/CIB1-based systems will be 





Chapter 2.3 Introduction 
Tools enabling the spatiotemporal control of protein expression, localization, and activity are 
powerful reagents for investigating the cellular and molecular mechanisms underlying various 
biological activities and the pathological basis of disease in live cells and animal models.  To date, 
several optogenetic tools have been developed in order to control and/or monitor mammalian 
transcription3,130,140-143, enzyme function144,145, protein translocation130,145-150, receptor tyrosine 
kinase activity151,152 and neuronal activity121,153. In order to develop an optogenetic tool,  that 
maintains a minimal background interaction in the dark, we previously developed a system using 
the light-induced binding of FKF1 (Flavin-binding, Kelch-repeat, F-box 1) to GIGANTEA (GI)134.  
Flavin mononucleotide, a chromophore of the FKF1 family, is known to form a covalent bond 
with a cysteine residue on a light, oxygen or voltage (LOV) domain in FKF1, leading to interaction 
with GI upon blue-light exposure.  Using a G128D variant of FKF1 family molecule 
ZEITLUPE154, we demonstrated light-dependent regulation of a split Gal4-VP16 transcriptional 
system in mammalian cells131.  The FKF1/GI-based system was used in further applications155,156.  
However, the induction of transcription using the existing FKF1/GI systems with light was modest 
(3-5 fold), such that it was not practical for application in vivo.  Here we describe an optimized 
FKF1/GI transcriptional system using a newly identified mutant (H105L) as well as a single vector 
construct, which shows a 94-fold and 292-fold induction with blue light respectively. In addition, 
we have also optimized the CRY2/CIB1-based light-inducible transcription (102-fold induction 
with blue light). When compared with other existing optogenetic approaches such as CRY2/CIB1 
to regulate transcription, this system using FKF1/GI is unique in showing a long-lived 





Chapter 2.4 Results 
Screening of FKF1 mutants to improve light-induced transcription 
To identify novel mutants that could demonstrate low basal activity in dark conditions but higher 
induction of transcription under blue light, we carried out random mutagenesis of the amino-
terminus and LOV domain (NLOV) in the FKF1 gene (Figure 40A, 41, and Table 1) and screened 
the functionality of the constructs in the split Gal4-VP16 system 157, using a Gal4 UAS-luciferase 
reporter. To conduct illumination in live mammalian cells, we have developed an illumination 
device that allowed us to monitor and control temperature, CO2 and illumination (Figure 40B and 
42).    
We then conducted a luciferase activity assay screen to compare the newly discovered eighty-
one candidates with the previously used mutant, G128D 131, and wild-type (WT) in dark conditions 
to identify novel mutants that have a lower background level of Luc transcription than WT. Of the 
81 initial mutants, 45 showed background levels comparable with G128D mutant in the dark 
(Figure 41). Six of these 45 mutants showed similar or higher levels of induction of Luc expression 
than the G128D mutant, following our previously established protocol herein called ‘Protocol A’ 
(Figure 40C inset and Figure 43). As most of these variants contained multiple point mutations, 
we generated and tested each of the point mutations individually in HEK 293T cells along with 
GI-Gal4DBD and the Luc reporters. FKF1 H105L exhibited significantly higher induction of Luc 
with light while maintaining a low dark background signal, compared with the original FKF1/GI 
system (Figure 40C). This construct was expressed equivalently in the cells, as examined with 





Figure 40 Test of FKF1 mutants.  
A) Strategic plans and outcomes of FKF1 mutant screens. The amino-terminus and LOV domain 
of FKF1 (NLOV) was used as a template for the mutagenesis. Luciferase (Luc) assay was 
conducted along with GI fused with Gal4 DNA binding domain (DBD) and Gal4-UAS Firefly Luc 
reporter in human embryonic kidney (HEK) 293T cells. The herpes simplex virus thymidine kinase 
(HSV-TK) promoter-Renilla luciferase plasmid was used as a control to normalize Firefly Luc 
activity.  
B) Illumination protocol (Protocol A) used for the Luc assay is indicated (blue LED, 447.5nm, 0.5 
mW, 6.25 μW/mm2).  
C) Luc assays using six positive candidates that showed low basal background and significant 
induction of Luc with light (inlet, n=3 in 2 independent experiments, mean ± s.d.). Each mutation 
identified was tested (* P<0.05 n=10 in 7 independent experiments, mean ± s.d.). The H105L 
mutant that was identified as mutant #90 significantly increased Luc induction with light compared 
to the G128D mutation. Blue dashed line shows the background of the G128D construct. Red 










Figure 41 Mutant screens of FKF1 under dark. 
A) A summary of FKF1 (NLOV) mutagenesis (n=160).  
B) Schematic representation of mutant tests using NLOV-VP16 and 
GI-Gal4DBD constructs in the dark.  
C) A summary of Luc assay using 81 mutant candidates under the dark conditions. Forty 
five samples (red numbers) showed low background (n=1-2). The G128D mutant (red column and 
dashed line) and wild-type 





Figure 42 Developing an illumination system in culture incubator. 
A block diagram (A) and a sketch (B) of our blue LED illuminator are shown. The illuminator 
was installed into a 
CO2 incubator (C) that enables precise control of temperature, CO2 and blue LED illumination 












ary of the Luc assay results testing the 45 candidates that show
ed low





90, 117, 119, 143 and 154) dem
onstrated sim





T, a light-insensitive 
m
utant. The result of the six 
candidates after repeated tests w
as show
n in Figure 40C
 (inset) w
ith statistical analyses. Figure 43 inset delineates the illum
ination 



































) and the full-length and deleted G
I fragm









) and the shorter fragm
ents of G






) For Figure 44 A
-C
, the arrow
heads indicate the w

















Optimization of FKF1/GI fusion combinations 
One limitation of the original FKF1/GI system is the large size of the GI protein with 1,173 
amino acid (aa) residues.  To address this concern, we attempted to identify a shorter truncation of 
GI that retained a light-dependent interaction with FKF1.  We first prepared and validated the 
expression of five different truncations of GI fused with the GAL4DBD through Western blot 
(Figure 44B and C) and then tested these constructs with NLOV (G128D)-VP16 and Luc reporters 
in HEK 293T cells (Figure 45B). While the 1-960 aa fragment retained some light-dependence, all 
other shorter truncations eliminated light dependence to bind NLOV. The full-length GI construct 
still showed better function than the shorter fragments with similar dark background but higher 
light induction. Therefore, we used the full length GI construct in all further experiments. 
We next examined the configuration of the DNA binding domain (DBD) and activation domain 
(AD) fusions with the FKF1/GI proteins for optimal light-dependent transcriptional regulation. 
We explored different N- and C-terminal fusions of NLOV (G128D) and full-length GI with the 
Gal4DBD and VP16 AD components (Figure 45C). After testing 12 possible configurations, we 
found that Gal4DBD-NLOV (G128D) and GI-VP16 constructs enabled significantly higher 
induction of Luc with light than the original tested configuration, NLOV (G128D)-VP16 and GI-
Gal4DBD131. Combined with our results from the mutagenesis screen, these experiments led to 
the optimized FKF1/GI-based system using Gal4DBD-NLOV (H105L) and GI-VP16 
combination, which could lead to slightly better induction, lower background leak compared to the 
G128D mutant (Figure 45D-H). In addition to these screens, we tested several modifications to the 
constructs in this system; for example, epitope tags such as FLAG and hemagglutinin (HA) can be 










Figure 45 Test of truncated GI variants and optimization of FKF1/GI fusion combinations. 
A) Illumination protocol used for the Luc assays is indicated (blue LED, 447.5nm, 0.5 mW, 6.25 
μW/mm2).  
B) A summary of Luc assay results to test the various truncated GI constructs fused with Gal4 
DNA binding domain (DBD) (** P<0.01, n=3-4 in 2 independent experiments, mean ± s.d.). The 
full-length (1,173 amino acids, aa) and deleted GI (1-960 aa) demonstrated significant increase in 
Luc activity with light compared to the dark condition. The smallest fragment of GI (1-100 aa) 
showed high basal binding to NLOV (G128D)-VP16 under dark.  
C) Optimization of fusion combinations of FKF1 (NLOV, G128D), GI (full-length), Gal4DBD 
and VP16 (n=6-15 in 5 independent experiments, mean ± s.d.). +, a Gly/Ser linker.  
D) Illumination protocol used for Figure 50 E-G (blue LED, 447.5nm, 0.5 mW, 6.25 μW/mm2).  
E) The H105L mutation in Gal4DBD-NLOV significantly reduced background in the dark 
compared to the G128D mutation 24 hour after transfection (** P<0.01, n=8 in three independent 
experiments). GI-VP16 was used. (F) The H105L mutation in Gal4DBD-NLOV significantly 
increased induction of Luc expression in the illumination compared to the G128D mutation 24 
hours post transfection (** P<0.01, n=8 in three independent experiments). The light-induced 
transcription system using the H105L mutant significantly increased  
On- (G) and Off-kinetics (H) compared with the G128D mutation (* P<0.05, ** P<0.01, n=6-8 at 




Comparison of the FKF1/GI-based system to LITE2.0 system 
To evaluate our optimized Gal4DBD-NLOV (H105L)/GI-VP16 system, we compared it to other 
currently available light mediated transcriptional systems. We tested the LITE2.0 system, fusions 
of CRY2PHR and CIB1 (NLS*, Δ318-334 aa), which were previously used to regulate 
transcription at endogenous sites in mammalian cells142. To compare these systems in the same 
experimental conditions, we prepared CRY2PHR and CIB1 (NLS*, Δ318-334 aa) constructs with 
Gal4DBD in the same mammalian expression vector pcDNA3 that were used for the NLOV/GI-
Figure 46 Examining the effects of FLAG-tag on the FKF1/GI-based system. 
A) The illumination protocol used is shown (blue LED, 447.5nm, 0.5 mW, 6.25 μW/mm2).  
B) Luciferase assay to examine the effect of a FLAG-tag addition on GI-VP16 with Gal4DBD-
NLOV (G128D)-HA-tag response to illumination (n.s., not significant n=6-9 in 2 independent 




based system. We then transfected the NLOV/GI or CRY2/CIB1 constructs along with the Gal4 
UAS-Luc reporters into HEK 293T cells.  The Luc assay results showed that the CRY2/CIB1 
constructs led to significantly higher basal background activity in the dark when compared with 
the NLOV/GI system (Figure 47 A-C). To examine a different reporter, we examined expression 
of a Gal4 UAS-regulated red fluorescent protein, mKate2. While the RFP-positive cells were 
detected in the CRY2/CIB1-based system under the dark condition (Figure 47D), there were no 
major differences in RFP expression between the NLOV/GI- and CRY2/CIB1-based systems with 
illumination, demonstrating that the NLOV/GI-based system leads to a similar level of RFP 
expression with “Protocol A” illumination as the CRY2/CIB1-based system but significantly 
lower basal background in the dark.   
To compare protein expression between the two systems more precisely, we prepared another 
Gal4-UAS reporter to express destabilized green fluorescent proteins (dsGFP) for further protein 
quantification using Western blot experiments. The results demonstrated that there was 
significantly higher leak of dsGFP proteins in the dark in the CRY2/CIB1-based system compared 
to the NLOV/GI-based system (Figure 47E and 47F). Taken together, these results demonstrated 
that the NLOV/GI-based light-inducible transcription had a much lower basal background leak in 
the dark but a similar induction of the target gene expression with light in mammalian cells, 










Optimization of the CRY2/CIB1-based system 
In the process of comparing the two systems, we modified the CRY2/CIB1-based system that was 
derived from a previous report for a more precise comparison142. The CRY2/CIB1-based system 
called LITE2.0, which was previously used with the transcription activator-like effector (TALE) 
system, may not be fully optimized for the Gal4 UAS system. We thought its format could be 
improved to fit the Gal4 UAS system better by finding the best fusion protein combination. 
Therefore, we tested a variety of combinations of CRY2/CIB1 fusion constructs and found that 
CRY2-VP16 and CIB1-Gal4DBD had the highest induction of Luc expression with light compared 
to the other constructs (Figure 48).  
Figure 47 Comparison of the FKF1/GI-based system to the CRY2/CIB1-based LITE2.0 
system to control transcription with light. 
A) The illumination protocol that was used (blue LED, 447.5nm, 0.5 mW, 6.25 μW/mm2). 
B) The short fragments of CRY2 (CRY2PHR) and modified CIB1 were used in the LITE2.0 
system3.  
C) Luc assay to test the FKF1 (NLOV, H105L)/GI-based system and LITE2.0. The LITE2.0 
system demonstrated significantly increased dark signal compared to the NLOV/-GI-based system 
(** P<0.01, n=8-10 in 4 independent experiments, mean ± s.d.).  
D) Fluorescent images using the NLOV/GI-based and LITE2.0 systems in HEK 293T cells to 
express red fluorescent proteins (RFP) in live cells. Hoechst 33285 was used for nuclear staining. 
Scale bar, 20 μm.  
E) Western blotting using the NLOV/GI-based and LITE2.0 systems to express destabilized green 
fluorescent protein (dsGFP) in HEK 293T cells. A housekeeping molecule, β-tubulin, was 
examined as an internal control in the cells. D, dark. L, light. (F) Quantification of dsGFP proteins 
to compare the NLOV/GI-based and LITE2.0 systems. The expression of dsGFP was normalized 
to β-tubulin expression (n.s., not significant ** P<0.01 n=4 in two independent experiments, mean 
± s.d.). The LITE2.0 system demonstrated significantly increased dark signal when compared to 






Figure 48 Optimization of the CRY2/CIB1-based system to control transcription 
with light. 
A) The illumination protocol used is shown.  
B) Optimization of fusion combinations of CRY2 (C2), CIB1 (C1), LITE2.0 constructs, 





Comparisons of the optimized FKF1/GI-based system to the other light-inducible systems  
In parallel, other light-inducible systems such as EL222 and VVD/LightOn141,158 were compared 
to the FKF1/GI-based system (Figure 49 and Table 2). To test the FKF1/GI, EL222 and VVD 
systems, we have used another illumination protocol called “Protocol B”, following the authors’ 
advice141. The VVD and EL222 showed significantly higher luciferase activity in the dark and 
lower induction.  Unexpectedly, we found that Protocol B141 led to a significant increase induction 
of the FKF1/GI-based systems (up to 91-fold, Figure 49). Therefore, for further characterization 
of the light-inducible systems, we focused on comparisons of the FKF1/GI- and CRY2/CIB1-
based systems using illumination Protocol B.  
Figure 49 Comparisons of the FKF1/GI-based system to the other light-inducible systems. 
Comparisons of the FKF1/GI-based systems to the other light-inducible systems, the 
VVD/LightOn- and EL222-based systems (n=4-16, mean ± s.d.). The DNA amounts indicated 
were used for transfection in a well of 24-well plates. Illumination protocol used is described in 





Comparisons of the optimized FKF1/GI-based system to the optimized CRY2/CIB1-based system 
First, we compared the background leak in dark conditions of the optimized NLOV/GI with 
CRY2/CIB1.  In the dark, we found that the background level of the FKF1/GI-based systems 48 
hours post transfection was still low, while the CRY2/CIB1-based systems showed significantly 
higher reporter activity at that same time point in the dark (Figure 50C). Next, to quantify 
fluorescent protein expression of each system in live cells, we tested the FKF1/GI-based systems 
with the Gal4 UAS-RFP (mKate2) reporter. We found that there was no obvious leak of the RFP 
expression in the live cells kept in the dark with the FKF1/GI-based system. However, some RFP 
positive cells are observable when using the CRY2/CIB1-based system evidencing an increased 
background activity of the latter system (Figures 50D). Thus, the CRY2/CIB1 system may not be 
useful for long-term expression such as in vivo applications using mouse models.  In addition, we 
found that the FKF1/GI-based system had significant Luc induction (4-5-fold) even 48 hours after 
illumination was terminated (Figure 51B). These results support the previous study131, confirming 
that the system does not require continuous exposure of live cells to light, which helps to reduce 
potential phototoxic effects of blue light compared to the other systems. 
 We next optimized the DNA transfection ratio of FKF1 to GI and CRY2 to CIB1. Interestingly, 
we found that the FKF1/GI system did not significantly benefit from any other DNA ratios tested. 
However, the CRY2/CIB1 system showed a significantly increased induction when using the 5:1 




CRY2:CIB1 DNA ratio (Figure 50E, 50F, and 51C-E). Therefore, we carried out the subsequent 
experiments with this new DNA ratio to summarize the results using optimized FKF1/GI- and 
CRY2/CIB1-based system. 
To test the reversibility of both systems, we exposed the cells to either 6 hours of illumination 
cycles followed by 6 hours of darkness or a 30-minute illumination followed by 23.5 hours in the 
dark (Figure 50G and 50H). From these experiments, we found that the FKF1 system did not show 
any significant decrease in induction while the CRY2/CIB1 system had a significantly less 
induction when kept in the dark after stimulation (Figure 50I and 50J).  Next, we tested the 
dependence of each system to the amount of light to which the cells were exposed. This was 
accomplished by decreasing the illumination length of each cycle in Protocol B to 8s and 2s 
illumination with 72s and 78s of darkness, respectively (51F and 51G).  FKF1/GI was not affected 
by the decrease from 20s to 8s illumination but was detrimentally affected by the decrease to 2s 
(Figure 51H). CRY2/CIB1, on the other hand, showed a significant decrease in induction when 
decreasing the illumination times to 8s and 2s (Figure 51I).  
To assess these optogenetic systems outside of the luciferase assay, we used a Gal4 UAS dsGFP 
reporter and gauged their activity through Western blot (Figure 50K and 50L). Here, the data 
demonstrates that the CRY2/CIB1 system has a significantly higher increase in dsGFP expression 
as compared with FKF1/GI.  In addition, we used FACS sorting to quantify the expression of Gal4 
UAS dsGFP in various mammalian cells: HEK 293T cells, human patient skin primary fibroblasts 
and NIH 3T3 cells as controlled by each system (Figure 50M, 50N, and 52). From this test, we 
found that the there was no difference in HEK 293T cells for either system while the expression 











Figure 50 Comparison of optimized FKF1/GI based system to optimized CRY2/CIB1-based 
system. 
A) Schematic representation of optimized NLOV/GI-based light-induced transcription. 
B) Schematic representation of optimized CRY2/CIB1-based light-induced transcription. C) 
Comparison between the leakiness of NLOV/GI and CRY2/CIB1 when kept in the dark. 
(**P<0.01, n=4-14, mean ± s.d.). The NLOV/-GI-based system showed significantly lower signal 
under dark conditions compared to the CRY2/CIB1-based system.  
D) Fluorescent images using the NLOV- and CRY2-based systems in HEK 293T cells to express 
red fluorescent proteins (RFP, mKate2) in live cells 24h post transfection. Hoechst 33285 was used 
for nuclear staining. Scale bar, 20 μm. Red arrowheads, 
mKate2-positive cells.  
E) Illumination protocol used in Figures 4 F, I-N (blue LED, 447.5 nm, 0.5 mW, 6.25 μW/mm2).  
F) DNA ratio optimization 
of the CRY2/CIB1-based system showing an increase in normalized luciferase signal when using 
5:1 Cry2-VP16:CIB1 (* P<0.05, n=3, 
in 3 independent experiments, mean ± s.d.).  
G) Illumination protocol used in Figures 4 I-J (6h off) using a blue LED, 447.5nm, 0.5mW, 6.25 
μW/mm2.  
H) Illumination protocol used in Figures 4 I-J (30 min EXP) using a blue light source (470 ± 20 
nm, 1.2 mW).  
I, J) Luciferase signal of NLOV/GI and CRY2/CIB1 respectively after variable illumination times 
followed by darkness. (n.s., non significant *** P<0.001 n=12 in 2 
independent experiments for 6h off and 30min EXP, n=27 and n=58 for CRY2 and FKF1 Protocol 
B, respectively as compiled legacy data was used , mean ± s.d.). CRY2/CIB1 has a significant 
decrease in induction when kept in dark after illumination. K) Western blotting using the 
NLOV/GI-based and CRY2/CIB1 systems expressing destabilized green fluorescent protein 
(dsGFP) in HEK 293T cells with Protocol B. A housekeeping molecule, β-tubulin, was examined 
as an internal control in the cells. D, dark. L, light.  
L) Quantification of dsGFP proteins to compare the NLOV/GI-based and CRY2/CIB1 systems. 
The expression of dsGFP was normalized to β-tubulin expression (* P<0.05, n=8, mean ± s.d.). 
The CRY2/CIB1 system demonstrated a significantly increased induction of dsGFP when 
compared with the FKF1/GI-based system.  
M,N) FACS results for NLOV/GI and CRY2/CIB1 systems transfected into HEK 293T cells and 
human patient primary skin fibroblasts, respectively (n.s., non significant * P<0.05, **P<0.01, 
n=6, mean ± s.d.). CRY2/CIB1 has a higher percentage of GFP+ cells in dark and light condition 






Figure 51 Comparison and optimization of the FKF1/GI and Cry2/CIB1 system. 
A) Illumination protocol used in Figure 4B is indicated (blue LED, 447.5nm, 0.5 mW, 6.25 
μW/mm2).  
B) Comparison of NLOV/GI and 1:1 DNA ratio CRY2/CIB1 (n=4 mean ± s.d.).  
C) Illumination protocol used for in Figure 4D,E,J and K is indicated (blue LED, 447.5nm, 0.5 
mW, 6.25 μW/mm2).  
D, E) DNA Ratio optimization of NLOV/GI and CRY2/CIBI respectively. (* P<0.05, n=3 in 3 
independent experiments , mean ± s.d.) CRY2/CIB1 benefits from a ratio of 5:1 
CRY2:CIB1.  
F, G) Illumination protocols used for in Figure 4H and I are indicated (blue LED, 447.5nm, 0.5 
mW, 6.25 μW/mm2). (H, I) Luciferase assay results of NLOV/GI and CRY2/CIB1 respectively 
with variable illumination cycles. (n.s., not significant, ** P<0.01, *** P<0.001, n=12 in 2 
independent experimens for Protocol B 8s and Protocol B 2s, n=27 and n=58 for CRY2 and FKF1 
Protocol B respectively as compiled Legacy data was used , mean ± s.d.). NLOV/GI has a 
significantly decreased induction when exposed to the 2s protocol. CRY2/CIB1 has a significantly 






Figure 52 Representative FACS images and NIH3T3 FACS results 
A-C) Representative FACS images for HEK 293T, Human Fibroblasts and NIH 3T3 cells 
respectively. The raw FACS data was sorted for live cells, then the mCherry+ (transfected cells) 
were selected. Finally, the GFP+ cells were selected for in order to yield the GFP positive 
population of transfected cells.  
D) A comparison of NLOV/GI and CRY2/CIB1 systems transfected into NIH3T3 cells 
illuminated following protocol B with Gal4-UAS-dsGFP (*** P<0.001, n=8-12 in 2 independent 





Further biological applications of the FKF1/GI-based system in vitro 
We were interested in testing the utility of the FKF1/GI system in controlling the expression of 
transcription factors. A recent publication noted that Sox9 is an important regulator in the 
differentiation of human pluripotent stem cells to cholangiocytes 159. Therefore we tested whether 
the FKF1/GI system can increase the expression of Sox9 in HEK 293T cells. To do this, we 
expressed Gal4 UAS-regulated Sox9 and illuminated the cells following protocol B. These 
experiments showed that the FKF1/GI system is capable of a significant induction of Sox9 
expression in this system (Figure 53B and 53C). To validate light-induced Sox9 expression with 
light further, we conducted quantitative RT-PCR and observed significantly increased expressions 
of Sox9 target genes such as Aggrecan, LXH2, GAS1 and TLE4 in the illuminated cells (Figure 
53D). These results reveal that the improved FKF1/GI-based system is capable of light-dependent 
induction of target gene expression in mammalian cells. 
   Then, we examined whether we could spatially control the expression of FKF1/GI using the 
Gal4 UAS-regulated expression of mKate2 red fluorescent proteins together with GFP plasmid as 
a transfection control.  The FKF1/GI system showed expression of mKate2 only in the stimulated 
regions that are delineated by the dashed blue boxes, with no leak outside of these areas (Figure 
53E).  This result reveals that spatiotemporal control of transcription is feasible using the optimized 






Figure 53 in vitro and in vivo utilization of NLOV-GI optogenetic system.  
A) Illumination protocol used in Figure 5 B-D is indicated (blue LED, 447.5nm, 0.5 mW, 6.25 
μW/mm2).  
B) Representative western blotting image of NLOV/GI inducing Sox9 gene expression in HEK 
293T cells.  
C) Quantification of Sox9 protein bands in dark and light conditions. The expression of Sox9 was 
normalized to β-tubulin expression (n=8, mean ± s.d.).  
D) Quantification of human Aggrecan, LHX2, GAS1 and TLE4 transcripts in HEK 293T cells 
with NLOV/GI-based Gal4 UAS Sox9 in dark and light conditions using quantitative RT-PCR (* 
P<0.05, *** P<0.001, n=7-8, mean ± s.d.).  
E) Fluorescent images of live cells transfected with NLOV/GI, Gal4 UAS mKate2 with eGFP as 
a transfection control. Dotted blue boxes delineate the illuminated sections of the cell area showing 
spatial control of NLOV/GI. White arrowheads indicate mKate2 positive cells (blue Digital 
Micromirror Device 475nm, 36μW/mm2 ). Scale bar, 100 μm.  
F) Representative images of mouse livers from mice after illumination (dark (left), light (right)) 
using Gal4-UAS-dsGFP with Gal4DBD-NLOV (H105L) and FLAG-GI-VP16 with 




Further application of the FKF1/GI-based system to in vivo mouse tissues 
   Finally, we tested whether the FKF1/GI-based system can be applied in in vivo applications such 
as a mouse animal model. Using a hydrodynamic tail vein (HTV) injection method158, we 
transiently transduced Gal4DBD-NLOV (H105L) and GI-VP64 in live mouse livers. Twelve hours 
after the HTV injection, the abdomen of the transfected mice were exposed to blue light. Because 
the binding of NLOV (H105) to GI is irreversible, we used a LED array for one-shot illumination 
(3 minutes) and then returned the mice to their darkened cages. We found that the livers of 
illuminated mice expressed GFP 12 hours after illumination while no expression of GFP proteins 
was detected in mice kept in the dark. On the other hand, CRY2/CIB1-based system did not 
successfully induce GFP in liver tissues (Figure 53F and 54A). These results demonstrate that the 





Figure 54 Cry2-VP16 and CIB1 NLOV/GI in vivo application, H105L with VP16, VP64 and 
NLOV/GI H105L G128D and NLOV homology model. 
A) Representative images of mouse livers from mice after illumination (dark (top), light (bottom) 
using Gal4-UAS-GFP with CRY2-VP16 and CIB1-Gal4DBD with hydrodynamic tail vein 
plasmid injection method (n=4). Scale bar, 2mm.  
B) Homology model of FKF1 NLOV domain highlighting the H105 (red), G128 (purple) amino 
acids and the FKF1 family conserved loop (green).  
C) Illumination protocol used in Figure 54D and 54E is indicated (blue LED, 447.5nm, 0.5 mW, 
6.25 μW/mm2).  
D) Luciferase assay results of NLOV/GI H105L and the NLOV/GI H105L G128D double mutant. 
(*** P<0.001, n=8 in 2 independent experiments, mean±s.d.). The double mutant has a 
significantly reduced induction amount compared with the NLOV/GI H105L.  
E) Luciferase assay results of NLOV with GI-VP16 and GI-VP64. (n.s., not significant, n=12 in 2 
independent experiments, mean ± s.d.). Using protocol B, there is no difference between the use 




Chapter 2.5 Discussion 
Here we describe an improved system for the spatiotemporal control of transcription in mammalian 
cells with light, based on the interaction between FKF1/GI. To do this, we conducted random 
mutagenesis of FKF1 (NLOV fragment), optimized the fusion constructs and compared this 
improved system with other existing tools that ultimately allowed us to improve transcription 
control with light in mammalians without a significant increase in unwanted background leak.  
Based on the results of mutagenesis and optimization of NLOV and GI constructs fused with 
Gal4DBD and VP16, we concluded that the H105L mutation in Gal4DBD-NLOV with GI-VP16 
is a significantly improved version of the FKF1/GI-based system for light-induced transcription in 
mammalians.   
Of note, using a homology model of the LOV domain (Figure 54B), it is apparent that H105 is 
located in a highly flexible loop (99-107aa), which was determined to be essential for NLOV 
binding to GI (data not shown).  Interestingly, this loop is unique to the FKF1 family (FKF1, 
ZEITLUPE and LKP2) compared to other LOV domain-containing molecules. In the previous 
study, we found that the loop alone did not bind GI131.  On the other hand, the previous mutation 
G128D is located in the beta-sheet binding cleft of the protein. Due to its location, the H105L 
mutation may affect the location of the flexible loop.  One potential possibility is that it is bound 
to the binding cleft before the cysteinyl bond is established. Once this bond if formed, the loop 
may be released from the domain’s binding cleft and allowed to bind GI. This sequestration of this 
integral loop may explain the extremely low background of the mutant.  Unexpectedly, another 
mutant hit #119 contains the H105R mutation, which also demonstrates slightly improved 
luciferase induction (7.9x) compared to the G128D mutant (4.8x) in the tested NLOV-VP16 




in the loop could be crucial for FKF1 binding to GI.  However, the mechanism by which the H105L 
mutation improved the light-inducible systems remained unclear.  To begin to address this concern, 
we compared the fold-induction of Luc using the H105L and G128D mutations in Gal4DBD-
NLOV with GI-VP16.  We found that the H105L mutation reduced the basal background leak in 
the dark and increased on/off kinetics more than the G128D mutation (Figures 41D-H).  
Interestingly, we found that the double mutant (G128D and H105L) showed no induction with 
light as compared to the H105L mutant (Figure 54C and 54D).  Further computational simulations 
and structural biophysical experiments should be required to unveil the mechanism underlying 
light-dependent binding of FKF1 to GI. 
To assess whether the H105L amino acid substitution in the Gal4DBD-NLOV construct was the 
most effective change, we replaced the histidine with all the other amino acids and measured each 
mutant’s performance on the leakiness of the tool in the dark and the fold induction in response to 
blue light as compared with the H105L (Figure 55).  From this we found that the H105L mutant 
performed similarly with H105I and H105K in response to blue light stimulation. Isoleucine and 
lysine, like leucine can behave in a hydrophobic manner meaning that they all may remain buried 
within the reactive site keeping the loop intact and preventing NLOV-GI binding and thereby 
decreasing the leakiness of the tool. On the other hand, H105D, H105S and H105D substitutions 
abolished the blue light dependence of the tool and had high background signals. These destructive 




the importance of the NLOV 105 residue however, further structural studies are needed to confirm 
the role of this residue. 
In this study, the NLOV/GI split construct and illumination optimizations were also essential for 
improving the FKF1/GI-based light-inducible transcription in mammalian cells.  Therefore, when 
we used the optimized constructs and illumination (Protocol B), we found that there was no 
difference in luciferase induction between VP16 and VP64 constructs (Figure 54E).  In addition 
to the FKF1/GI-based system, we then optimized the CRY2/CIB1 system, using similar strategies 
for split construct, transfection and illumination optimizations. The optimized CRY2/CIB1 system 
showed a comparable induction of firefly luciferase with the FKF1/GI (H105L). When the 
luciferase signal with light is normalized to dark, we found an increase of approximately 100-fold.  
Of note, the CRY2/CIB1 system had a consistently higher light-dependent induction with a notable 
Figure 55 Alternative amino acid substitution of the H105 residue.  
All other available amino acids were substituted for the histidine amino acid. Please note, the 





amount of leakiness as shown by the higher luciferase signal in dark compared to the FKF1/GI-
based system. This may make the CRY2/CIB1 a more attractive option in systems where a higher 
amount of transcription induction is required with spatiotemporal control.  
For further improvement of the FKF1/GI-based system, we examined whether single vector 
construct containing both FKF1 and GI constructs improves gene transduction compared to co-
transfection of the FKF1 and GI plasmids. Interestingly, we found that the new IRES constructs 
demonstrated >200-fold induction of Luc with light while 2A self-cleavage constructs did not work 
(Figure 55A). The best IRES-based single construct (FLAG-GI-VP16-IRES-Gal4DBD-NLOV 
H105L-HA) showed significantly improved induction with light (~292-fold) compared to the 
former results using co-transfection of two plasmids (~94-fold, Gal4DBD-NLOV H105L-HA and 
FLAG-GI-VP16).  Using the new IRES construct, we performed light-induced Myod1 expression 
in mouse embryonic fibroblasts (MEF) because Myod1 overexpression could induce trans-
differentiation of MEF into myoblasts160.  We confirm that illumination could increase the 
expressions of Luc reporter and Myod1 transcripts in MEF using the new IRES-based plasmid 
(Figure 55B and 55C). Also, we observed Myod1 protein expression and morphological changes 
of MEF following Protocol B illumination after 5 days (Figure 55D). These results demonstrate 
further evidence that our improved FKF1/GI-based system is capable of light-induced transcription 






Figure 56 The application of the IRES version of FKF1/GI-based light-induced transcription 
system for Myod1 expression. 
A) Luciferase assay results of HEK 293T cells with co-transfection of two plasmids: Gal4DBD-
NLOV (H105L)-HA (G4D-NLOV) and FLAG-GI-VP16 (GI-VP16) and single transfection using 
the 2A self-cleavage and internal ribosome entry site (IRES) systems (*** P<0.001, n=8 in 2 
independent experiments, mean ± s.d.).  
B) Luciferase assay results of mouse embryonic fibroblasts (MEF) with the new IRES construct: 
FLAG-GI-VP16-IRES-Gal4DBD-NLOV (H105L)-HA and Gal4 UAS firefly luciferase (n=9 in 2 
independent experiments, mean ± s.d.).  
C) Quantification of Myod1 transcript expression in MEF with the new IRES construct: FLAG-
GI-VP16-IRES-Gal4DBD-NLOV (H105L)-HA and Gal4 UAS-Myod1 (**P<0.01 n=7 in 2 
independent experiments, mean ± s.d.).  
D) Representative fluorescent images of immunocytochemistry for Myod1 protein expression in 
illuminated MEF with FLAG-GI-VP16-IRES-Gal4DBD-NLOV (H105L)-HA and Gal4 UAS-
Myod1. Hoechst 33285 (blue) was used for nuclear staining. Anti mouse Myod1 antibody was 




One of the key features of the FKF1/GI-based system is the non-reversible interaction of FKF1 
with GI upon stimulation with light 131,134 while other systems such as CRY2/CIB1 are 
reversible161.  Unlike the CRY2/CIB1 system, the FKF1/GI system does not require continuous 
exposure of live cells to light, which could reduce the potential phototoxic effects of blue light 
unlike the CRY2/CIB1 (Figure 50 G-J and Figure 51A and 51B).  Tucker and colleagues described 
that the performance of a given optogenetic tool is dependent on the system in which the study is 
conducted119. Thus, side-by-side comparisons - even if well intended as certainly the case in this 
study - could be challenging.  Therefore, further optimizations of construct and transduction for 
the EL222 and VVD systems may improve the background leak in dark conditions (Figure 49).  
The low background signal consistently seen in the FKF1/GI-based system will enable the wider 
application of this system, including its use in target cells to address developmental questions with 
fine spatiotemporal resolution.  In the case of the CRY2/CIB1-based system, the background leak 
in the dark became worse later after the transfection (Figure 50C and 50D).  This result suggests 
that it might be difficult to develop biological models such as transgenic mouse stably expressing 
the CRY2/CIB1 constructs.  Therefore, the new version of the light-inducible transcription system 
using FKF1 (NLOV, H105L) and GI will be of great interest to many researchers for use in further 
applications of this FKF1/GI-based system with their biological models and to address their 





Chapter 2.6 Conclusion 
In this study we developed an improved version of the FKF1/GI optogenetic tool, initially leading 
to NLOV(H105L)/GI and a blue-light dependent induction of 98x, 20 times higher than the 
original G128D mutant developed previously131. This was accomplished through random 
mutagenesis and the optimization of the construct pairings affecting which half of the is anchored 
to the DNA and which is the prey. This was then compared with the CRY2/CIB1 tool optimized 
for the Gal4UAS system and found to have a lower background leak making it an ideal tool for 
the expression of genes that need to be tightly controlled. NLOV(H105L)/GI binding was less 
dependent on the duration of the blue light stimulation with a slower off kinetics when compared 
with CRY2/CIB1. Comparing the ability for both tools to express mCherry at levels that can then 
be FACS sorted, CRY2/CIB1 outperformed FKF1/GI in human fibroblasts and NIH3T3 cells 
while their performance was indistinguishable in HEK293T cells. 
FKF1/GI was then taken forward and shown to be able to allow for the spatial control of mKate2 
as well as induce the expression of Sox9 leading to the expression of its downstream factors. 
FKF1/GI was found to respond to blue light stimulation leading to the expression of GFP in the 
murine liver after introduction by hydrodynamic tail vein injection. Lastly, an all in one FKF1/GI 
construct was created using the IRES system to express both factors separately and this version of 








Human embryonic kidney (HEK) 293T cells (ATCC, #CRL-3216) and NIH 3T3 cells (ATCC, 
#CRL-1658) were cultured in Dulbecco’s Modified Eagle Media (DMEM, Invitrogen #10313021) 
supplemented with 1% GlutaMax I and 100 unit / ml penicillin and 100 μg / ml streptomycin (P.S., 
all reagents from Life Technologies) and 10% fetal bovine serum (FBS, not heat-inactivated, 
HyClone, #SH30071.03, Thermo Scientific) under normoxia (20% O2, 5% CO2, at 37oC) using 
HERAcell (Thermo Scientific).  Human patient skin fibroblasts (Congenital heart disease patient, 
#CDH01-0634) were cultured in DMEM supplemented with 1% GlutaMax I, P.S. and 20% FBS 
under normoxia (20% O2, 5% CO2, at 37oC) using HERAcell.  The patient fibroblasts were 
obtained by taking a small piece of skin at the incision at the time of surgery following a protocol 
approved by the Columbia Institutional Review Board (IRB, for W.K. Chung) 119. Mouse 
embryonic fibroblasts (MEF) cells were isolated from E12.5 mouse pups. MEF cells were cultured 
in DMEM supplemented with 1% GlutaMax I, P.S and 10% FBS under normoxia (20% O2, 5% 
CO2, at 37°C) using HERAcell. Human fibroblasts, MEF and NIH3T3 cells were passaged using 
0.25% trypsin + 0.03% EDTA while HEK 293T cells were passaged using 0.05 % trypsin + 0.03 
% EDTA solution (both from Gibco/Life Technologies). 
Plasmid construction: 
Plasmid DNA constructs were generated using standard methods with restriction enzymes (New 
England BioLabs) and ligase (TaKaRa, DNA ligation kit, mighty mix) and PCR using Phusion 
polymerase (Thermo Scientific, 2x master mix).  The transient expression vector pcDNA3 
(Invitrogen/Life Technologies) was used for all experiments to test the improved FKF1/GI and 




(Stratagene/Agilent) following the manufacturer’s instructions.  Briefly, 0.5 μg of pcDNA3-HA-
tagged-NLOV (WT)-VP16 was used as a template for PCR with Mutazyme II polymerase (50 μl 
reaction) using two primers:  
“BamHI-Kozak-HA-F”, 5’-cggatccgccaccATGGCTTACCCATACGATGTTCCAGATTAC-3’ 
“FKF1-LOV-KpnI-R”, 5’-gcggtaccCGTTTCAGAGAAGACCTGTATCCCAATTAC-3’ 
PCR products were digested with BamHI and KpnI restriction enzymes, then subcloned into 
pcDNA3 (BamHI and NotI sites) along with a VP16 fragment (triple repeat of 13 amino acid 
residues) that was digested with KpnI and NotI.  Site-directed mutagenesis was done using 
QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene/Agilent) following the 
manufacturer’s instructions.  Published LITE2.0 CRY2 and CIB1 constructs 142 (Addgene #47455 
and 47458) were used as templates for PCR subcloning into pcDNA3.  The Gal4 DNA binding 
domain (DBD, residues 1-148) was fused with the amino-terminus of CIB1 (NLS*, Δ318-334 aa) 
instead of the NEUROG2 TALE domain used in the LITE 2.0 system 142.  All plasmids containing 
PCR products were confirmed by DNA sequencing (Eton Bioscience).  The original CRY2 and 
CIB1 plasmids (Gal4BD-CRY2 and Gal4AD-CIB1) were kindly provided by Dr. C. Tucker 130.  
Using KpnI, NotI and XbaI sites, we subcloned CRY2 (or CRY2PHR fragment), CIB1, Gal4DBD 
and VP16 into the pcDNA3 vector for experiments in Figures 47, 48, 50, 52, and 54.  Plasmids 
pVP-EL222 and its reporter pGL4.32 C120-Luc plasmids were kindly provided by Drs. L.B. 
Mottta-Mena and K.H. Gardner 141.   
Gal4 UAS was amplified from pFR-Luc plasmid (Promega) using Pfu Ultra (Stratagene/Agilent) 






The PCR product of Gal4 UAS was digested with BglII and NotI enzymes and then subcloned into 
pcDNA3 vector fragment that was digested with BglII and NotI enzymes, thus replacing the CMV 
promoter in pcDNA3 with Gal4 UAS. The Gal4 UAS vectors containing mouse Sox9 cDNA, 
which was prepared from mouse brain RNA samples (TaKaRA/Clontech), mKate2, a monomeric 
red fluorescent protein, or destabilized green fluorescent protein (dsGFP) were prepared using 
NotI and ApaI sites of the vector. Mouse Myod1 full-length DNA fragment containing NotI, Kozak 
in the 5’ end and XbaI in the 3’ end was synthesized using the codon optimization program 
(Integrated DNA Technologies) and subcloned into the Gal4 UAS vector using the NotI and XbaI 
sites. 
To prepare the 2A self-cleavage construct, we synthesized and subcloned KpnI-PacI-2A-AcsI-




Gal4DBD-NLOV (H105L)-HA and FLAG-GI-VP16 were subcloned using PCR, Phusion 
polymerase and KpnI/PacI or AscI/XbaI into pcDNA3-KpnI-PacI-2A-AcsI-XbaI vector. 
pcDNA3-Gal4DBD-NLOV (H105L)-HA-2A-FLAG-GI-VP16 and pcDNA3-FLAG-GI-VP16-
2A-Gal4DBD-NLOV (H105L)-HA were generated. To generate internal ribosome entry site 
(IRES) version of constructs, we amplified IRES fragment using PCR, STOP-eGFP-Rosa26TV 







The 2A fragments in the above 2A constructs were replaced with the amplified IRES fragment 
using PacI and AscI to generate pcDNA3-Gal4DBD-NLOV (H105L)-HA-IRES-FLAG-GI-VP16 
and pcDNA3-FLAG-GI-VP16-IRES-Gal4DBD-NLOV (H105L)-HA. 
Luciferase assays: 
HEK 293T cells were plated at 0.5 x 105 cell/well in 24-well plates (Corning) coated with poly-
ornithine (Sigma-Aldrich, #P0421) and transfected the following day with 0.9 μg of DNA in 2 μl 
of Lipofectamine 2000 (Invitrogen/Life Technologies) into 100 μl of OptiMEM (Gibco/Life 
Technologies) in 400 μl of DMEM 10% FBS (PS-free).  The standard ratio of FKF1: GI: pFR-Luc 
(Firefly): HSV-TK-Renilla Luc was as follows: 1: 1: 1: 0.01. However, the ratios for FKF1/GI and 
CRY2/CIB1 were examined to identify optimized conditions (Figure 51D and 51E).  The cells 
were then exposed to blue light (total 24 hours, 2 min light / 18 min dark cycle) 9.6 hours after 
transfection at 37 °C in a CO2 incubator (Thermo Fisher), also known as “protocol A”.  The blue 
LED illuminator (447.5nm, 0.5 mW, 6.25 μW mm-2) with heat control and a fan was designed and 
developed by J. Jung (Supplementary Note). Luciferase activity levels were assayed 14.4 hours 
after illumination was terminated using Dual Luciferase assay kit and a Veritas 96-well 
luminometer (Promega) following the manufacturer’s instructions.  Other illumination protocols 
were also examined to compare the FKF1/GI-based system to CRY2/CIB1-based system (Figure 
51 F-I).  The luminescence of each sample was measured by integrating for 2 seconds after 
injection of the luciferase substrate.  As a negative control, a light-insensitive FKF1 NLOV mutant 




MEF cells were plated at 0.5 x 105 cell/well in 24-well plates (Corning) coated with Geltrex® 
(Thermo-Fisher/Life Technologies) and transfected the following day using 0.5µg DNA, 1µl 
P3000 and 1.5µl Lipofectamine 3000 (Invitrogen/Life Technologies) into 50µl of OptiMEM 
(Gibco/Life Technologies) in 400 μl of DMEM 10% FBS (PS-free). The DNA was maintained at 
a ratio of GIVP16-IRES-FKF1(H105L): pcDNA3 empty vector: pFR-Luc (Firefly): HSV-TK-
Renilla Luc as follows: 1: 1: 1: 0.01. The cells were illuminated and tested using the same 
illuminator and luciferase assay protocol as the HEK 293T cells while being exposed to blue light 
(total 12 hours, 20 sec light / 60 sec dark cycle) 12 hours after transfection at 37 °C in a CO2 
incubator (Thermo Fisher), also known as “protocol B”.  
Expression profiling: 
HEK 293T cells were plated at 0.5 x 105 cell/well in 24-well plates coated with poly-ornithine 
and transfected the next day with 0.9 μg of DNA in 2 μl of Lipofectamine 2000 in 100 μl of 
OptiMEM.  In case of live cell imaging to detect mKate2, glass coverslips (15 mm diameter, 
Warner Instruments) were used in the 24-well plates.  The ratio of FKF1: GI : Gal4-UAS-
dsGFP/mKate2 was as follows: 1: 1: 1.  The ratio of CRY2: CIB1: Gal4-UAS-dsGFP/mKate2 was 
as follows: 5: 1: 3.  The same illumination conditions used for luciferase assays were used for 
fluorescent protein reporters, following the results of illumination protocol comparisons.  To 
harvest cell lysates for Western blotting, a lysis buffer containing 1% Triton X-100, 150 mM NaCl, 
50 mM Tris-HCl (pH 7.4) and 1% protease inhibitor cocktails (all, Sigma-Aldrich) was used.  Cells 
were incubated for 10 min at room temperature with gentle rocking.  After incubation, the samples 
were placed on ice for 20 min to complete permeabilization.  To remove cell debris, lysates were 
centrifuged at 12,000 rpm for 10 min at 4 °C, then moved to new tubes.   An equal volume of 2x 




added to the lysate samples and boiled for 5 min. SDS-PAGE was performed using Tris-Glycine-
based gels (Bio-Rad) containing either 5 or 10% Acrylamide-Bis (Fisher Scientific), and the 
protein samples were then transferred to PVDF membranes using XCell SureLock® Mini-Cell and 
XCell II™ Blot Module system (Life Technologies).  Primary antibodies to GFP (MBL, #598, 
1/4,000 dilution), β-tubulin (Sigma-Aldrich, #t5201, 1/4,000 dilution) and Sox9 (Cell signalling 
technology, #82360, 1/1000 dilution) were used.  The mouse secondary antibody (Invitrogen, 
#31430, 1/8,000 dilution) and rabbit secondary antibody (Thermo Scientific, #31460, 1/8,000 
dilution) was used.  SuperBlock Blocking Buffer (PBS-based, Thermo Scientific, #37515) was 
used for blocking and antibody incubations of the PVDF membranes in trays (Sigma-Aldrich, # 
BAF451000001).  Pierce ECL Western blotting substrate (Thermo Scientific, #32209) was used 
for chemiluminescent reaction.  Western blot bands were quantified through Fiji/Image-J by 
deducting the background from the signal bands.  This was then normalized to the β-tubulin as an 
internal control to quantify the light and dark protein induction for each optogenetic system.  
 Quantitiative RT-PCR was conducted using RNA from illuminated HEK293T cells 
following ‘Protocol B’. Hek293T cells were transfected as mentioned before while 8 light and 8 
dark samples were either exposed to illumination or not, respectively. The cells in each individual 
well were lysed with 350µl RLT buffer (included in Qiagen #74106) and stored at -80°C until use. 
The RNA was prepared using the RNeasy Mini kit and RNase-Free DNase set (Qiagen #74106). 
During the extraction, the samples were treated with RNase-Free DNase set (Qiagen #79254) for 
15 minutes at RT. Once completed, the RNA was quantified using a NanoVueTM (GE #28924402). 
cDNA was synthesized using the SuperScript III First-Strand Synthesis System for RT–PCR using 
OligoDT (Invitrogen #18080-051). These products were then treated with RNaseH for 20 minutes 




final volume of 105µl. 1 μl of each sample was used for qPCR analysis. SYBR Advantage qPCR 
Premix (Clontech/TaKaRa Bio) and StepOnePlus real time PCR systems (Life Technologies) were 
used for qPCR. The samples were plated in a 96-well plate format (Life Technologies #4346906). 
The qPCR assay was conducted in three stages: holding at 95°C for 20s, cycling between 95°C for 
3s and 60°C for 30s (conducted 40x) and melt curve beginning at 95°C for 15s followed by 60°C 
for 1 min increasing to 95°C at a rate of 0.3°C/s. The specificity of the reaction was checked 
through the melt curves ensuring that there is only a single prominent peak present. The CT value 
of each sample at 50% of the amplification curve was used and GAPDH was used to as a reference 
gene to normalize the expression of the target genes. The formula for normalization is 2(-CTsample)/2(-
CTGAPDH). 
The primer sets for detecting mSOX9 (#Q04887), Aggrecan (#P16112), LXH2 (#P50458), GAS1 
(#P54826), TLE4 (#Q04727), codon optimized MyoD1 and GAPDH (#P04406) were 
manufactured by Eton Bio. Their sequences and amplicon length are as follows:  
SOX9 Forward (Exon 1) 5’- AGGAAGCTGGCAGACCAGTA-3’, Reverse (Exon 2) 5’- 
CTCCTCCACGAAGGGTCTCT-3’; Amplicon Length: 110bp; Aggrecan Forward (Exon 2) 5’-
TCTGGGTTTTCGTGACTCTGA-3’, Reverse (Exon 3) 5’-TCCACTTGATTCTTGGGGCC-3’; 
Amplicon Length: 212bp; LXH2 Forward (Exon 4) 5’-TTTGCCATTAACCACAACCC-3’, 
Reverse (Exon 5) 5’-TGTTTTCCTGCCGTAAGAGG-3’; Amplicon Length: 138bp; GAS1 
Forward (Exon 1) 5’-GAAACTCCCAACTCGTCTGC-3’, Reverse (Exon 1) 5’-
CCCAACCCTTCAAATTGCTA-3’; Amplicon Length: 148bp; TLE4 Forward (Exon 7) 5’-
GCTCTAGGAGGTCAGTCCCA-3’, Reverse (Exon 9) 5’-CTTCTCAGCACCTCGGAAAC-3’; 
Amplicon Length: 131bp; codon optimized MyoD1 Forward 5’-




Amplicon Length: 115bp; GAPDH, Forward (Exon 8) 5’-GATGACATCAAGAAGGTGGTGA-
3’, Reverse (Exon 9) 5’-GTCTACATGGCAACTGTGAGGA-3’ Amplicon Length: 369bp.  
 The Fluorescence activated cell sorting (FACS) procedure was conducted as follows. 
Illuminated cells, cultured as mentioned above in a 24-well plate, were detached with trypsin 
(0.25% trypsin + 0.03% EDTA for NIH 3T3 cells and human fibroblasts while HEK 293T cells 
were detached using 0.05 % trypsin + 0.006 % EDTA solution (both from Gibco/Life 
Technologies)).  DMEM (500µL, 10% FBS, for NIH 3T3 and HEK 293T cells) and 20% FBS 
DMEM (for human fibroblasts) were added to the trypsinized cells.  Following this, the cells were 
harvested manually and filtered through a single cell filter tube (Corning, #352235) and 
centrifuged at 0.2 rcf for 2 min at room temperature. The media was then aspirated and the cells 
were resuspended in 1xPBS. The cells were then sorted on a BD FACS Canto II using the FITC 
and PE-A lasers. The resulting data was analysed using the FlowJo software v10.   
 Spatiotemporal control of live cell illumination was conducted using a custom Nikon 
microscope Ti-E (Andor Zyla sCMOS camera; Nikon CFI Plan Apo Lambda, 20x/0.75/1.0mm) 
with automated motorized stage and environmental controls set at 5% CO2, 20% O2 and 37°C 
(TOKAI HIT). 1x105 cells were plated on a 35mm glass bottom (MatTek Corporation, P35G-1.5-
20-C) dish coated with poly-ornithine (Sigma-Aldrich, #P0421).  Twenty four hours after plating, 
the cellular media was replaced with 10% FBS-supplemented phenol red-free media (GIBCO, 
#3105-028) and were transfected with 3.6µg DNA and 8µL Lipofectamine 2000 per dish.  These 
cells were transferred directly to the microscope stage and illuminated using a digital micromirror 
device (DMD) set at 475nm and 36µW/mm2 following ‘Protocol B’. These cells were imaged after 
the illumination protocol was completed using TXRED (560nm) and GFP (470nm).  




MEF cells were plated on a 24 well plate with a glass coverslip coated with Geltrex® (Thermo-
Fisher/Life Technologies). These samples were transfected the following day using 0.5µg DNA, 
1µL P3000 and 1.5µL Lipofectamine 3000 in each well. The cells were then illuminated 12 hours 
after transfection. Subsequently, the samples were cultured in DMEM supplemented with 1% 
GlutaMax I, P.S. and 2% horse serum under normoxia (20% O2, 5% CO2, at 37oC) using HERAcell 
(29). The media was changed every 2 days in a dark room for 5 days after which they were prepared 
for immunocytochemistry experiments.  
Immunocytochemistry 
Illuminated MEF cells were fixed in freshly prepared fixing solution (phosphate buffered saline 
with 4% paraformaldehyde and 2% sucrose) for 15 minutes. This was then blocked with blocking 
solution (phosphate buffered saline with 3% BSA and 0.1% Triton X-100) followed by overnight 
incubation with mouse anti-MyoD1 monoclonal antibody (Abcam ab16148). The samples were 
then stained with anti-mouse Alexa 488 secondary antibody (Thermo-Fisher #: A-11001) followed 
by a Hoescht 33258 stain (Invitrogen Cat#: H3569) and mounted using Aquapoly (Polysciences 
#: 18606). The samples were imaged with GFP (470nm) and Dapi (395nm). 
Mouse study:  
Experiments using mice were performed in accordance with the Guidelines for Care and Use of 
Laboratory Animals as stated by Columbia University IACUC. In all the experiments, we used 4-
6 week-old C57BL/6 mice (both male and female from Charles River). The abdominal surface fur 
of mice was removed using a hand trimmer. The fur-removed mice were rested for 24 h at least in 
a cage, and intraperitoneally injected with cDNAs encoding pcDNA3-Gal4DBD-NLOV (H105L)-




procedure 158. The total amount of injected DNA and the volume of delivery solution are 0.5 μg 
and 0.1 mL per mouse weight (g), respectively. After the hydrodynamic injection of plasmid DNA, 
the mice were kept in the dark for 12 h, and then illuminated with an LED light source (470 ± 20 
nm, 1.2 mW) for 3 min in a cage.  After illumination, the mice were kept in the dark to recover.  
Twenty hours after the plasmid DNA injection, the mice were sacrificed using the standard 
procedure approved in our animal protocol and their livers were immediately harvested for 
fluorescent imaging with fluorescent stereoscope (Zeiss). 
Homology Modelling: 
The FKF1 LOV domain was determined to be between amino acids 1-168 131. This amino acid 
sequence was used to match with known templates in SWISS-MODEL (Biozentrum) that 
produced a high identity with the putative blue right receptor (1.n9o.1.A). This was used to 
generate a homology model that was visualized using CueMol2. 
LED illuminator development: 
The blue LED illuminator with heat control and a built-in fan was designed and developed by J. 
Jung.   
The illuminator has following expandable features:   
1) Switch on/off (automatically/manual) is available using a LED assembly consisting of 7 rebel 
LEDs (Luxeion, #SR-02-R0500).  The intensity/brightness of the LED can be adjusted from 0% 
(off) to 100% (max brightness). 
2) Typical characteristics of one LED Assembly is 6W, fixed wavelength 447.5nm (other 
assemblies are also available). 




which the LED assembly is mounted. 
4) The fan mounted above the heat sinks can be turned on (automatically or manually) to enforce 
the airflow through the heat sinks to ensure a homogeneous temperature below the LEDs. 
5) While the LEDs are turned off, heat elements can be switched on (automatic/manual). These 
elements should emit the same amount of thermal heat as when the LEF’s are turned on. This 
would help stabilize the temperature in the incubator. 
6) Small, enclosed high precision temperature sensors (+/- 0.065 °C resolution) are used to monitor 
temperature of the sample and control areas below the LEDs.  Temperature data are logged with 
time/date stamps and stored on an SD card.  Data is also shown on a display. 
7) A programmed sequence (turn the LED/heater/fan on and off, measure the temperature and log 
the data) can last several days and is started by pushing the start button on the controller.  The time 
sequence limit is set by the software (Arduino). 
8) Interval length adjustments and LED intensity settings are determined (0.5 mW, 6.25 μW/mm2) 
by changing the appropriate parameters in the software, which can be easily updated when 
connecting the micro controller to a computer using the USB interface. 
EL222 transfection: 
Following Dr. Motta-Mena’s protocol and advices, we transfected the EL222 system in HEK 293T 
cells using the following ratio of plasmids: VP-EL222: pGL-C120-Luc: HSV-TK-Renilla = 5: 1: 





The statistical significance (P value) used to compare the samples with/without light exposure was 
determined using an F-test and Student’s t-test (Excel, Microsoft). The statistical significance of 
the comparison of multiple samples for the luciferase assay was computed using the Bartlett test 




































Chapter 3.1 Introduction to the Lactate indicator development project 
 
Introduction 
Lactate is a much-maligned compound previously considered to be the harmful end product of 
anaerobic glycolysis that needs to be removed162. As research into lactate and its biological role is 
furthered, lactate has been found to be a metabolic fuel that is distributed, and may have many 
roles, throughout the body163-165. Lactate is moved, following the lactate shuttle hypothesis, 
between glycolytic to oxidative spaces either intracellularly or between cells extracellularly166,167. 
Lactate is thought to be important in cellular respiration, gluconeogenesis and metabolic regulation 
through an autocrine, paracrine or endocrine like functions163,168-171. Through lactylation of histone 
lysine resides in metabolically challenged M1 macrophages, lactate serves as an epigenetic 
modification and is directly implicated in gene regulation172. In disease, hyperlactatemia is 
correlated with poor patient outcomes and is often associated with hypoxia but may result from 
other cellular mechanisms like aerobic glycolysis173-175. The Warburg effect describes the finding 
that, certain tumor cells generate lactate despite the presence of oxygen leading to a change in the 
tumor microenvironment promoting angiogenesis, metastasis and immunosuppression176,177. As 
such, altered lactate handling is both a marker and a target for oncological interventions178,179. 
Measuring the levels of lactate is of increasing importance to better understand how it influences 
normal and pathophysiological states.  
Current methods to measure lactate are largely destructive as they depend on the direct biochemical 
or mass-spectral measurement of lactate180-182. These methods do not facilitate the dynamic 
measurement of lactate levels in vitro and in vivo. To address this, a genetically encoded Förster 
resonance energy transfer (FRET) sensor Laconic was developed utilizing the bacterial LldR 




protein functions like Chaski, a lactate/pyruvate shuttle in Drosophila, a basis of a drug screening 
tool MitoToxy, and to further investigate neuronal energetics184-188. However, Laconic is limited 
in a few ways. As a FRET sensor, it is difficult to use in tandem with other metabolic indicators, 
and the in vivo application of the tool is dependent on the use of Adeno Associate Viruses (AAV) 
to induce its expression186,189.  
Seeing room for improvement, we sought to develop a new lactate indicator through the use of 
split superfolder fluorescent molecules in place of a FRET pair. We called these tools Genetically 
Encoded Metabolic Indicators for Lactate (GEM-IL), as the initial part of the GEM indicator series.  
This allows for a single wavelength observation of lactate levels in vivo and in vitro which enables 
the study of multiple metabolites in tandem190-192. Additionally, single fluorescent indicators have 
inherently low background signals and necessitate a comparatively simple detection method to 
those needed to use FRET-based indicators193. 
Project Aims/Why the project matters 
The aim of the project was to develop a single-color tool to measure the levels of lactate both in 
vitro and in vivo. The use of a single color for interrogation is important as this allows for the use 
of multiple single-color probes in tandem allowing for the measurement of several metabolites at 
once. This is was accomplished by adapting a split fluorescent molecule flanking the bacterial 
ΔDBD LldR lactate binding domain, this tool is called C-GEM-IL 1.0. This indicator was then 
improved further through targeted mutagenesis affecting the CFP1-10 fluorescence barrel making a 
I146N mutation and the LldR binding domain with an E103D mutation leading to C-GEM-IL 2.0 
and 3.0 respectively. In vivo mouse models of C-GEM-IL 2.0 and 3.0 were developed and the 
isolated cardiomyocytes were found to respond to lactate. C-GEM-IL 3.0 was used in vitro and 




progenitor cells and NIH 3T3 cells. Of note, this tool was also found to be able to be used in 
tandem with C-GEM-IP (a pyruvate indicator we developed) as well as together with R-GECO1 
(a calcium indicator) as a proof of principle showing that the tool can be used while measuring 
other metabolites of interest149. 
This project is important as lactate has been found to have an expanding role in cellular processes. 
Lactate, once considered a waste product, has now been shown to be involved in DNA 
transcription regulation through lactylation, oncology through the Warburg effect, and in medicine 
as a measurement of the severity of disease like a myocardial infarction and sepsis172,194-197. 
Through further study and optimization, it is my hope that C-GEM-IL can be used widely in 
research to better understand lactate flux and, later, translationally in patients. Its use in research 
may involve the measurement of lactate together with other metabolites under different conditions 
and stressors. Translationally, C-GEM-IL may be useful in understanding lactate dynamics and its 
impact of patient health and outcomes in cancer, myocardial infarction and sepsis.  
My Contribution 
The development and initial testing of C-GEM-IL 1.0, 2.0, and 3.0 as well as C-GEM-IP 2.0 was 
conducted by Shunnosuke Ueno. The utilization C-GEM-IL and C-GEM-IP was accomplished by 
Ramsey Bekdash. Together with Ramsey Bekdash, we created the materials (i.e. plasmids) and the 
C-GEM-IL 3.0 mouse targeting vector. My contribution to this project was in the development of 
experimental plans, establishing and troubleshooting of the experimental protocols, coordination 
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Chapter 3.2 Introduction 
Lactate, once viewed simply as a waste product, has garnered increasing importance as an active 
metabolite that is shuttled between cells and organs165,198. Neurologically, it has been identified as 
a component of brain energy metabolism and may also act as an important signaling molecule that 
controls food intake in response to glucose levels171,199,200. Neuronal energetics has focused on the 
metabolic relationships of glucose, pyruvate and lactate accumulation and shuttling between 
astrocytes and neurons184-186,201. In arterial blood, lactate concentrations have been negatively 
correlated to patient survival following an ischemic event such as myocardial infarction as well as 
septic shock194-196. In cancer cells, the notably different metabolic profile of lactate has led to 
research in studying lactate transporters as a therapeutic target197. Cancer cells that are more prone 
to metastasize have been found to take up lactate more efficiently than those that are not prone202. 
Recently in genetics, lactate has garnered attention as histone lysine residues have been found to 
be lactylated, controlling gene expression in M1 macrophages172.  The multidimensionality and 
impact of lactate highlights the necessity to develop optimized tools to enhance the ability to 
measure lactate in order to better understand its role203,204.  
Despite the increasing interest and importance of lactate metabolism, methods to measure lactate 
dynamics in situ and in vivo are still limited203,204. Previously, indicators have proven to be useful 
in metabolic studies with multiple tools developed for metabolites such as glucose and 
nicotinamide adenine dinucleotide205-207. The first genetically encoded lactate fluorescent 
indicator, Laconic, is based on Förster resonance energy transfer (FRET) and the bacterial lactate-
binding molecule LldR183. Laconic has been utilized in subsequent studies to better understand 
neuronal energetics, identify the function of Chaski, a Drosophila lactate/pyruvate shuttle, as well 




FRET sensor, however, it is limited in its utility to be used in tandem with multiple fluorescent 
indicators, a feature which would be of great utility given the dynamic and intertwined nature of 
metabolite levels. The in vivo studies using Laconic relied on the use of Adeno Associated Virus 
(AAV) to induce its expression, a process which has been known to be immunogenic186,189. We 
sought to improve upon this lactate indicator, by utilizing molecular biological approaches and 
mutagenesis to develop single superfolder split fluorescent protein-based indicators built around 
LldR. The advances in this new generation of tools expand the ability to observe lactate dynamics 
in situ and in vivo. The use of single fluorescence indicators allows for the utilization of multiple 
fluorescent molecules simultaneously to monitor several metabolites or other biological events 
such as calcium signaling190-192. The single fluorescent indicators have inherently low background 
signals as well as comparatively simple detection methods to those necessitated by FRET-based 
indicators193. 
Here, we have developed and applied Genetically Encoded Metabolite (GEM) indicators to study 
the dynamics and role of lactate in physiology and disease. Mouse in vivo models were developed 
allowing for the cell/tissue specific monitoring of lactate dynamics as demonstrated using isolated 
primary cells. In human neural progenitors, we were able to use GEM-IL to examine the effect of 
c-Myc, an oncogene, which heightened lactate levels. Using simultaneous live cell imaging, we 
were able to examine the interplay between lactate and calcium ions as well as assess the effect of 
glucose withdrawal on lactate and pyruvate levels. Altogether, we report the development and 
application of GEM-IL, showing its potential as a tool to enhance our understanding of the function 





Chapter 3.3 Results 
Development of a Genetically Encoded Metabolic Indicator for Lactate (GEM-IL) 
Genetically Encoded Metabolite Indicator for Lactate, GEM-IL was developed with the goal of 
developing a lactate indicator that can directly measure the metabolite both in situ and in vivo. 
Three split fluorescent proteins: superfolder cyan (sfCFP), green (sfGFP) and yellow (sfYFP) were 
used. As previously reported, superfolder fluorescent variants show improved stability, kinetics, 
and resistance to chemical denaturants, making them an ideal reporter for studying lactate 
dynamics compared with non superfolder fluorescent probes208,209. The split-fluorescent protein, 
separates the 11th β-strand of sfGFP (sfGFP11) from the first 10 β-strands (sfGFP1-10)210-212. This 
strategy was used to construct GFP (G), YFP (Y), or CFP (C) GEM-IL by fusing either 
sfG/Y/CFP1-10 to the amino-terminus and sfGFP11 to the carboxyl-terminus of LldR. We 
hypothesized that the mature split fluorescent molecule would undergo a conformational shift upon 
lactate binding to LldR resulting in a detectable and reversible fluorescence change (Figure 57a). 
This is supported by the development of a single fluorescent indicator using conformationally 
sensitive GFP (csGFP) that can be conformationally manipulated through inducing strain on the 
molecule213,214. As expected through the known excitation and emission spectra of each fluorescent 
protein, we observed cyan and green fluorescence when expressing C-GEM-IL in mammalian 
cells, HEK 293T and NIH 3T3 cells, as well as green and yellow fluorescence for G-GEM-IL and 
Y-GEM-IL (Figure 58a) 215. The ability of GEM-IL to detect the change in lactate levels in situ 
was then assessed through the exogenous administration of 10mM sodium lactate. Notably, an 
exogenous infusion of 10mM lactate led to an increase of cellular cytoplasmic levels from 33μM 
to 545μM, which is within a physiologically relevant range, while not having an effect on the 




absolute fluorescence change compared with G-GEM-IL and Y-GEM-IL with signals changes of 
11.1%, 4.6% and 10.2%, respectively, which were lower than the original FRET-based lactate 
indicator, Laconic, under the same experimental conditions (Figure 57c and 57d). The binding of 
lactate to C-GEM-IL resulted in an increase in the fluorescence signal, inverse of what is seen with 
G- and Y-GEM-IL. Although the exact mechanism behind this inversion is unknown, it is 
consistent with the previous experiments using csGFP213. Concurrent with the development of the 
different fluorescent indicators, various linkers: flexible, rigid and hinged were tested to optimize 
the indicator using G-GEM-IL as a template. The hinge linker between LldR and sfGFP11 increased 
the absolute fluorescence change of G-GEM-IL to 9.4% (Figure 57e). A hinge linker was then 
integrated to the cyan version of the indicator to further optimize this tool, leading to the 
development of C-GEM-IL 1.0 (Figure 57f). 
C-GEM-IL 1.0 formed prominent puncta in NIH 3T3 cells (Figure 57g)183. This may be evidence 
of protein aggregation brought by poor indicator stability and folding. To alleviate this, we deleted 
the DNA binding domain of the LldR portion of the indicator (ΔDBD), and designated it as C-
GEM-IL 1.1. The deletion eradicated the previously seen puncta, resulted in a uniform distribution 
of the indicator in the cytoplasm and significantly increased the response of this indicator to lactate 
perfusion to 18.3%, significantly greater than that of the C-GEM-IL 1.0’s 4.5% change (Figure 











Figure 57 Development of a genetically encoded metabolic indicator for lactate (GEM-IL).   
A) Overview of the lactate indicator GEM-IL binding upon introduction of lactate.  
B) Cytoplasmic lactate change in NIH 3T3 cells when exposed to 10mM sodium lactate externally. 
Error bars represent standard deviations (n=6 for both from two independent experiments). 
Student’s t-test with Welch’s correction (***P<0.001). 
C) Relative fluorescence change of the cyan, green and yellow fluorescent protein-based GEM-IL 
constructs after lactate addition in NIH 3T3 cells with the Laconic signal change as a reference. 
Error bars represent standard deviations (n=16, 12 and 18 samples, respectively). Red dashed line 
demonstrates the average of FRET change of the original Laconic lactate indicator to the same 
lactate exposure.  
D) Representative fluorescence changes of cyan fluorescent protein-based GEM-IL (C-GEM-IL) 
in NIH 3T3 cells.  
E) Average fluorescence changes of the G-GEM-IL with various linker types after addition of 
10mM lactate (i.e., [Lactate]i = ~545 µM according to Figure 57b) to imaging solution. Error bars 
represent standard deviations (n=12, 8, 9, 10, 7, 9, 6, 15 respectively). One-way ANOVA with 
multiple comparison tests (*P<0.05, **P<0.01) was used.  
F) C-GEM-IL 1.0 construct map.  
G) Cyan fluorescent and bright filed images of C-GEM-IL full-length and C-GEM-IL ΔDBD in 
NIH 3T3 cells. Arrowheads indicate the puncta formation seen when overexpressing C-GEM-IL. 
Scale bar, 10µm.  
H) Fluorescence changes of the full-length and ΔDBD C-GEM-IL. Error bars represent standard 
deviations (n=93 and 31 samples, respectively. using unpaired two-tailed t-test, ***P<0.001).  





   
Figure 58 Development of C-GEM-IL 1.0.  
A) Images of the CFP, GFP and YFP GEM-IL (full-length LldR version) using multiple 
fluorescence filters in HEK 293T and NIH 3T3 cells. Scale bar = 50µm.  
B) Representative trace of the effect of 10mM extracellular lactate exposure on CFP expressed in 




Fluorophore mutagenesis in C-GEM-IL  
Investigating the cause behind the aforementioned inversion of fluorescence changes between C-
GEM-IL and Y/G-GEM-IL, we aligned the amino acid sequences of the fluorescent proteins and 
found that sfCFP alone had an isoleucine in the 146th position compared to an asparagine in the 
other proteins (Figure 57c, 59a, and 60). Suspecting this amino acid to be the cause of the inverted 
response of C-GEM-IL to lactate, we generated an I146N mutant of C-GEM-IL 1.1 (Figure 59b). 
Interestingly, this did not lead to an inversion of the fluorescence change. Instead, the I146N 
mutation significantly enhanced the fluorescence change of C-GEM-IL 1.1 in response to lactate 
to 24.4% (Figure 59c), leading to an improved version: C-GEM-IL 2.0. Although this is in contrast 
to previous findings that the I146N mutation leads to a decrease in the fluorescence of CFP, this 
discrepancy may be due to a difference in the folding of the mature superfolder split-fluorescence 
protein as well as the labile nature of I146 in relation to the chromophore216-218. 
Next, to further characterize the indicator, we used a bacterial expression system to obtain purified 
recombinant form of C-GEM-IL 2.0 protein. Characteristic of CFP, we found that when excited at 
425nm, the emission spectra remained as a single peak with a maximum emission of 490nm 
(Figure 59d). The dissociation constant of the indicator (KD) was found to be 1.76mM (Figure 
59e). Measuring the response of the in vitro recombinant protein to various metabolites, C-GEM-
IL 2.0 showed a specificity for lactate of 41.1% change with no significant change in fluorescence 
in the presence of other metabolites (Figure 59f). Although non-significant, the indicator’s 
fluorescence changed in response to glucose, pyruvate and acetate were at notable levels of 15.3%, 







Figure 59 Development of a genetically encoded metabolic indicator for lactate (C-GEM-IL 
2.0).   
A) Amino acid sequence alignment showing the inclusion of the I146N mutation (red outline) in 
C-GEM-IL (Grey, a match; yellow, a mismatch).  
B) C-GEM-IL 2.0 construct map.  
C) Fluorescence intensity changes of the wild-type (WT) and I146N mutant in NIH 3T3 cells. Error 
bars represent standard deviations (n=31 and 43 traces, using unpaired t-test. ** P<0.01).   
D) Emission spectra of recombinant C-GEM-IL 2.0 proteins purified from bacterial expression 
system.  
E) Lactate binding curve of the purified recombinant C-GEM-IL 2.0 proteins.  
F) Substrate binding tests of the recombinant C-GEM-IL 2.0 protein with 10mM of each substrate. 
Error bars represent standard deviations (pH 7.0, n=3, using one-way ANOVA with multiple 




Development of C-GEM-IP pyruvate indicator 
Pyruvate is an important metabolite that can be converted into multiple downstream chemicals, 
including lactate, and the two metabolites are often intertwined depending on the energetic needs 
of the cell219,220. The lactate-pyruvate ratio has been used as an indicator for mitochondrial 
disorders as well as an indicator for patient outcome following traumatic brain injury221,222. 
Therefore, a genetically encoded pyruvate indicator would be similarly useful223. We employed a 
similar design for the pyruvate indicator, flanking a ΔDBD PdhR with a split superfolder 
fluorescent protein (with the I146N mutation) leading to a functional indicator C-GEM-IP 2.0 
(Figure 61a). Using NIH 3T3 cells in situ, the indicator was shown to respond to an exogenous 
addition of 10mM pyruvate with a 40.3% fluorescence change (Figure 61b). The in vitro 
recombinant form of C-GEM-IP 2.0 evidenced a single emission peak with a maximum intensity 
at 490nm (Figure 61c). The dissociation constant (KD) of the indicator is 612µM (Figure 61d). In 
Figure 60 Multiple alignment of various fluorescent subunits.  
Amino acid sequence alignment of superfolder (sf) BFP, CFP, GFP and YFP. Grey shading is a 
match and yellow is a mismatch while cyan is a mismatch to an amino acid with similar properties. 




addition, the recombinant protein showed substrate specificity, only having a significant change 
in fluorescent intensity in response to pyruvate and not to the other metabolites (Figure 61e). 
With the goal of expanding the functionality of this indicator, we developed a superfolder YFP 
version of this indicator: Y-GEM-IP 2.0 (Figure 62a). As with Y-GEM-IL (Figure 57c), the 
fluorescent response to metabolite infusion is inverted, resulting in a decrease in fluorescence in 
response to lactate. The recombinant proteins of Y-GEM-IP 2.0 showed a single emission peak 
with a maximum intensity at 535nm (Figure 62b). The dissociation constant (KD) of the indicator 
was found to be 379μM (Figure 62c). The substrate specificity of Y-GEM-IP 2.0 showed a similar 
specificity to C-GEM-IP 2.0, with the indicator only responding significantly to pyruvate and not 





   
Figure 61 Development of a genetically encoded metabolic indicator for pyruvate (GEM-
IP).   
A) Cyan fluorescent protein-based GEM-IP (C-GEM-IP) construct map. I146N mutation and 
DNA binding domain deletion (∆DBD) were also applied to this construct (C-GEM-IP 2.0), 
following C-GEM-IL development.  
B) Cumulative trace of fluorescence changes of C-GEM-IP 2.0 in NIH 3T3 cells. Error bars 
represent standard deviations.  
C) Emission spectra of recombinant C-GEM-IP 2.0 protein.  
D) Pyruvate binding curve of the recombinant C-GEM-IP 2.0 protein.  
E) Substrate binding test of the C-GEM-IP 2.0 proteins with 10mM of each substrate. Error 
bars represent standard deviations (one-way ANOVA with multiple comparisons test, ** 




   
Figure 62 Yellow fluorescent genetically metabolic indicator for pyruvate (Y-GEM-IP).  
A) Yellow fluorescent protein-based GEM-IP (Y-GEM-IP) construct map. DNA binding domain 
deletion (∆DBD) was also applied to this construct (Y-GEM-IP 2.0), following C-GEM-IP 2.0 
development.  
B) Emission spectra of recombinant Y-GEM-IP 2.0 proteins purified from bacterial expression.  
C) Pyruvate binding curve of the purified recombinant Y-GEM-IP 2.0 proteins.  
D) Substrate binding test of the purified recombinant Y-GEM-IP 2.0 proteins with 10mM of each 
substrate. Error bars represent standard deviations (one-way ANOVA with multiple comparisons 




Lactate binding domain characterization and mutagenesis in C-GEM-IL 
To further identify the conserved regions or amino acids critical for lactate binding, we aligned the 
amino acid sequences of the lactate binding domains from three organisms: Escherichia coli (E. 
Coli), Pseudomonas aeruginosa (P. Aerg) and Corynebacterium glutamicum (C. Glut) (Figure 
64a). From this alignment and computational prediction tools, SWISS-MODEL and I-TASSER, 
several conserved residues were targeted for mutagenesis to improve binding affinity and further 
optimize C-GEM-IL 2.0 (Figure 63a, 63b, 64a, and 64b). Of all the mutants tested, the E103D 
mutation resulted in the largest increase in fluorescence of 42.9% in response to lactate as 
compared to 24.4% of C-GEM-IL 2.0 leading to the development of C-GEM-IL 3.0 (Figure 63b 
and 63c). The mutation studies bore a non-responsive form of the indicator, with the H151M 
substitution effectively abolishing the indicator’s response to lactate with a 2.2% fluorescence 
change (Figure 63b). This construct is useful as a negative control as fluorescent signals are often 
affected by a variety of factors such as temperature, ion concentrations and pH. LldR proteins have 
been observed to oligomerize and bind lactate224. 
To determine whether the fluorescence change of C-GEM-IL 3.0 is in response to the influx of 
lactate, NIH 3T3 cells were treated with lactate in the presence or absence of AR-C155858, a 
monocarboxylate 1 transport inhibitor, which inhibits the influx of lactate into the cell (Figure 
63d)197. Following exposure of NIH 3T3 cells to AR-C155858, C-GEM-IL 3.0 fluorescence did 
not change significantly (Figure 63e), evidencing that the fluorescence change observed is due to 
the MCT-mediated lactate influx. To test whether C-GEM-IL 3.0 can detect an endogenous 
increase in lactate produced through glycolysis, we provided either glucose or 2-Deoxy-D-glucose 
(2DG, a non-metabolizable glucose analog) to NIH 3T3 cells that were preconditioned in glucose-




produced through glycolysis with a fluorescence change of 12.0% while the fluorescence change 
in response to 2DG was not different from baseline (Figure 63g). 
The bacterial recombinant protein was purified and imaged using a coomassie brilliant blue stain 
evidencing a single band at ~50 kDa representing C-GEM-IL 3.0 (Figure 63h and 64c). The 
recombinant protein has a single emission peak with a maximum intensity at 490nm (Figure 63i). 
To investigate whether C-GEM-IL 3.0 had multiple oligomerization states, size exclusion 
chromatography-based HPLC was conducted using the purified protein, and we found that the 
recombinant proteins showed a single peak (Figure 64d). Of note, there is a noticeable shoulder 
peak in the HPLC data that accumulates after multiple freeze/thaw cycles, suggesting the 
aggregation of the purified proteins. C-GEM-IL 3.0 had an improved in vitro dissociation constant 
(KD) of 594 µM compared to C-GEM-IL 2.0 of 1.76 mM (Figure 59e and 63j). The bacterial 
recombinant form of C-GEM-IL 3.0 displayed increased specificity for lactate with a significant 
87.5% change compared to C-GEM-IL 2.0 (Figure 59f and 63k). 
The amount of lactate to which C-GEM-IL 3.0 is exposed in the cells may not be the same as the 
lactate concentration in the external bath solution. To take this into account, the internal lactate 
concentration was measured after exposure of NIH 3T3 cells from 0mM to 100mM lactate using 
a biochemical assay (Figure 64e and 64f). The in situ response of C-GEM-IL 3.0 in live cells was 
then tested at various levels of lactate to measure the KD of the indicator. The results of the 
biochemical assay were then used to convert the lactate concentration of the bath solution to ones 
that taken up by the cells. The in situ KD of C-GEM-IL 3.0 was found to be 515µM similar to what 
was found in vitro using the recombinant proteins (Figure 63j and 64g). 
As seen with other fluorescence-based systems, the fluorescent intensity of recombinant C-GEM-




3.0 was then exposed to 0mM or 10mM lactate at pH 6.5 and found to increase by 51.5% (Figure 
64i). Additionally, to assess whether the fluorescence change seen in situ in NIH 3T3 cells was 
affected by a change in intracellular pH caused by the lactate infusion, the response of the 
recombinant form of the indicator was measured after exposure to 30μM or 500μM lactate, to 
mimic the increase in cytoplasmic lactate observed with a 10mM exogenous addition of lactate in 
situ (Figure 57b). This led to a 37.8% and 40.7% increase in the recombinant protein fluorescence 
isolated from bacterial and mammalian cells (HEK 293T), respectively (Figure 64j). This in vitro 
change is consistent to what is observed in NIH3T3 cells in situ of 42.9%, revealing that the 
fluorescence shift can reliably be attributed to lactate binding to C-GEM-IL 3.0. Following a 
previous study identifying a pH stable GFP variant, a pH insensitive mutant of (N149Y/Q204H) 
C-GEM-IL 3.0p was developed225. However, this mutation led to a fluorescent change of 21.7% 
in situ, a significant decrease compared with C-GEM-IL 3.0 (Figure 64k).  Importantly, the 
purified recombinant form of C-GEM-IL 3.0p still showed a specific significant response to lactate 
with no significant change in the fluorescence of the sensor in response to either glucose, pyruvate 
or acetate (Figure 64l). 
In an effort to further optimize GEM-IP, we aligned the amino acid sequence of LldR and PdhR 
(pyruvate dehydrogenase regulator) and found that there is little similarity between the two binding 
domains but the glutamic acid is maintained (Figure 64m). In contrast to C-GEM-IL 2.0, the 
representative amino acid substitution of PdhR (E102D) in C-GEM-IP 2.0 led to a decrease in 
response to pyruvate of 29.3% in comparison to 40.3% change of C-GEM-IP 2.0, suggesting that 
this amino acid residue may play an important role in lactate and pyruvate binding of LldR and 
PdhR, respectively (Figure 63b, 64n, and 64o). The putative structure of C-GEM-IL 3.0 was 




lactate is thought to bind the LldR and cause a conformational shift in the 11th beta strand of the 










Figure 63 Development of C-GEM-IL 3.0.  
A) Model of the LldR structure with the predicted lactate binding site (purple) and E103 (red)  
B) Effect of targeted amino acid substitutions E103D and H151M in the lactate binding domain 
on lactate-induced fluorescence of C-GEM-IL 2.0 in NIH 3T3 cells. Error bars represent standard 
deviations (n=63 and 37). One-way ANOVA using Tukey’s multiple comparison tests (*P<0.05 
and ***P<0.001).  
C) C-GEM-IL 3.0 construct map.  
D), Overview of C-GEM-IL binding upon introduction of lactate and the effect of AR-C155858 
(MCT1 inhibitor).  
E) Fluorescence intensity changes of C-GEM-IL 3.0 and its response to lactate addition with 
(10mM, black) and without treatment with AR-C155858 (100 nM, blue). Student’s t-test was used 
(***P<0.0001).  
F) Schematic representation of C-GEM-IL lactate sensing upon introduction of glucose after NIH 
3T3 cells are glucose-starved.  
G) Average fluorescence intensity changes of the C-GEM-IL 3.0 and its response to glucose 
(10mM, red) and a non-metabolizable glucose analog, 2DG (10mM, green). Before adding glucose 
or 2DG, the cells were kept in glucose-free Tyrode’s solution. Error bars represent standard 
deviations. Student’s t-test was used (***P<0.0001).  
H) SDS-PAGE gel image of purified recombinant C-GEM-IL 3.0 proteins (arrow).  
I) Emission spectra of the purified recombinant proteins of C-GEM-IL 3.0.  
J) Lactate binding curve of the purified recombinant C-GEM-IL 3.0 proteins (relative, normalized 
to 200mM).  
K) Substrate binding test of the recombinant C-GEM-IL 3.0 with 10mM of each substrate. Error 
bars represent standard deviations (n=3, using one-way ANOVA with multiple comparisons test, 










Figure 64 C-GEM-IL 3.0 further characterization and development of C-GEM IL 3.0p.  
A) Amino acid sequence alignment of LldR expressed in E.Coli, P.Aerg and C.Glut. DNA binding 
domain is outlined in light blue while the amino acids of interest are outlined in red. Grey shading 
is a match and yellow is a mismatch while cyan is a mismatch to an amino acid with similar 
properties.  
B) Effect of targeted amino acid substitutions in the lactate binding domain on lactate-induced 
fluorescence of C-GEM-IL 2.0 in NIH 3T3 cells. Error bars represent standard deviations (n=63, 
9, 37, 8, 29, 10, 10, 4, 15 and 5, respectively).  
C) Coomassie blue stain of an SDS-PAGE gel for the purification of the bacterial recombinant 
protein of C-GEM-IL 3.0.  
D)  Fluorescence HPLC using the recombinant C-GEM-IL 3.0 proteins. Arrowhead shows the 
peak fluorescent signal. #, this fraction was increased after once repeated freeze-thaw cycle, 
suggesting potential protein aggregates.  
E) Overview of in situ C-GEM-IL binding upon introduction of lactate highlighting the 
discrepancy between external and internal levels of lactate. The internal lactate levels at various 
concentrations of external lactate was measured through biochemical assays and used to adjust the 
in vitro KD.  
F) Internal lactate concentration after exposure of NIH 3T3 cells to various external lactate 
concentrations. Error bars represent standard deviations (n≥6 for each concentration).  
G) in situ KD of C-GEM-IL 3.0 expressed in NIH 3T3 cells. Lactate concentrations represent 
internal lactate concentrations attained from the biochemical lactate measurement corresponding 
to the external lactate levels (Figure 64f).  
H) Emission spectra of recombinant C-GEM-IL 3.0 proteins purified from bacterial expression 
system at various pH levels.  
I) Fluorescent intensity change of bacterial recombinant C-GEM-IL 3.0 protein upon exposure to 
30μM and 500μM lactate at pH 6.5. (n=11, using unpaired two-tailed t-test with Welch’s 
correction, **P<0.01)  
J) Fluorescent intensity change of recombinant C-GEM-IL 3.0 protein derived from bacteria and 
mammalian HEK 293T expression systems upon exposure to 30μM and 500μM lactate. Error bars 
represent standard deviations (n=3, using unpaired two-tailed t-test, each compared with the 
respective 30μM lactate data points. *P<0.05, **P<0.01).  
K) Average fluorescent changes of C-GEM-IL 3.0 and 3.0p (pH-insensitive fluorescent protein 
mutant) after exposure to 10mM lactate. Error bars represent standard deviations (n=49 and 27 
traces, respectively, using unpaired two-tailed t-test with Welch’s correction, ***P<0.001).  
L) Substrate binding test of the recombinant proteins of C-GEM-IL 3.0p with 10mM of each 
substrate. Error bars represent standard deviations (n=4, using one-way ANOVA with multiple 
comparisons test, *** P<0.001; n.s., no other significantly differences among the groups).  
M) Amino acid sequence alignment of the E.Coli LldR and PdhR. Grey shading is a match and 
yellow is a mismatch while cyan is a mismatch to an amino acid with similar properties.  
N) Cumulative traces of WT and E102D C-GEM-IP mutants upon addition of 10mM pyruvate.  
O) Quantification of the average fluorescence change of the WT and E102D C-GEM-IP 2.0 
indicator in NIH 3T3 cells during 10mM pyruvate addition to the imaging solution. Error bars 
represent standard deviations (n=31 and 29 samples in three independent experiments, using 




Comparison of C-GEM-IL 3.0 and Laconic 
The aim of this study is to develop an improved lactate indicator to enable more researchers to 
better measure lactate dynamics. The previously developed genetically encoded lactate sensor, 
Laconic, has been utilized in various studies but has some characteristics that may limit its use. C-
GEM-IL 3.0 improves upon this indicator in three significant ways. The first is that C-GEM-IL 
3.0 does not form puncta when genetically overexpressed in NIH 3T3 cells, as was observed with 
Laconic and C-GEM-IL 1.0, and was addressed in C-GEM-IL 1.1 onwards (Figure 57g and 65a). 
The next is that C-GEM-IL 2.0 and 3.0 are capable of measuring the production of lactate after 
exposure of glucose-deprived NIH 3T3 cells to glucose while Laconic could not (Figure 65b). 
Third is that the protein expression of the C-GEM-IL series shows a single band through Western 
blotting as compared to the dual unidentified bands seen with the original Laconic tool, suggesting 
that Laconic construct was truncated (Figure 65c). To see whether any of the alterations conducted 
on C-GEM-IL development would be applicable for Laconic, E103D, ΔDBD/E103D and H151D 
versions of Laconic were prepared. Each change led to a significantly less responsive form for the 
sensor with FRET changes of 6.5%, 6.2%, and 5.5% in response to lactate in situ, respectively 
(Figure 65d). These results suggest that Laconic is limited in its ability to reflect lactate dynamics 






Figure 65 Comparison of C-GEM-IL and Laconic.  
A) Representative cyan fluorescence and bright field images of NIH 3T3 cells expressing Laconic 
and C-GEM-IL 3.0 (scale bar = 5µm).  
B) Fluorescent change of Laconic (mTFP/Venus), C-GEM-IL 2.0 and 3.0 (cyan) in response to 
10mM glucose perfusions to glucose-starved NIH 3T3 cells. The experimental design is identical 
with one conduced in Figure 63f. Error bars represent standard deviations (n=32, 17 and 45 traces, 
respectively, using one-way ANOVA with multiple comparisons test, ***P<0.001).  
C) Anti-GFP western blot results interrogating the expression of the various iterations of Laconic 
and C-GEM-IL expressed in NIH 3T3 cells. Arrowheads show Laconic (black) and C-GEM-IL 
proteins (red). *, truncated Laconic proteins. beta-tubulin, a housekeeping molecule, was also 
tested as reference.  
D) Fluorescence change of Laconic and various iterations in response to the exposure of NIH 3T3 
cells to 10mM lactate. Red dashed line represents the fluorescence change observed with C-GEM-




Ratiometric versions of C-GEM-IL 3.0 
As the fluorescence change of C-GEM-IL 3.0 is based on the conformational change of a mature 
split fluorescent protein, it is a single-wavelength indicator. Although it is useful in the detection 
of lactate flux and enhances the number of indicators that can be used in tandem, it does not allow 
for the exact quantification of lactate due to factors extrinsic to the stimulant226,227. Therefore, we 
developed a ratiometric version of C-GEM-IL 3.0 by co-expressing a fluorescent molecule (either 
YFP or RFP) with the indicator after a linker (Figure 66b). Interrogating the expression of 
appending YFP to C-GEM-IL 3.0 through Western blotting showed a single band at 75kDa (Figure 
66c and 66d). C-GEM-IL 3.0 linked to YFP through either an Ala-Ser (AS) or rigid linker rendered 
the mature CFP unresponsive to lactate while the YFP signal decreased, possibly a FRET change 
of 29.7% and 16.0%, respectively (Figure 66e and 66f). Adding a carboxyl-terminal mKate2 fusion 
after a rigid linker to C-GEM-IL 3.0 led to two bands between 50 and 75kDa in Western blotting 
due to an unknown degradation/truncation mechanism as observed in Laconic (Figure 65c and 
66c). As another RFP source, mCherry was appended to the carboxyl-terminus of C-GEM-IL 3.0, 
and similarly unknown protein bands were found between 50 and 75kDa. As an alternative 
approach, a self-cleaving peptide P2A sequence was applied for developing ratiometric version, 
C-GEM-IL 3.0r (Figure 66g)228,229. The P2A cleavage was not fully efficient with a band at 75kDa 
(non-cleaved, ~10%) and 50kDa (cleaved, ~90%) (Figure 66h). Of note, there was a band that is 
evident between 75 and 50kDa potentially due to the truncation of the non-cleaved proteins. 
Exposure of NIH 3T3 cells transfected with C-GEM-IL 3.0r responded to lactate exposure in situ 
which when normalized to the mKate2 fluorescent signal had a ratiometric response of 30.0% 




the resistance of fluorescent molecules to cellular changes due to lactate influx in the cells as also 









Simultaneous imaging to examine the effect of glucose deprivation on lactate and pyruvate 
A major advantage of using a split fluorescence protein is the ability to employ multiple fluorescent 
sensors simultaneously. The effect of glucose deprivation on the levels of lactate and pyruvate 
were monitored simultaneously in NIH 3T3 cells. To do this, C-GEM-IL 3.0 and Y-GEM-IP 2.0 
were transfected into NIH 3T3 cells and their change in fluorescence was measured after the 
removal of glucose. After glucose withdrawal, the amount of pyruvate increased while the amount 
of lactate decreased (Figure 67a and 67b). As aforementioned, the simultaneous monitoring of 
lactate and pyruvate holds diagnostic utility, and the development and utilization of these two 
sensors allowed for the observation of these changes continuously which was previously 
unavailable. 
Figure 66 Putative structure of C-GEM-IL 3.0 and characterization of quantitative C-GEM-
IL versions.  
A) The ΔDBD LldR, CFP1-10, and GFP 11 subunits were modelled using I-TASSER 
independently and measured using cuemol. These were then assembled displaying the binding of 
lactate to the LldR.  
B) Construct map for C-GEM-IL 3.0 fused with reference fluorescent protein.  
C) Anti-GFP western blot results interrogating the expression of C-GEM-IL 3.0 fused with YFP 
(AS and rigid linker) and mKate2 (rigid linker) in NIH 3T3 cells. Arrowheads evidence expected 
band, # designate unknown bands, suggesting truncated proteins.  
D) Anti-GFP western blot results interrogating the expression of C-GEM-IL 3.0, 3.0p and C-
GEM-IL 3.0 with mCherry (rigid linker). Arrowheads evidence expected band, #, truncated 
proteins.  
E) Representative traces of the CFP and YFP fluorescence change of C-GEM-IL 3.0 +YFP (AS 
linker) in NIH 3T3 cells in response to exposure to 10mM lactate. Error bars represent standard 
deviations (n=26).  
F) Representative traces of the CFP and YFP fluorescence change of C-GEM-IL 3.0 +YFP (rigid 
linker) in NIH 3T3 cells in response to exposure to 10mM lactate. Error bars represent standard 
deviations (n=15).  
G) C-GEM-IL 3.0r construct map.  
H) Anti-GFP western blot results interrogating the expression of C-GEM-IL 3.0r. Arrowhead 
evidences expected protein band, * is the non-cleaved version of the indicators and # designates 
protein bands truncated from the non-cleaved proteins.  
I) Representative traces of the cyan and mKate2 (red) fluorescence change of C-GEM-IL 3.0r in 






Applications of C-GEM-IL to imaging of the lactate response to Octyl-R-2HG and c-Myc 
Octyl-R-2HG, a precursor for D-2-hydroxyglutarate, is an onco-metabolite that inhibits ATP 
synthase and mTOR signaling230. Increasing levels of D-2-hydroxyglutarate were found to 
increase the levels of lactate231. To determine whether C-GEM-IL 3.0 could detect a change in 
lactate levels in response to this compound, NIH 3T3 cells were treated with Octyl-R-HG and 
measured against a vehicle control. It was found that addition of Octyl-R-HG led to a detectable 
increase of lactate of 27.9% in these cells (Figure 67c), revealing the indicator’s ability to respond 
to changes in cellular metabolism due to chemical interactions.  
Overexpression of c-Myc, an oncogene, has been shown to alter the metabolic state of cells with 
the increased need to support cellular proliferation accompanied by an increase in lactate 
production232. To assess if our indicator can detect this change, we virally overexpressed c-Myc in 
NIH 3T3 cells and human neuronal progenitors derived from induced pluripotent stem cells 
(iPSCs) as a model of central nervous system primitive neuro-ectodermal tumor (CNS-PNET)233. 
Here we found that the response of the indicator upon lactate addition was significantly lower in 
the c-Myc-infected cells showing that the indicator can distinguish between the two metabolic 
states (Figure 67d-g). The lower response seen could be due to the heightened metabolic state 
induced by increased c-Myc expression, resulting in significantly higher endogenous lactate 
concentrations compared to non-infected controls, which was supported by a lactate biochemical 
assay of the cell lysate and culture media (Figure 68a-c).  
Effect of lactate on calcium handling 
To further demonstrate possibility of simultaneous fluorescence imaging using C-GEM-IL 3.0, we 




genetically encoded red fluorescent calcium indicator149. We found that the cytoplasmic calcium 
levels significantly decreased with the increase in lactate in the cells (Figure 68d and 68e). This 
finding further evidences that the GEM indicators can be used in tandem with other indicators, 
even those that monitor metabolites not traditionally associated with the metabolic pathway. This 
will allow for the observance of the fluctuations in the levels of various chemicals in response to 
varying levels in lactate. 
Generation of C-GEM-IL mouse lines 
The measurement of lactate in organs and tissue relies on indirect measurements including the use 
of electrodes measuring extracellular lactate or radioisotope labeled metabolites coupled with mass 
spectrometry effectively allowing for only snapshots of lactate handling180,234. An improved in 
vivo model would be invaluable to study lactate dynamics in healthy and disease models. To enable 
the monitoring of lactate dynamics during normal physiology and disease, an in vivo mouse model 
expressing either C-GEM-IL 2.0 or 3.0 was generated by inserting either version of the indicator 
into the Rosa26 locus (Rosa26-Cag-lox-stop-lox-C-GEM-IL, Figure 67h and 68f). Notably, an 
increase in the serum level of lactate correlates negatively with patient survival after heart 
failure194,195. The C-GEM-IL mouse models were used to induce the expression of either indicator 
in cardiac tissue by crossing the C-GEM-IL 2.0 and 3.0 mouse lines with either a tamoxifen-
inducible alpha-myosin heavy chain promoter-driven Cre-expression mouse (αMHC/Myh6-
MerCreMer/CREERT), which restricts the expression of C-GEM-IL to the heart in response to 
tamoxifen or a non-tamoxifen inducible αMHC-Cre mouse, respectively235. The expression of 
either indicator was confirmed through PCR showing Cre-loxP recombination specifically in 
cardiac tissue and the expression of C-GEM-IL 2.0 and 3.0 was further confirmed by Western 




tissues such as liver (Figure 68g-k). The overexpression of the indicator did not deleteriously affect 
the architecture of the mouse hearts as evidenced by the echocardiograms (Figure 68l).  C-GEM-
IL 2.0 and 3.0 maintained functionality in vivo as evidenced by the change in fluorescence of the 
isolated adult ventricular cardiomyocytes after lactate exposure with the C-GEM-IL 3.0 having a 
significantly higher dynamic range of 68.8% compared to the 12.9% change observed with the 2.0 
version (Figure 67i, 67j, and 68m). The results reveal that C-GEM-IL 3.0 mouse line is generated 











Figure 67 Applications of GEM-IL.  
A) Representative cumulative traces of the fluorescence changes of dual imaging using C-GEM-
IL 3.0 and Y-GEM-IP 2.0 in NIH 3T3 after glucose withdrawal. Error bars represent standard 
deviations.  
B) Quantification of the average fluorescence changes of C-GEM-IL 3.0 and Y-GEM-IP 2.0 in 
NIH 3T3 cells at each time point. Error bars represent standard deviations.  
C) Quantification of the average fluorescence changes of C-GEM-IL 3.0 in NIH 3T3 cells upon 
exposure to 1mM octyl-R-HG and control (ethanol only). Error bars represent standard deviations 
(n=20, 54 and 27 samples in three independent experiments, using unpaired two-tailed t-test with 
Welch’s correction, ***P<0.001).  
D) Cumulative trace overlay of c-Myc-infected and non-infected human neural progenitors upon 
addition of 10mM lactate to imaging solution. Error bars represent standard deviations (n=46 and 
31 traces in two independent experiments).  
E) C-GEM-IL 3.0 fluorescence changes in c-Myc-infected human neuronal progenitors. Error bars 
represent standard deviations (n=46 and 31 traces in two independent experiments, using unpaired 
two-tailed t-test with Welch’s correction, ***P<0.001).  
F) Cumulative trace overlay of c-Myc-infected and non-infected NIH 3T3 cells upon addition of 
10mM lactate. Error bars represent standard deviations.  
G) Fluorescence changes in c-Myc-infected NIH 3T3 cells and controls. Error bars represent 
standard deviations (n=31 and 15 samples, using unpaired two-tailed Student’s t-test with Welch’s 
correction, ***P<0.001).  
H) Simplified diagram showing the insertion of the C-GEM-IL 2.0 or 3.0 indicator into mouse 
Rosa26 locus and the effect of crossing with Cre line.  
I) Cumulative traces showing the extracellular lactate-induced fluorescence increase in adult 
ventricular myocytes isolated from C-GEM-IL 2.0 and 3.0 mice crossed with cardiac Cre drivers. 
Error bars represent standard deviations.  
J) Quantification of the fluorescence changes upon introduction of 10mM lactate in the imaging 
solution to the cardiomyocytes isolated C-GEM-IL 2.0 and 3.0 expressing mice. Error bars 
represent standard deviations (n=36 and 34 traces respectively, using unpaired two-tailed t-test 










Figure 68 c-Myc infection of NIH 3T3 cells and C-GEM-IL 2.0/3.0 mouse generation.  
A) Timeline of the infection of NIH 3T3 cells with c-Myc and the subsequent harvest.  
Lactate concentration of NIH 3T3 cells infected in their culture media (B) and lysate (C), 
respectively. Dotted line delineates the amount of lactate measured in 10% FBS culture media. 
Error bars represent standard deviations (n=6 wells in two independent experiments, using 
unpaired two-tailed t-test with Welch’s correction and unpaired two-tailed t-test, respectively, 
*P<0.05, **P<0.01).  
D) Cumulative trace of the fluorescence changes in NIH 3T3 cells transfected with C-GEM-IL 3.0 
and R-GECO1 red fluorescent calcium indicator with 10mM lactate exposure. Error bars represent 
standard deviations.  
E) Average fluorescence changes of the C-GEM-IL 3.0 and R-GECO indicators after addition of 
10mM lactate. Error bars represent standard deviations (n=18 in two independent experiments, 
using unpaired two-tailed t-test with Welch’s correction and unpaired two-tailed t-test compared 
to each fluorescent before lactate addition, respectively, ***P<0.001).  
F) Detailed targeting vector used to generate the genetic insertion of the C-GEM-IL 2.0 or 3.0 
construct into the Rosa26 locus using the Ai38 (GCaMP3) targeting vector as a template. The 
construct was inserted in the intron 1 between the exon 1 and 2. LoxP-F and Lac-R are PCR 
primers used to assess genetic recombination.  
G) Visualization of the PCR amplified product evidencing the Cre-loxP recombination specific to 
the cardiac tissue, not the peripheral tissue such as tail, of a tamoxifen-injected C-GEM-IL 2.0 
mouse crossed with aMHC-MerCreMer line (cardiac inducible Cre driver). Grey arrow indicates 
the non-floxed genomic DNA while the black arrow indicates the floxed version.  
H) Representative Western blot result of cardiac tissue samples from tamoxifen-injected mice 
showing expression of C-GEM-IL 2.0 proteins with no band seen with the WT control. The 
proteins of C-GEM-IL 2.0 in the heart tissue lysate samples were detected with GFP antibody. β-
tubulin was used as loading control (n=3).  
Visualization of the PCR amplified product evidencing the Cre-loxP recombination specific to the 
cardiac tissue (I) and liver (J), not the peripheral tissue such as tail, of Cre-positive C-GEM-IL 3.0 
mice. Grey arrow indicates the non-floxed genomic DNA while the black arrow indicates the 
floxed version.  
K) Representative Western blot result of liver tissue samples from Cre plasmid-injected mice 
showing expression of C-GEM-IL 3.0 protein (n=2) with no band seen with the Cre-negative 
control littermate (n=3).  
L) Representative echocardiogram of sham (sunflower oil) injected and tamoxifen-injected C-
GEM-IL 2.0 mice (n=3 for both) and C-GEM-IL 3.0: αMHC-Cre double-positive mice each with 
summary data generated from the echocardiograms.  
M) Representative phase contrast and cyan fluorescent images of isolated adult mouse primary 





Chapter 3.4 Discussion 
This work describes the development and applications of C-GEM-IL 3.0 and C/Y-GEM-IP 2.0 
lactate and pyruvate metabolic indicators, respectively. C-GEM-IL 3.0 improves upon the 
previously available lactate indicator, Laconic, as it utilizes a split fluorescent molecule rather than 
a FRET pair allowing for a simpler detection method as well as a lower background fluorescence 
signal making C-GEM-IL easier to adopt and use. In this study, protein expression characterization 
reveals that the Laconic construct has putative truncated forms (Figure 65c), suggesting that the 
fluorescence of Laconic could not reflect lactate concentration precisely and that the experimental 
outcomes and conclusions from the previous literatures could be unsure as none of the previous 
studies have investigated the protein expression of Laconic in mammalian cells184-188.  
The development of C-GEM-IL involved multiple iterations. C-GEM-IL 1.0 was a functional split 
that had a 4.5% fluorescence change and formed puncta when expressed in situ. The removal of 
the DNA binding domain (C-GEM-IL 1.1) alleviated the puncta seen. Two mutations to the sensor, 
I146N in the sfCFP portion as well as E103D in the LldR, subsequently increased the dynamic 
range of C-GEM-IL making version 2.0 and 3.0, respectively. C-GEM-IL 2.0 and 3.0 were 
significant improvements with fluorescent responses to lactate of 24.4% and 42.9% as compared 
to the original FRET-based Laconic that evidenced a 15% change. Importantly, E103D improves 
the lactate specificity of the indicator. Further development is ongoing to generate GEM indicators 
with varying kinetics and expression to targeted subcellular organelles such as the nucleus, plasma 
membrane and endoplasmic reticulum. To this point, pH stable and ratiometric versions, C-GEM-
IL 3.0p and 3.0r, were developed to increase potential applications of lactate fluorescent imaging. 
As the levels of pyruvate are also of importance in cellular metabolism, we developed a pyruvate 




Together with C-GEM-IL 3.0, we were able to monitor the levels of pyruvate and lactate in 
response to glucose depletion. Here, it was shown that the upon withdrawal, lactate levels decrease 
while pyruvate concentrations increased. 
Employing C-GEM-IL 3.0 allowed us to detect the difference in lactate response of metabolically 
disparate cells driven by c-Myc overexpression in NIH 3T3 cells and human NPCs. The decreased 
response of the c-Myc infected cells may be due to an increase in cytoplasmic lactate 
concentration. Octyl-R-HG led to a detectable increase of lactate in live cells, revealing the ability 
of C-GEM-IL 3.0 to respond to changes in cellular metabolism induced by chemical interactions. 
In chemical biology research, our GEM indicators can be beneficial to determine the metabolic 
effect of various chemicals on the levels of pyruvate and lactate as well as being used as a screening 
tool to assess the utility of these compounds in biomedical research. 
A benefit of developing a split fluorescence indicator is the ability to use multiple fluorescent 
sensors at the same time to measure different metabolites. As evidence of this, C-GEM-IL 3.0 was 
successfully used in tandem with R-GECO1 (a calcium indicator) showing a negative correlation 
between lactate administration and the R-GECO1 calcium signal.  
To enable the investigation of lactate levels in vivo, we developed new mouse strains that contain 
Cre-inducible cassette for the expression of either C-GEM-IL 2.0 or 3.0 by inserting the sequences 
into the Rosa 26 locus. When crossed with cardiac Cre drivers such as αMHC-Cre, isolated adult 
primary cardiomyocytes responded to lactate perfusion, demonstrating that the indicator was 





Chapter 3.5 Conclusion 
Overall, the GEM indicators are a powerful tool set that allowed us to obtain more insight into the 
roles of lactate and pyruvate as active essential metabolites in live cells with single cell resolution. 
As this is the initial set of iterations on the indicator, future work should focus on refining the 
kinetics and subcellular expression of C-GEM-IL. We hope that this further use and development 
of GEM indicators similar to C-GEM-IL and C/Y-GEM-IP metabolic indicators will be used in 
other applications that probe lactate dynamics both in normal and disease states to better 







Human embryonic kidney (HEK) 293T cells (ATCC, #CRL-3216) and NIH 3T3 cells (ATCC, 
#CRL-1658) were cultured in Dulbecco’s Modified Eagle Media (DMEM, Thermo-Fisher/Gibco 
#10313021) supplemented with GlutaMax-I and penicillin/streptomycin (PS) and 10% fetal 
bovine serum (FBS, not heat-inactivated, HyClone, #SH30071.03, Thermo-Fisher) under 
normoxia (20% O2, 5% CO2, at 37°C) as described previously 236. 
Culture of human induced pluripotent stem cells and differentiation into neural progenitors 
Human iPSCs were generated and cultured using a standard feeder-free protocol with Essential 8 
medium and Geltrex (Thermo-Fisher/Gibco #A1517001) following our established protocols 119. 
Human control iPSC lines were differentiated using Neural Induction Media (NIM, Thermo-
Fisher/Gibco #A1647801) to generate neural progenitor cells (NPCs). The progenitors were 
cultured using NIM supplement, neurobasal and advanced DMEM media (Thermo-Fisher/Gibco) 
following the NIM manufacturer’s instruction. 
Lentiviral generation and infection of NPCs and NIH 3T3 cells 
Lentiviral production and infection were conducted as described previously1. Briefly, HEK 293T 
cells were transfected with lentiviral human c-Myc vectors together with pCMV-dR7.2 dvpr and 
pCMV-VSV-G (Addgene #8455 & 8454). Lentivira c-Myc plasmid was generated using standard 
PCR and LV-Cre-SD (Addgene, #12105, no longer available currently) with EcoRI and XhoI 
cloning sites. The lentivirus was then concentrated using a Lenti-X concentrator 





Plasmid DNA transfection  
Plasmid transfection of HEK 293T and NIH 3T3 cells was conducted as described previously 236. 
Briefly, HEK 293T and NIH 3T3 cells were plated at 0.5x105 cells/well in a 24-well plate format 
on poly-ornithine coated (Sigma-Aldrich/Millipore-Sigma, #P0421) glass cover slips (Warner 
instruments).  HEK 293T cells were transfected with 0.9µg of DNA in 2µL of Lipofectamine 2000 
(Invitrogen/Life Technologies #11668027) into 100µL of OptiMEM (Thermo-Fisher/Gibco 
#31985070) in 400µL: of DMEM 10% FBS (PS-free). NIH 3T3 cells were transfected with 0.5µg 
DNA, 1µL P3000 and 1.5µL Lipofectamine 3000 (Invitrogen/Thermo-Fisher #L3000008) into 
50µL OptiMEM in 400µL of DMEM 10% FBS (PS-free).  
Expression and purification of recombinant proteins from bacteria 
Recombinant forms of the protein were purified through batch nickel purification, taking 
advantage of the 6xHis tag (GE Healthcare #17-5318-01) in the pCold_2 vector as described 
previously237,238. Briefly, Rosetta (DE3)pLysS Competent cells (Novagen #70956) were 
transfected with the pCold_2 vector with the respective inserts and grown at 37°C overnight. These 
primary cultures were then used for larger scale production at a 1:100 inoculation. The larger 
cultures were grown for 4-6 hours at 37°C (or until the O.D. was between 0.4-0.8). The cultures 
were then placed in ice for 1 hour, followed by addition of 0.5mM IPTG. These cold-shocked 
cultures were then placed in a 16°C shaker for 24 hours at 250 rpm. Samples were then spun down 
and resuspended in lysis buffer (20mM Na3PO4, 500mM NaCl, 20mM Imidazole, 1mM EDTA, 
0.1% Triton X-100, 150mM sucrose) followed by sonication (Branson sonifier 450). The lysed 
samples were then then added to the beads, washed, and then eluted (elution buffer: 20mM Na-
3PO4, 500mM NaCl, 500mM Imidazole, 1mM EDTA, 150mM sucrose). The protein was then 




resuspended in cytoplasmic buffer (pH 7-7.4, 10mM NaCl, 130mM KCl, 1.25mM MgSO4, 10mM 
HEPES). 
Purification of recombinant proteins from HEK 293T cells 
HEK 293T cells were transfected with C-GEM-IL3.0 as described above. 48 hours after 
transfection, the cells were lysed with cell lysis buffer (CST, #9803). The protein was then isolated 
with nickel beads similarly to that from bacteria. 
Fluorescence measurements of recombinant proteins 
100 nM of purified recombinant protein was added to a flat black bottom 96-well plate (costar 
3916) in the respective solutions. The plates were then read in Spectramax ID3. 
Cellular perfusion experiments 
Cultured cells were plated at 0.5 x105 cells/well in a 24-well plate format on poly-ornithine coated 
(Sigma-Aldrich/Millipore-Sigma, #P0421) glass cover slips. Cells were transfected as described 
above. For dual imaging experiments, cells were transfected with C-GEM-IL 3.0 and R-GECO1 
or C-GEM-IL 3.0 and Y-GEM-IP simultaneously using the same transfection protocol. 24-48 
hours following transfection cover slips were washed three times with normal Tyrode’s solution 
three times (normal Tyrode’s solution: 1.8mM CaCl2, 1mM MgCl2, 140mM NaCl, 5.4mM KCl, 
10mM glucose, and 10mM HEPES (pH7.4 adjusted with NaOH at 25 oC), After wash, the 
coverslips were picked and placed in the imaging chamber (Warner Instruments/Harvard 
Apparatus, RC-20H, #64-0223). Cells were imaged and fluorescence was traced throughout the 
perfusions using an inverted Nikon Eclipse Ti microscope with a Nikon 20x objective and 
MetaFluor Software Version 7.8.1.0 (Molecular Devices). Baseline fluorescence in Tyrode’s 




dissolved in Tyrode’s solution with recording for 300 seconds, followed by a 2 mL perfusion of 
Tyrode’s solution as a wash. Changes in fluorescent data were quantified and analyzed relative to 
baseline in Excel.  
Multi-filter fluorescent imaging 
Cells were plated 1.5 x105 cells/dish in 35mm glass bottom poly-ornithine coated dishes. Cells 
were transfected as previously described. 24-48 hours post-transfection cells were washed three 
times with Tyrode’s solution and then imaged using MetaMorph Imaging Software. A Sutter 
Lambda DG-4 Illumination System was used with standard BFP, CFP, GFP, and YFP filters 
(Chroma).    
Mouse generation 
The synthesized C-GEM-IL 2.0 and 3.0 DNA fragments (Integrated DNA Technologies) was 
inserted into the Ai38 targeting construct (Addgene, #34883) utilizing the FseI restriction site 
(NEB, R0588S). The construct was then linearized using PvuI-HF digestion enzyme (NEB, 
R3150S). The linearized construct was electroporated into mouse embryonic stem cells (C-S. L 
generated) using a standard protocol. The germ-line transmitted C-GEM-IL 2.0 and 3.0 mice were 
crossed with the αMHC-MerCreMer line (JAX #5657) and the subsequent progeny were injected 
intraperitonially with 50mg/kg body weight of tamoxifen (Sigma-Aldrich, dissolved in sunflower 
oil, 1 dose/day, 3 days) to induce the cardiac specific expression of C-GEM-IL. αMHC-Cre 
(#11038) was also used for the mouse experiments. 




Cardiomyocytes were isolated from tamoxifen-injected C-GEM-IL 2.0 and 3.0 mice following an 
established protocol 239. These cells were then calcium adapted and imaged as described in the 
above perfusion section. 
Echocardiographic measurements 
Echocardiography was similarly conducted as previously reported 240. Briefly, C-GEM-IL mice 
were placed under light anesthesia (2% isoflurane) and imaged using VEVo770 (for C-GEM-IL 
2.0) or SONOS (for C-GEM-IL 3.0), equipped with a 40 MHz transducer. M-mode images and 
greyscale two-dimensional parasternal short-axis images at the mid-papillary level were recorded 
in each mouse.  
Homology modelling 
The LldR lactate binding domain was determined using known templates in the SWISS-MODEL 
(Biozentrum) that produced a high identity with the transcriptional factor CGL2914 from 
Corynebacterium glutamicum (2DI3a) 241. This was used to generate a homology model that was 
visualized using CueMol2. 
Lactate biochemical assay 
The lactate content of the cells and the media was measured using a lactate assay kit (Sigma-
Aldrich/Millipore-Sigma, #MAK064) following the manufacturer’s instructions. In brief, the cells 
were infected with the c-Myc virus for 24 hours. The cell media was then replaced by phenol red-
free DMEM (Thermo-Fisher/Gibco, #31053028) supplemented with GlutaMax-I, PS and 10% 
FBS. Twenty four hours later, the media and cells were harvested and filtered through a 10kDa 
filter (Amicon, UFC801024). The samples were then plated on a flat bottom 96-well plate (Falcon, 





Western blot experiments were conducted as described previously 119. In brief, cardiac samples 
harvested from C-GEM-IL 2.0 and 3.0 positive and wild-type mice were homogenized and lysed 
in 10x cell lysis buffer (Cell Signaling Technology, #9803) with 1% protease inhibitor cocktail 
(Sigma-Aldrich/Millipore-Sigma). SDS-polyacrylamide gel electrophoresis was performed using 
Tris-Glycine-based gels (Bio-Rad) containing 10% Acrylamide-Bis (Fisher Scientific) which was 
then transferred to polyvinylidene difluoride (PVDF) membranes. Primary bodies to GFP 
(MBL#598, 1/4,000 dilution) and β-tubulin (Sigma-Aldrich, #t5201, 1/4000 dilution). Secondary 
antibody α-mouse (Invitrogen, #31430, 1/8,000 dilution) and α-rabbit (Thermo Scientific, #31430, 
1/8,000 dilution). SuperBlock blocking buffer (PBS based, Thermo Scientific #37515) was used 
for blocking and antibody incubations of the PVDF membranes. Pierce ECL western blotting 
substrate (Thermo Scientific, #32209) was used for the chemiluminescent reaction.  
Genotyping polymerase chain reaction (PCR) 
Genomic DNA was extracted from the cardiac and tail samples from C-GEM-IL 2.0 and 3.0 
positive mice using standard phenol/chloroform-ethanol precipitation method. The target sequence 
was then amplified evidencing the cardiac-specific Cre-lox recombination utilizing Ex Taq DNA 
polymerase (TaKaRa/Clontech, RR001B). 
Mouse study approval 
All animal experiments were performed according to National Institutes of Health guidelines. The 
Institutional Animal Care and Use Committee at Columbia University approved all animal 
experiments (#AC-AAAU2453). 




5-6 week-old C-GEM-IL 3.0 positive mice were injected with PAC-Cre plasmid using TransIT ®-
EE Delivery Solution (Mirus Bio LLC) respectively according to the manufacturer’s protocol as 
described previously 228,236. The amount of injected DNA was 10μg per mouse. The volume of 
delivery solution was 0.1mL per mouse weight (g). After the hydrodynamic injection of DNA, the 
mice were allowed to recover for 48 hours. The mice were then sacrificed using standard procedure 
approved in our animal protocol and their livers were immediately harvested for fluorescent 
imaging with fluorescent stereoscope (Zeiss). 
Fluorescent HPLC 
We used the autosampler SIL-20ACHT to inject 100-µl protein samples into the Superose 6 10/30 
gel filtration chromatography column connected to the Shimadzu HPLC. The samples were 
monitored using the RF-20A spectrofluorometric detector at the excitation wavelength of 435 nm 
and the emission wavelength of 485 nm. 
Quantification and Statistical Analysis 
Two-tailed Student’s t-test was used when comparing two separate groups of observations. 
Welch’s correction was used when the variance between the two groups was statistically different. 
Two-tailed paired Student’s t-test was used when comparing data sets conducted on samples before 
and after treatment. One-way ANOVA with Bonferroni or Sidak’s comparison corrections was 
used for comparison between multiple sets of observations. One-way ANOVA with Dunnet’s 
correction was used for multiple comparisons against a specified data set. All error bars 
represented standard deviation. P values <0.05 were considered significant. Unless otherwise 



































Chapter 4.1 Introduction to the Sigma non-opioid receptor 1 as a drug target for long QT 
syndrome project 
Introduction 
Long QT syndrome (LQTS) is characterized by QT interval prolongation (>470ms in women and 
>450ms in men) and T-wave abnormalities as measured by electrocardiogram242,243. Untreated, 
LQTS is a life-threatening cardiac arrythmia syndrome and is a leading cause of sudden death in 
the young243. As the QT interval is a choreography of ion channel openings and closings involved 
in the cardiac action potential, genetic mutations leading to aberrant sodium, calcium and 
potassium channel function lead to LQTS243,244. LQTS2 is the second most common cause of 
LQTS and is due to mutations in the potassium channel α-subunit KCNH2 leading to a decreased 
delayed rectifier current IKr245,246. Timothy syndrome (LQTS8) is characterized by a dysfunction 
of the calcium channel Cav 1.2 due to a G406R mutation. This leads to a delayed inactivation. 
Patients with timothy syndrome often present with syndactyl, hypoglycemia, and cognitive 
abnormalities and an average life span of 2.5 years247. Direct LQTS treatment includes the use of 
beta-blockers, implantable cardioverter defibrillator (ICD), and life-style modifications243. 
Specifically for timothy syndrome, verapamil (an L-type calcium channel blocker) and Ranolazine 
(a multipotent ion channel inhibitor) have been explored as therapies to treat the disease248,249. 
However, as shown by the low average lifespan of timothy syndrome patients, the current 





Project Aims/Why the project matters 
Herein we explore the use cardiomyocytes differentiated from patient derived human induced 
pluripotent stem cells (hiPSC) to test therapies for the disease. Both LQTS2 and timothy syndrome 
have previously been modelled using this system251,252. Using this platform, this project focused 
on the testing and development of a Sigma 1 receptor agonist therapy to treat long QT syndromes. 
This stems from work by Dr. Song, in which our lab found that the delayed inactivation of the 
mutant calcium channel can be treated using CDK5 inhibitors like roscovitine1. However, CDK5 
inhibitors are generally toxic potentially due to the off target effects affecting other CDKs253. In 
fact, PHA-793887 which targets CDK1/2/4 was found to be hepatotoxic in clinical trials of the 
drug254. Further research suggested that CDK5 activity can be inhibited through the use of Sigma 
1 receptor agonists as its activity leads to the increased degradation of the CDK5 activator p35 
and, therefore, lesser CDK5 activity255. Following this, we tested the efficacy of Sigma 1 receptor 
agonists fluvoxamine and dextromethorphan256-260.  Results from the in vitro experiments using 
cardiomyocytes differentiated from hiPSC and mouse in vivo models of timothy syndrome found 
them to be effective treatments. This project is important as there are no reliable treatment 
modalities for timothy syndrome and drugs that show promise as a therapy may one day have a 






The conception, planning and writing of the manuscript and project was done my Drs. Yazawa 
and Song. The electrophysiology work was completed by Dr. Yazawa. The ECG experiments were 
conducted by Dr. Morikawa. The iPSC differentiation and maintenance were completed by Dr. 
Morikawa and Alison Klein.  
My participation in this project was focused on the development and use of the time lapse assay to 
enable us to test the effect of the compounds of interest on the calcium transience of the cells. To 
do this, the calcium transience of GCaMP6f infected iPSC derived cardiomyocytes are measured 
through the observation of their fluorescence. This technique was used to analyze the effect of 
Dextromethorphan as well as other chemicals on the calcium handling of the cells (patient and 
control) totaling >3000 data sets (~20 cell clusters per experiment measured every 30 minutes for 
2 hours with at least two independent experimental preparations). I then worked with and mentored 
several other researchers in the use of the protocol including a current graduate student Danielle 
Baum, a previous undergraduate student Hannah Yamamoto, and a high school student Amy 
Chalan. As a team, we were able to analyze this data and assess the effect of the drug on the cell 
clusters. My involvement in the project has continued to date as we address the reviewer comments 
we received. This includes the design and creation of various plasmids containing tagged ion 
channels as well as planning and preparing the ICC and proximity ligation assays necessary to 
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Chapter 4.2 Abstract 
Calcium is essential for heart function. Missense mutations in the calcium channel lead to lethal 
long QT syndrome in patients with Timothy syndrome, resulting in a life span of ~3 years247. While 
previous studies explored several therapeutics targets1,248,249,252,261-267, no clinically-effective 
therapeutics are currently available for Timothy syndrome. Here we report that an FDA-approved 
cough suppressant, dextromethorphan257, can be used as an agonist of sigma non-opioid 
intracellular receptor 1, which restored electrophysiological function in Timothy syndrome as well 
as a common form of long QT syndrome, type 2, which is caused by missense mutations in 
KCNH2/hERG channel. Calcium imaging and electrophysiological recordings demonstrate that 
dextromethorphan shortened the prolonged action potential, by reducing calcium currents and 
increasing potassium currents in Timothy syndrome cardiomyocytes. Also, by increasing 
potassium current, dextromethorphan restored action potentials in human cellular model of long 
QT syndrome type 2. To validate the effect of dextromethorphan further, we generated a new 
cardiac mouse model of Timothy syndrome showing QT prolongation. Electrocardiography 
demonstrated that dextromethorphan shortened the prolonged QT intervals in Timothy syndrome 
mice, indicating a beneficial effect. Moreover, dextromethorphan also showed the therapeutic 
effect on global pathophysiological changes in Timothy syndrome hearts, as revealed by global 
proteomics analysis. Our study suggests that dextromethorphan repurposing could be potentially 





Chapter 4.3 Results 
Ca2+ plays an essential role in cardiac excitation-contraction (EC) coupling268,269. Ca2+ handling 
dysfunction is associated with various cardiac arrhythmias such as LQTS247,270. De novo gain-of-
function mutations such as G406R in cardiac L-type voltage-gated calcium channel CaV1.2 cause 
lethal LQTS (type 8, also named Timothy syndrome)247,252. Previously, taking advantage of human 
patient-specific induced pluripotent stem cells (iPSCs), we found that increased activity of cyclin-
dependent kinase 5 (CDK5) is involved in cardiac pathophysiological basis underlying Timothy 
syndrome (Figure 69a, red) and also that CDK5 inhibition using genetic approaches and chemical 
inhibitors alleviates the cellular phenotypes in Timothy syndrome iPSC-derived cardiomyocytes2. 
For example, a potent CDK5 inhibitor, PHA-793887 (IC50, 5nM), could rescue the cellular 
phenotypes in Timothy syndrome iPSC-derived cardiomyocytes1. However, cyclic dependent 
kinases are known to play a critical role in cell-cycle regulation and the specific inhibition of CDK5 
by chemical compounds is difficult to achieve due to the structural similarity of the catalytic site 
between different CDKs253. The potent CDK5 inhibitor PHA-793887 also showed inhibitory 
effects on CDK1/2/4 and caused hepatotoxicity in a clinical trial254. The tools for a specific 
inhibition of CDK5 are still under development and are not ready for clinical application to fulfill 
the unmet medical needs of Timothy syndrome patients. We aim at the translational application of 
our findings ultimately and therefore we decided to search for new targets and FDA-approved 
drugs that may modulate CDK5 activity in human cardiomyocytes. From the literature search, 
sigma non-opioid intracellular receptor 1 (SIGMAR1) caught our interest. SIGMAR1 is recently 
an emerging target for neurodegenerative diseases and cancer271-273 and it plays an important role 
as a chaperon protein in endoplasmic reticulum membranes for regulating protein homeostasis, 




activation of SIGMAR1 has been reported to suppress CDK5 activity in rodent neurons255. The 
structure of SIGMAR1 has been characterized275, which greatly facilitated the understanding of 
the interactions between SIGMAR1 and its ligands. Several SIGMAR1 agonists have been 
identified, including a potent and specific agonist PRE-084276, and two FDA-approved drugs 
Fluvoxamine256 and dextromethorphan (Dxm)257-260 (Figure 69a, 69b, 70a). However, to our 
knowledge, little is known regarding the role of SIGMAR1 in cardiac ion channel regulation and 
pathophysiological conditions in cardiac arrhythmias. In this study, we examined the role of 
SIGMAR1 in the pathogenesis of LQT syndrome as a new therapeutic target and tested the 
hypothesis that SIGMAR1 agonists, such as PRE-084, Fluvoxamine and Dxm, could restore 
cardiac EC coupling in Timothy syndrome (Figure 69a, blue).   
To examine whether SIGMAR1 activation modulates CDK5 activity in human 
cardiomyocytes as it did in neurons255, we conducted in vitro luminescence-based CDK5 activity 
assay1 using Timothy syndrome iPSC-derived cardiomyocytes treated with the SIGMAR1 agonist 
PRE-084. The result indicated that PRE-084 treatment significantly reduced CDK5 activity in 
Timothy syndrome iPSC-derived cardiomyocytes (Figure 70b). While it was reported that the 
protein expression of a CDK5-specific activator, CDK5R1/p35, was reduced by SIGMAR1 in 
neurons255, interestingly we found no significantly difference in p35 protein expression between 
Timothy syndrome cardiomyocytes with and without PRE-084 treatment (Figure 70c and 70d). 
On the other hand, the protein expression of CDK5 was significantly reduced in Timothy syndrome 
cardiomyocytes treated with PRE-084 while no significant changes of CDK5 transcripts were 
detected (Figure 70c-e). These results revealed that the activation of SIGMAR1 using an agonist 
could modulate CDK5 activity in Timothy syndrome cardiomyocytes although there could be 




regulation of CDK5 and CDK5R1/p35 proteins between neurons and cardiomyocytes. The 
positive effect of SIGMAR1 activation on CDK5 activity prompted us to examine the effects of 
SIGMAR1 agonists on the cardiac phenotypes in Timothy syndrome cardiomyocytes.  
We examined the effects of not only PRE-084 but also Fluvoxamine and Dxm, which are FDA-
approved drugs and SIGMAR1 agonists, on the phenotypes in Timothy syndrome cardiomyocytes 
because Fluvoxamine and Dxm have a greater clinical applicability for Timothy syndrome if the 
drugs prove to be effective on the human cellular model. Electrophysiological recordings reveal 
that all three SIGMAR1 agonists (PRE-084, fluvoxamine and Dxm) rescued the prolonged action 
potentials of Timothy syndrome cardiomyocytes (Figure 69c, 69d, 70f, and 70g). In addition, at 
the dose that they rescued the phenotype in Timothy syndrome cardiomyocytes, Fluvoxamine and 
Dxm did not significantly changed the action potential duration of normal cardiomyocytes 
generated from isogenic control iPSC lines in which Timothy syndrome mutation was previously 
corrected by gene editing technology (Figure 69e, 69f, 70h, and 70i)1. The observed beneficial 
effects of Fluvoxamine and Dxm on Timothy syndrome were encouraging and Dxm seems to have 
a higher potential for repurposing and direct clinical applications due to its wider age range for 
clinical usage and lower potential risks of side effects256,260,277-279. Thus, we decided to focus on 





Figure 69 The effect of SIGMAR1 agonists on the phenotypes in cardiac action potentials in 
Timothy syndrome iPSC-derived cardiomyocytes.  
(a) Schematic representation of altered molecules (red) and therapeutic strategy (blue) in Timothy 
syndrome (TS) cardiomyocytes using SIGMAR1 agonists1. (b) Docking model of SIGMAR1 and 
its ligand, PRE-084. (c) Representative traces of paced action potentials in TS cardiomyocytes 2-
hr treated with 5μM SIGMAR1 agonists, PRE-084 (+PRE), fluvoxamine (+Fluvo) and 
dextromethorphan (+Dxm) or without treatment. (d) Action potential duration (APD90, 90% 
reduction from peak) was significantly shortened by PRE, Fluvo and Dxm in TS cardiomyocytes. 
(e) Representative traces of paced action potentials in isogenic control (Ctrl) iPSC-derived 
cardiomyocytes treated with Dxm and Fluvo (each, 5μM, 2hr) or without treatment. (f) APD90 
was not changed by either Fluvo or Dxm in the control cells. One-way ANOVA with multiple 








Figure 70 The effect of SIGMAR1 agonists on the phenotypes in cardiac action potentials in 
Timothy syndrome iPSC-derived cardiomyocytes.  
(a) Docking models of SIGMAR1-Fluvo, -Dxm and -PRE using BSP-SLIM. (b) PRE (5μM, 2hr, 
n=6) and PHA-793887 (PHA, 5μM, 2hr), a potent CDK5 chemical inhibitor, significantly reduced 
CDK5 kinase activity in human TS myocytes. *P<0.05 using One-way ANOVA with multiple 
comparisons. The effects of PRE (5μM, 2hr) on CDK5R1/p35 and CDK5 proteins (c,d) and 
mRNA (e) were analyzed using Student’s t-test (P*<0.05; n.s., not significant). (f) Action potential 
properties (f, resting potentials and g, peak amplitude) in TS cardiomyocytes 2-hr treated with 
5μM SIGMAR1 agonists, PRE-084 (+PRE), fluvoxamine (+Fluvo) and dextromethorphan 
(+Dxm) or without treatment. Action potential properties (h, resting potentials and i, peak 
amplitutde) in isogenic control (Ctrl) cardiomyocytes 2-hr treated with 5μM SIGMAR1 agonists, 
Fluvo and Dxm or without treatment. 
 
To further examine the effect of Dxm on cardiac EC coupling, we conducted Ca2+ imaging using 
a genetically encoded fluorescent indicator for calcium ions, GCaMP6f153, in Timothy syndrome 
iPSC-derived cardiomyocytes. Compared to whole-cell patch clamp recordings, the GCaMP6f-
based Ca2+ imaging has the distinct advantage that the target cells are intact and in physiological 
state, and we could continuously monitor the changes in Ca2+ handling after compound treatment 
at any time points for a long duration to characterize the treatment effects. Using GCaMP6f-based 
Ca2+imaging, we found that approximately 2 hours was required for Dxm to exhibit homogeneous 
and significant beneficial effects on the abnormal Ca2+ handling such as low transient frequency 
and prolonged duration in Timothy syndrome iPSC-derived cardiomyocytes (Figure 71a-c), and 2 
hours is also the time point that we observed a significant beneficial effect of Dxm treatment on 
the action potential phenotype in patient myocytes (Figure 69c and 69d). Next, to further 
characterize the effect of Dxm on the L-type calcium channel function in Timothy syndrome 
cardiomyocytes, we utilized whole-cell voltage clamp mode to evaluate voltage- and calcium-
dependent channel inactivation using Ba2+ current and Ca2+ current recordings, respectively. We 
found that Dxm significantly enhanced voltage-dependent channel inactivation (Figure 71d and 




In addition, to investigate whether the positive effect of Dxm on calcium channel function comes 
from SIGMAR1 activation, we tested PRE-084 and fluvoxamine as additional SIGMAR1 agonists 
on the same voltage clamp recording using Ba2+ solution. We found that similar to Dxm, PRE-084 
and fluvoxamine also significantly enhanced voltage-dependent channel inactivation in Timothy 
syndrome cardiomyocytes (Figure 72a and 72b) at 2 hours after treatment while the phenotype in 
voltage-dependent channel inactivation in Timothy syndrome cardiomyocytes was not 
significantly improved by acute treatment of PRE-084 (Figure 72c and 72d). 
 
SIGMAR1 has also been reported to regulate potassium channel function in non-excitable cells274. 
The previous report demonstrated that SIGMAR1 activation induced by agonists increased 
Kcnh2/hERG localization in the plasma membranes and elevated hERG current (IKr) in oocytes 
and a leukemia cell line280. However, the effect of SIGMAR1 activation on potassium handling in 
cardiomyocytes remains to be characterized. To investigate the effect of SIGMAR1 activation on 
cardiac potassium channel function, we first performed voltage-clamp recordings to measure 
hERG currents in Timothy syndrome cardiomyocytes to examine the changes in potassium 
channel function in Timothy syndrome. We found that there was slightly lower IKr current 
amplitude in Timothy syndrome cardiomyocytes compared with isogenic control myocytes 
(Figure 71h, 71i, and 72e-h). However, interestingly, Dxm significantly increased IKr current 
amplitude in Timothy syndrome cardiomyocytes as well as induced a trend towards increased IKr 
current amplitude in isogenic control cardiomyocytes (Figure 71h, 71i, 72e-h). These results 
indicated that Dxm-mediated SIGMAR1 activation might rescue the prolonged action potential in 
Timothy syndrome cardiomyocytes by enhancing potassium efflux in addition to reducing calcium 









Figure 71 Testing dextromethorphan on cardiac calcium handling and ion channels in 
human iPSC model of Timothy syndrome.  
(a) Representative traces of time-course calcium imaging in TS cardiomyocytes treated with Dxm 
(5μM, until 2hr). (b) Cardiac transient frequency was significantly increased by Dxm in TS 
cardiomyocytes. (c) Cardiac transient duration was significantly shortened by Dxm in TS 
cardiomyocytes. One-way ANOVA with multiple comparisons vs. the ‘before’ group (*P<0.05; 
**P<0.01) was used for (b)(c). (d) Representative traces of Ba2+ current in TS cardiomyocytes 
treated with Dxm (5μM, 2hr) or without treatment. The detail comparisons with other agonists are 
shown in figures 72a and 72b. (e) Voltage-dependent calcium channel inactivation was 
significantly increased by Dxm in TS cardiomyocytes. (f) Representative traces of Ca2+ current in 
TS cardiomyocytes treated with Dxm (5μM, 2hr) or without treatment. (g) Calcium channel 
inactivation was significantly increased by Dxm in TS cardiomyocytes. Student t-test was used 
(**P<0.01). (h) Representative traces of IKr current in TS cardiomyocytes treated with Dxm (5μM, 
2hr, n=7) or without treatment (n=5). E-4031-sensitive currents were measured and analyzed as 
IKr current. (i) IKr current amplitude was significantly increased by Dxm in TS cardiomyocytes. 









The fact that Dxm increases IKr currents in Timothy syndrome cardiomyocytes motivated us to 
test Dxm on LQTS type 2 (LQTS2) cardiomyocytes, which carry missense loss-of-function 
mutations in KCNH2/hERG gene, characterized by potassium channel dysfunctions and is the 
second most common LQTS281-283. We used the iPSC lines carrying the classical LQT2 mutation 
(A561V) for electrophysiological recordings and the results revealed that consistent with previous 
reports284, LQTS2 iPSC-derived cardiomyocytes with A561V mutation showed prolonged action 
potentials and reduced IKr currents compared to normal cardiomyocytes. Consistent with the 
positive effect of Dxm on the IKr currents in Timothy syndrome cardiomyocytes, Dxm also 
significantly shortened the action potential and facilitated IKr currents in LQTS2 cardiomyocytes 
(Figure 73 and 74). These results demonstrated that Dxm may also be beneficial for treating 
LQTS2, a more common form of LQTS compared with Timothy syndrome, through its effect on 
potassium channel.  
Figure 72 Testing dextromethorphan on cardiac calcium channels in human cardiomyocytes 
derived from Timothy syndrome and isogenic control iPSCs.  
(a) Representative traces of Ba2+ current in TS cardiomyocytes treated with PRE-084 (+PRE), 
fluvoxamine (+Fluvo)(each, 5μM, 2hr) or without treatment (TS) and isogenic control 
cardiomyocytes (Ctrl). (b) Voltage-dependent calcium channel inactivation was significantly 
increased by PRE, Fluvo and Dxm in TS cardiomyocytes. One-way ANOVA with multiple 
comparisons were used (**P<0.01). n.d., no significant difference among +PRE, +Fluvo, +Dxm 
and isogenic Ctrl groups. +Dxm representative trace was shown in Figure 71d. (c) Representative 
traces of Ba2+ current in TS cardiomyocytes acutely treated with PRE (5μM, ~5-10min) or without 
treatment. (d) Voltage-dependent calcium channel inactivation was not significantly changed by 
PRE in 10min in TS cardiomyocytes. Student t-test (paired) was used (n.d., no significant 
difference, n=4). (e) IKr current (tail) was not significantly changed by Dxm in TS cardiomyocytes. 
Student t-test was used at each voltage. (f) Representative traces of IKr current in isogenic Ctrl 
cardiomyocytes treated with Dxm (5μM, 2hr, n=5) or without treatment (n=6). E-4031-sensitive 
currents were measured and analyzed as IKr current. (g) IKr current amplitude were slightly 
increased by Dxm in TS cardiomyocytes while not significant. (h) Tail IKr current were not 







Figure 73 The effect of dextromethorphan on the phenotypes in long QT syndrome type 2.  
(a) Representative traces of action potentials in long QT syndrome type 2 (LQTS2) iPSC-derived 
cardiomyocytes treated with Dxm (5μM, 2hr). (b) Action potential duration (APD90) was 
significantly shortened by Dxm in LQTS2 cardiomyocytes. (c) Representative traces of IKr current 
in LQTS2 cardiomyocytes treated with Dxm (5μM, 2hr, n=7) or without treatment (n=6). E-4031-
sensitive currents were measured and analyzed as IKr current. (d) IKr current was significantly 






Figure 74 The effect of dextromethorphan on the phenotypes in long QT syndrome type 2.  
Action potential properties: resting (a), peak amplitude (b) and APD50 (c) in LQTS2 
cardiomyocytes 2-hr treated with 5μM Dxm or without treatment. Student t-test was used (n.s., not 
significant). (d) IKr current (tail) was not significantly changed by Dxm in LQTS2 cardiomyocytes 
while the amplitude was increased by Dxm (Figure 71d). Student t-test was used at each voltage. 
 
Based on the intriguing in vitro results, we decided to move to in vivo study to examine the effect 
of Dxm on Timothy syndrome further. We generated a cardiac-specific mouse model of Timothy 
syndrome, taking advantage of an inducible expression system using the Rosa26 locus, a cardiac 
Cre driver (alpha-MHC/Myf6-MerCreMer), and a loxP pair with stop cassette in order to 
conditionally overexpress Timothy syndrome mutant channels in heart (Figure 75a)264. The 
inducible expression system allows us to express the mutant channels at adult stage so as to avoid 
the heart developmental phenotypes that may lead to early lethality. A common challenge in the 
field of LQTS concerning animal models is that most mouse models of LQTS fail to recapitulate 
arrhythmic phenotypes in vivo285 due to the fact that mice have different ion channels and a 
remarkably higher heart rate compared with humans. Fortunately, our mouse model did 




tamoxifen administration, as revealed in electrocardiography (ECG) (Figure 75b and 75c). Next, 
we examined the effect of Dxm on the LQTS phenotype in this model by ECG. Dxm was added 
to the drinking water for dosing and a low dose of quinidine was added with Dxm to improve the 
pharmacokinetic profile of Dxm in vivo since quinidine is known to competitively inhibit the 
metabolism of Dxm to dextrorphan and the formulation of low dose quinidine and Dxm has been 
used in clinic to maintain a stable increase in the plasma concentration of Dxm in humans257,260. 
To examine the pharmacokinetic profile of Dxm with the dosing strategy, blood was sampled from 
the animals at different time point on day 4 and 11 to measure Dxm concentration in plasma. The 
result indicated that the dosing strategy for Dxm used in the study achieved a stable increase in 
plasma Dxm level through the day (Figure 76a) and the plasma level of Dxm in the dosed animals 
was comparable to the Dxm level in human subjects who take 30 mg/day of Dxm for 7 days (~10-
60ng/ml)257. We examined the effect of Dxm on the LQTS phenotype in Timothy syndrome mice 
using ECG at day 4 and day 11. Dxm/quinidine significantly shortened the prolonged QT interval 
in Timothy syndrome mice at both time points (Figure 75c, 75d, 76b, and 76c). Moreover, 
Dxm/quinidine did not affect the QT intervals in the control littermate mice (Figure 75c and 75d), 
which is consistent with the clinical reports indicating that Dxm/quinidine did not significantly 
alter the QT intervals in human subjects when used to treat pseudobulbar affect257,260. The overall 
result demonstrated that Dxm not only rescued the phenotypes in Timothy syndrome iPSC-derived 
cardiomyocytes in vitro, but also alleviated the LQTS phenotype in Timothy syndrome mice in 
vivo.  
 
Lastly, to elucidate the pathophysiological mechanism underlying Timothy syndrome mouse 




performed global proteomics to profile protein expression changes in the hearts of controls, non-
treated and Dxm-treated Timothy syndrome mice at day 11. The proteomics results demonstrated 
that the expressions of many important molecules involved in cardiac EC coupling, heart failure, 
fibrosis and cardiomyopathy286-289such as mitochondrial proteins, Tmem38a/TRIC channel, 
Nppa/ANP, Pstn/Periostin and Xirp2/Cmya3 (Cardiomyopathy-associated gene 3) were altered in 
Timothy syndrome mouse hearts. Dxm treatment restored the expression of these molecule to a 
similar level as controls, which could be indicative of its efficacy (Figure 75e and 76), although 
the rescuing effects of Dxm were not observed in all the molecules involved in the pathways related 
to cardiac dysfunction and arrhythmias. In addition, interestingly, Dxm treatment induced a 
significant increase in the expression of two LQTS-related molecules, Ank2 and Kcnq1, in 
Timothy syndrome hearts. Loss-of-function mutations of the Ank2 and Kcnq1 are known to cause 
QT prolongation290,291 and the increase in Ank2 and Kcnq1 expression could contribute to the 
beneficial effect of Dxm on prolonged QT interval in Timothy syndrome mouse model. Overall, 
the proteomics analysis revealed significant global pathological changes in Timothy syndrome 
mouse hearts compared with control mouse hearts, and Dxm treatment induced a positive but not 
complete shift in the proteomic profile of Timothy syndrome mouse hearts towards the proteomic 






Figure 75 Testing dextromethorphan in Timothy syndrome mouse model.  
(a) Targeting design of Timothy syndrome mutant (G406R in the calcium channel Cacna1c gene) 
in mouse Rosa26 locus. (b) Experimental design for inducing the expression of Timothy syndrome 
mutant with Dxm treatment. Dxm concentration in the plasma was measured (see Figure 75a). (c) 
Representative traces of electrocardiography (ECG) in Timothy syndrome mice (TS) and the 
control littermate (Ctrl) treated with Dxm (+Dxm) or without treatment at day 4. (d) Prolonged 
QT intervals in Timothy syndrome mice were significantly shortened by Dxm. QT intervals were 
corrected using mouse formula (QTc). One-way ANOVA with multiple comparisons were used 
(**P<0.01; n.d., no significant difference). (e) Proteomics analysis at day 11 in control littermates, 
non-treated and Dxm-treated Timothy syndrome hearts. ECG at day 11 also confirmed the 
beneficial effect of Dxm on QT prolongation in the mutant mice (Figure 75c). Additional analysis 















Figure 76 Testing dextromethorphan in Timothy syndrome mouse model.  
(a) A summary of Dxm measurement in the plasma in normal mice (n=5). Dxm was provided into 
water since day 1 at 8am. OL, outlier statistically; <LOQ (below limit of quantitation), outlier. (b) 
Detail analysis procedures in ECG traces in Timothy syndrome mice treated with Dxm or without 
treatment at day 4 (used in Figure 75c). (c) QT intervals were significantly shortened by 
dextromethorphan in Timothy syndrome mouse line at day 11. (d) Altered protein expressions in 
control littermates (Ctrl), non-treated (TS) and Dxm-treated Timothy syndrome hearts (TS+Dxm). 
ECG at day 11 (used for Figure 75e). One-way ANOVA with multiple comparisons were used 




Chapter 4.4 Conclusion 
In summary, our study demonstrates that SIGMAR1 agonists such as Dxm, PRE-084 and 
fluvoxamine rescued the phenotypes in Timothy syndrome iPSC-derived cardiomyocytes and 
Dxm treatment also alleviated the QT prolongation in Timothy syndrome mice. Among the 
agonists, Dxm is of particular interest to us since it has been approved to be used in children as a 
cough suppressant259 and Timothy syndrome patients are mostly children. Although Timothy 
syndrome is a multiple-organ disorder that involves not only cardiac arrhythmias but also 
syndactyly, autism and hypoglycemia264,268,292, and the effects of Dxm on the dysfunction of other 
affected organs remain to be investigated, our findings revealed the potential of Dxm as a 
therapeutic agent and SIGMAR1 as a new therapeutic target for Timothy syndrome and potentially 
LQTS2 for the first time. Further investigations are necessary to profile the global effects of 
SIGMAR1 activation and Dxm on different organs and tissues, and on disease associated 






Human iPSC culture 
Human iPSCs were cultured with Essential 8 medium (Thermo Fisher Scientific) with 100 unit/ml 
penicillin and 100 μg/ml streptomycin on plates or dishes (Corning) coated with Geltrex (Thermo 
Fisher Scientific) following the manufacturer’s instruction. Dispase (Thermo Fisher Scientific) 
dissolved in the culture medium was used for cell dissociation/passaging. The iPSCs were 
differentiated into cardiomyocytes following a monolayer-based protocol that we reported 
previously1. 
Patch-Clamp Recording  
Human iPSC-derived cardiomyocytes were dissociated into single cells for whole-cell patch clamp 
recordings at 1-2 months after cardiac differentiation was induced, and the dissociated cells were 
used for patch clamp recording 4-8 days after the dissociation, following a protocol reported 
previously 1. Whole-cell patch-clamp recordings of iPSC-derived cardiomyocytes were conducted 
using a MultiClap 700B patch-clamp amplifier (Molecular Devices) and an inverted microscope 
equipped with differential interface optics (Nikon, Ti-U). The glass pipettes were prepared using 
borosilicate glass (Sutter Instrument, BF150-110-10) using a micropipette puller (Sutter 
Instrument, Model P-97). Voltage-clamp measurements for voltage-dependent calcium channel 
inactivation were conducted using an extracellular solution consisting of 5mM BaCl2, 160mM 
TEA and 10mM HEPES (pH7.4 at 25 oC) and a pipette solution of 125mM CsCl, 0.1mM CaCl2, 
10mM EGTA, 1mM MgCl2, 4mM MgATP and 10mM HEPES (pH 7.4 with CsOH at 25 oC). For 
calcium current recordings, instead another extracellular solution was used: 5mM CaCl2, 137mM 
NMDG, 0.5 mM MgCl2, 25mM CsCl, 10mM TEA-Cl, 10mM glucose and 10mM HEPES (pH 7.4 




to +20 for the current-voltage relationship of the Ba2+ currents. The recordings were conducted 
under room temperature. Voltage-clamp recording for IKr measurements was conducted in normal 
Tyrode’s solution containing 140 mM NaCl, 5.4 mM KCl, 1 mM MgCl2, 10 mM glucose, 1.8 mM 
CaCl2 and 10 mM HEPES (pH 7.4 with NaOH at 25 °C) supplemented with 10 μM nisoldipine 
(ICa current blocker) and 10 μM Chromanol-293B (IKs current blocker) using the pipette solution 
120 mM K d-gluconate, 25 mM KCl, 4 mM MgATP, 2 mM NaGTP, 4 mM Na2-phospho-creatine, 
10 mM EGTA, 1 mM CaCl2 and 10 mM HEPES (pH 7.4 with KCl at 25 °C). The following pulse 
protocol was used: 5-s voltage clamp applied from 10 mV to 50mV (Δ20mV, holding at −40 mV, 
0.1 Hz, at 25 °C). All of the components used for above recording solutions were purchased from 
Sigma-Aldrich except Chromanol-293B (TOCRIS). After recordings, the extracellular solution 
was switched to one containing 1 μM E-4031 (TOCRIS) using perfusion. E-4031-sensitive current 
was measured and analyzed as IKr current using Clampfit 10.4 (Axon Instruments). 
Current-clamp recordings were conducted in normal Tyrode solution containing 140mM NaCl, 
5.4mM KCl, 1mM MgCl2, 10mM glucose, 1.8mM CaCl2 and 10mM HEPES (pH7.4 with NaOH 
at 25oC) using the pipette solution: 120mM K D-gluconate, 25mM KCl, 4mM MgATP, 2mM 
NaGTP, 4mM Na2-phospho-creatin, 10mM EGTA, 1mM CaCl2 and 10mM HEPES (pH 7.4 with 
KCl at 25oC). The recordings were conducted at 37 oC. Cardiac action potentials were stimulated 
(2ms, 1nA, 0.5 Hz) in current clamp mode at 37 oC. Recorded action potentials were analyzed 
using Clampfit 10.4. Control recordings were obtained from cardiomyocytes without treatment. 
The after treatment recordings were obtained from cardiomyocytes that had been treated with 
either dextromethorphan (Sigma-Aldrich, # D2531), fluvoxamine (Sigma-Aldrich, # F2802) or 
PRE-084 (TOCRIS, # 5891) at the dose of 5μM for two hours in the cardiomyocyte culture media 




Calcium imaging  
For the calcium transient recordings to examine the effects of dextromethorphan on the abnormal 
spontaneous calcium transients in Timothy syndrome cardiomyocytes, the cardiomyocytes were 
prepared with the same experimental schedule as described in electrophysiology method section. 
The Nikon automatic microscope (Nikon Eclipse TiE with a motorized stage) connected to 
sCMOS camera (Andor Zyla sCMOS 4.2 MP) together with a stage top incubator (at 37oC, 5% 
CO2 and 20% O2, controlled by TOKAI HIT Hypoxia gas delivery system) were used for this 
experiment. Nikon objective lens 40x (Nikon CFI Plan Apo Lambda, NA 0.95) was used for single 
cell recordings and the cardiomyocyte culture media was used as bath solution. The cells were 
infected with AAV9-GCaMP6f (UPenn Vector Core) within a week of when the calcium imaging 
was performed. A basal recording was acquired from each cell before the treatment of 
dextromethorphan and after the basal recording, the solution was changed to cardiomyocyte 
culture media with 5 μM dextromethorphan. The recordings were then measured every thirty 
minutes for two hours after the treatment of dextromethorphan from the same cell. During 
measurement, the cells were electrically stimulated (Warner instruments, SIU-102) with a 
perfusion insert with electrical field stimulation fitted for a 35mm dish (Warner instruments, RC-
37FS) to pace the cells (bipolar pulse, 4 volts, 2ms, 0.2Hz).The calcium transient frequency, 
duration and the calcium transient half (50%) decay time from the recordings before and after 
treatment were analyzed. One-way ANOVA with Dunnett’s multiple comparisons vs. the ‘before’ 
group was used for statistical analysis.   
in vitro CDK5 activity assay 
To examine the endogenous CDK5 activity, an CDK5 activity assay was conducted following the 




syndrome iPSCs were collected at day 26 or day 27 for the assay. For the compound-treated 
groups, the cardiomyocytes were treated with either Fluvoxamine or PRE-084 at the dose of 5μM 
or 10μM for two hours before being collected for the assay. Cardiomyocytes were isolated from 
monolayer culture and lysed with the cell lysis buffer containing 1% NP-40, 20mM Tris-HCl, 
137mM NaCl, 1x protease inhibitor cocktail, 1x phosphatase inhibitor cocktail 3 (Sigma-Aldrich, 
# P0044) and 1x phosphatase inhibitor cocktail (Sigma-Aldrich, # P8340), pH 7.4. The protein 
concentration in the samples was measured using a standard bicinchoninic acid (BCA) assay kit 
(Piers/Thermo Fisher Scientific). 40 μg of proteins from each sample were aliquoted and used as 
one sample for CDK5 immunoprecipitation. The sample was incubated with CDK5 antibody-
conjugated agarose beads (CDK5 (J-3) AC, Santa Cruz Biotechnology, #:sc-6247 AC,) for 2 hours 
at 4oC (rocking continuously) for CDK5 immunoprecipitation. 5μl resuspended bead solution was 
used for the immunoprecipitation of CDK5 from each sample. After immunoprecipitation, the 
beads were washed three times with cold Tris-buffered saline (TBS) and twice with room 
temperature TBS. A reaction mix containing 1X Reaction Buffer A, 50 μM DTT, 50 μM ATP, 1 
μg Histone H1 in distilled water was added to each sample for detecting CDK5 activity. The stock 
of PHA-793887 (Selleckchem) was diluted with DMSO (Sigma-Aldrich) and added to the 
corresponding samples in the PHA-793887 treated Timothy syndrome groups at the concentration 
of 5 μM. The same volume of DMSO was added to the rest of the samples to achieve the same 
concentration of DMSO in all the reactions. A series of samples for a standard curve were prepared 
based on the manufacturer’s instructions to determine the ATP-ADP conversion from the 
luminescence signals in every round of experiment. The kinase reaction tubes with the reaction 
mixes were incubated at 26-27oC for 60 minutes for the kinase reaction. The ADP-GloTM reagent 




the ATP in the reactions. Next the detection reagent was added to the reactions for an incubation 
of 45 minutes at 26-27oC. 20µl of the sample from each tube was then transferred into a 96 well 
microplate and the luminescence was measured with the GloMax® 96 Microplate Luminometer 
(Promega) with an integration time of 1.5s. The luminescence values were converted into the ATP-
ADP conversion values based on the standard curve. Four rounds of experiment were conducted. 
The values from each round of experiments were normalized to the average value of the Timothy 
syndrome cardiomyocyte samples without PHA-793887 addition before being pooled together for 
the final analysis that is showed in Figure 70a. 
Western blot  
Anti-CDK5R1/p35 (Rabbit polyclonal Ab, Catalog # sc-820, Clone # C-19, 1: 1,000 dilution, 
Santa Cruz), anti-CDK5 antibody (Mouse monoclonal Ab, Catalog # MABS50, Clone # 1H3, 
1:1000 dilution, Millipore) and anti-beta-Tubulin antibody (Mouse mAb, Catalog # T5201, Clone 
# TUB 2.1, 1:4,000 dilution, Sigma Aldrich) were used for Western blotting. For western blot 
analysis, the cardiomyocytes were used at day 26 or day 27 after differentiation. Some of the 
Timothy syndrome cardiomyocytes were treated with 5 μM PRE-084 in cardiomyocyte culture 
media for two hours before being collected for Western blotting. The Timothy syndrome 
cardiomyocytes from the same round of differentiation were collected as control. The cells were 
isolated from the monolayer and lysed with the cell lysis buffer containing 1% Triton X-100, 
50mM Tris-HCl, 150mM NaCl, 250mM sucrose, 1x protease inhibitor cocktail, 1x phosphatase 
inhibitor cocktail 3 and 1x phosphatase inhibitor cocktail, pH 7.4. The concentration of total 
proteins in each sample was measured using BCA assay kit). Next, 20 μg of proteins from each 
sample were aliquoted and denatured with the sample buffer containing Urea and being boiled for 




stacking gel and 10% separation gel along with the ladder (Prestained SDS-PAGE standards, broad 
range, catalog # 161-0318, Biorad). The proteins were electro-transferred to PVDF-membranes 
(InvitrolonTM PVDF, Catalog # LC2005, NOVEX/ Thermo Fisher Scientific) using the XCell 
SureLockTM Mini-Cell system (Thermo Fisher Scientific) overnight at 4 oC. Next day, the 
membranes were blocked with the SuperBlock Blocking Buffer in PBS (phosphate-buffered 
saline, Thermo Fisher Scientific, # 27515) for 30 minutes at room temperature and then incubated 
with the primary antibody (diluted in the SuperBlock Blocking buffer) overnight, followed by an 
incubation of the corresponding secondary antibody (Pierce/Thermo Fisher Scientific, anti-mouse 
# 31430; anti-rabbit, #31460,1:8,000 dilution in the SuperBlock Blocking buffer) for 30 minutes 
at room temperature. The membranes were then incubated with the Pierce ECL western blotting 
substrate (Thermo Fisher Scientific, # 32209) followed by exposing to X-ray films (CL-X 
posureTM film, Thermo Fisher Scientific, # 34091) in a dark room. For sequential 
immunoblotting, the membranes were stripped with the stripping buffer containing 62.5mM Tris-
HCl, 2% SDS, 114mM beta-mercaptoethanol at 42oC for 15-20 minutes, and washed six times 
with PBS. The stripped membranes were then re-blocked with SuperBlock Blocking Buffer for 
the next immunoblotting. For the immunoblotting of beta-tubulin, the membrane was stripped, re-
blocked with the SuperBlock Blocking Buffer and incubated with the beta-tubulin antibody at 
room temperature for 30 minutes. The rest of the steps were the same. The western blot analysis 
to examine p35 protein expression in Timothy syndrome cardiomyocytes before and after 5 μM 
PRE-084 treatment was repeated nine times with independent samples from different rounds of 
differentiation for validation. The western blot analysis to examine CDK5 expression in Timothy 
syndrome cardiomyocytes before and after 5 μM PRE-084 treatment was repeated three times with 




intensities were quantified using Image J and the values were normalized to the corresponding 
beta-tubulin band intensities. The values from Timothy syndrome cardiomyocytes two hours after 
the treatment of 5 μM PRE-084 were normalized to the values from Timothy syndrome 
cardiomyocytes without treatment for the presentation in the corresponding figure.  
Quantitative RT–PCR 
RNA from the Timothy syndrome cardiomyocytes before and two hours after the treatment of 5 
μM PRE-084 was prepared using the RNeasy Mini kit and RNase-Free DNase set (Qiagen). cDNA 
was synthesized using the SuperScript III First-Strand Synthesis System for RT–PCR (Thermo 
Fisher Scientific). The cDNA (21 μl) was diluted with DNase-free water (Thermo Fisher 
Scientific) at 1:1 and 1 μl of the samples was used for qPCR analysis. SYBR Advantage qPCR 
Premix (Clontech/TaKaRa Bio) and StepOnePlus real time PCR systems (Thermo Fisher 
Scientific) were used for qPCR. The primer sets for detecting the CDK5 and GAPDH transcripts 
were as follows: CDK5 Forward 5’- GGCTTCAGGTCCCTGTGTAG-3’, Reverse 5’- 
ATGGTGACCTCGATCCTGAG-3’; GAPDH, Forward 5’- 
GATGACATCAAGAAGGTGGTGA-3’, Reverse 5’- GTCTACATGGCAACTGTGAGGA-3’ 
(oligo synthesis by IDT). The CT value of each sample at 50% of the amplification curve was used 
and GAPDH was used to normalize the expression of CDK5.  
Mouse Electrocardiography  
Conditional mouse model of Timothy Syndrome was generated by M.Y., targeting the Rosa26 
locus with a G406R mutant in the calcium channel Cacna1c gene264(Figure 75a). We used αMHC-
MerCreMer transgenic mice (Myh6-cre/Esr1, JAX #5657) for this mouse study. When αMHC-




sequences, tamoxifen-inducible Cre-mediated recombination is expected to result in deletion of 
the floxed sequences in heart cells of the offspring to overexpress Timothy syndrome mutant 
channels in the hearts. Subcutaneous 4-lead electrocardiograms of isoflurane-anesthetized 12-
week old mice were performed using emka ECG and recorded using iox 2.8.0.19. Recordings were 
conducted a day 4 and 11 after tamoxifen (Sigma-Aldrich, 50μg/B.W.(g)/day/mouse, i.e., 
approximately 1mg/day/mouse) was administrated at day 1-3. Dextromethorphan/quinidine 
(Sigma-Aldrich, # Q0875; ratio, dextromethorphan : quinidine = 2:1) was dissolved in the drinking 
water. Total amount of taken dextromethorphan was estimated based on water consumption in 
each mouse (23-44mg/kg). To obtain an accurate amount of dextromethorphan administered to the 
mice, the concentration of dextromethorphan in the plasma was measured and analyzed at 
Columbia University Biomarkers Core Laboratory using a validated customized Liquid 
Chromatography Mass Spectrometry (Agilent 6410A mass spectrometer coupled with an Agilent 
1290 Infinity UHPLC) based assay measuring the plasma levels of dextromethorphan administered 
to 8 week old C57BL/6 mice (Envigo, # 044). The mice were dosed similarly to that of the ECG 
experiments and the plasma was collected through the tail vein using a heparinized 
microhematocrit capillary tube (Fisherbrand, Cat#: 22-362566) and transferred to a 1.5 mL clear 
Eppendorf tube (Eppendorf, Cat #: 22364120) containing 5µL of 0.5M EDTA (Invitrogen, Cat#: 
15575020) at the designated days 4 and 11 during the treatment regimen at 8am, noon and 8pm of 
each day. RR and QT intervals were measured manually using ecgAUTO v2.8.1.27, Excel and 
Prism 6/7 software. 
Statistical analysis  
The statistics used for every figure have been indicated in the corresponding figure legends. The 




software. The Student t-test was two tails. The one-way ANOVA with Bonferroni or Dunnett’s 
post-hoc multiple comparison analysis was conducted with the Graphpad Prism 6/7 software. All 
the data meet the assumptions of the statistical tests. All the samples used in this study were 
biological repeats, not technical repeats. No samples were excluded from the analysis in this study, 
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